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Constantin N. Takacs, Ph.D.
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The hepatocyte is one of the major secretory cell types in the body. It fulfills
many of the liver's essential functions in protein secretion, lipid storage and transport, and
excretion. Some of these functions are carried out via polarized secretion of simple
protein cargo, such as serum albumin, or large macromolecular lipid-protein complexes,
the lipoproteins. The hepatocyte is also the site of infection of several hepatotropic
viruses. Of these, hepatitis C virus (HCV) is peculiar due to its close structural and
functional association with the hepatic lipoproteins. All these cargoes are transported
from the endoplasmic reticulum (ER) to the cell surface by the vesicular secretory
pathway, yet insufficient knowledge exists regarding the molecular regulation of their
secretion by the hepatocyte. Furthermore, differential modalities of regulation may be
involved in the shuttling of such a diverse set of cargoes as albumin, the lipoproteins and
HCV.
The work presented here head-starts a comprehensive examination of how the
hepatocyte regulates the secretion of the following cargoes: serum albumin, the
apolipoproteins E and B100 (ApoE and ApoB100, respectively, both lipoprotein
components, and surrogate markers for these complex macromolecular particles), and
HCV, a lipoprotein-associated virus. I propose to combine genetic, biochemical,
virological and imaging approaches to identify which vesicular secretory pathways are

utilized by each of these cargoes. These approaches include inactivation of specific
vesicular transport pathways, accompanied by measurements of their effects on cargo
secretion efficiencies, and establishment of functional fluorescent protein-tagged cargo
markers to be used in live cell imaging experiments.
I begin by describing a dominant negative (DN) Rab GTPase screen that I
performed to identify Rab proteins involved in ApoE, ApoB100 or albumin secretion.
The small Rab GTPases control individual steps of vesicular transport. I analyzed how
expression of individual dominant negative Rab proteins affected cargo secretion
compared to expression of their wild type (WT) counterparts. I identified several Rabs
that caused significant changes in secretion, many of which had previously been
described as regulators of various exocytic vesicular transport steps.
I next present ongoing work that aims to define the involvement of the Rabs 11a,
11b, 8a, and 8b in hepatic cargo secretion. Their dominant negative mutants exhibited
some of the largest secretion phenotypes in my dominant negative Rab screen. These
Rabs have been implicated in various aspects of post-Golgi secretion in polarized and
non-polarized cell types. I thus discuss the implications of their involvement in cargo
secretion in the polarized hepatocyte and outline my ongoing efforts to define the
parameters of this involvement.
I also investigated the function of Rab1b in hepatic secretion. I show that
inactivation of Rab1 function, by expression of a set of dominant negative mutants, or by
expression of a bacterial effector which affects Rab1 function, led to impairment of
albumin, ApoE, ApoB100 and HCV secretion. I implicate Rab1, for the first time to my
knowledge, in the transport of these cargoes. I also document differences in the

sensitivity of cargo secretion to the various means of Rab1 inactivation. ApoE secretion,
in particular, was insensitive to several means of transport inactivation, consistent with
existing models of differential regulation of hepatic cargo transport.
Lastly, I functionally characterize an ApoE-green fluorescent protein fusion
(ApoE-GFP). I show that while ApoE-GFP does not support infectious HCV release, a
hallmark function of untagged ApoE, ApoE-GFP nevertheless reproduces several known
behaviors of ApoE that have been associated with lipoprotein release. I thus conclude that
ApoE-GFP may be a useful marker for live cell imaging of lipoprotein release.
This work therefore identifies potential regulators of hepatic cargo transport,
establishes molecular tools useful for the continued study of cargo secretion in
hepatocytes and elsewhere, and advances the understanding of the involvement of Rabs
11, 8, and, in particular, Rab1, in the regulation of hepatic cargo transport. I propose that
this work forms a solid foundation for extensive studies on how these biomedically
relevant hepatic cargoes are secreted.
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Chapter 1
Introduction

1.1 General overview
This thesis describes my efforts, part of a larger and more ambitious endeavor, to
molecularly characterize the regulation of the secretion of some complex and
biomedically important hepatocyte-derived cargoes. My work focused on understanding
the release of the following hepatic cargoes: serum albumin, the lipoprotein components
ApoE and ApoB100, and the lipoprotein-associated HCV. My work also touched on the
regulation of intracellular secretory vesicular transport, in part in the context of cell
polarization. To place these efforts into greater context, and to introduce relevant facts
and concepts regarding the major players in this work, I start by providing some
background information. I first introduce some general principles of intracellular
vesicular traffic regulation and I mention peculiarities of transport regulation in polarized
cell systems. Since the greatest part of my work focused on how members of the Rab
family of small GTPases control hepatic cargo secretion, I describe the general functional
principles applicable to these proteins in greater details, and also introduce some widely
used methods to investigate Rab function. I next discuss the hepatocyte, the cell type
whose secretory function I investigate, and draw connections between its organization
and the processes it carries out. I more extensively introduce the hepatic secretory
cargoes that this work focuses on, namely serum albumin, the hepatic lipoproteins, and
HCV. For HCV, I place particular emphasis on the functional association between the
virion assembly and release portions of the viral life cycle, and the assembly and release
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of the hepatic lipoproteins. I conclude by summarizing the goals of this project, the study
of which will be expanded upon in greater detail in the following chapters.
1.2. Intracellular vesicular transport
A hallmark organizational principle governing eukaryotic cell structure and
function is compartmentalization. For example, the nucleus stores and expresses genetic
information, the ER fulfills numerous biosynthetic functions, mitochondria deal with
energy production, and lysosomes carry out many degradative processes. Functional
segregation is in part achieved by encasing the respective functions in membranous
compartments: the membrane-bound organelles. Integration of function also requires
communication between the various systems, ensuring that distinct or even opposite
processes, such as protein synthesis and degradation, nevertheless occur under
harmonious regulation.
An important process that ensures communication between distinct organelles and
integration of their functions is vesicular transport (Bonifacino and Glick, 2004; Palade,
1975). The paradigm is simple, as depicted in Figure 1.1A: a portion of the limiting
membrane of a donor organelle pinches off as a sealed vesicle, or even as a bigger and
pleiomorphic tubulo-vesicular structure. This transport carrier then travels to a target
compartment, tethers to it, and the carrier and target membranes fuse, thus releasing the
contents of the carrier. The cargo transported may be a soluble lumenal component, such
as a secreted protein, a membrane-associated molecule, such as a transmembrane
receptor, or the very lipids that form the membrane.

2

Figure 1.1. Principles of intracellular vesicular transport. (A) Simplified schematic of
vesicular traffic between membrane-bound intracellular organelles (for detailed model
see Figure 1.3). A vesicle loaded with cargo pinches off a donor organelle membrane,
then travels to a target compartment, where the vesicle and target membranes fuse,
releasing the cargo. (B) Simplified depiction of major vesicular transport pathways.
Green, the biosynthetic or secretory pathway; orange, the endocytic pathway. ERGIC,
ER-Golgi intermediate compartment; TGN, trans-Golgi network; PM, plasma membrane;
EE, early endosome; LE, late endosome; Ly, lysosome; RE, recycling endosome; RR,
rapid recycling from an early endosome; SR, slow recycling from a recycling endosome.
Figures adapted by permission from Macmillan Publishers Ltd: Nature Rev. Mol. Cell.
Biol. (Stenmark, 2009) ©2009.
3

In an overly simplified model of intracellular transport, several major vesicular
transport pathways can be easily identified (Figure 1.1B). The secretory (or biosynthetic)
route transports cargo from a major biosynthetic site, the ER, to the plasma membrane
(Palade, 1975). Important way stations along this route are the protein synthesis
organelle, the ER, as well as the Golgi system and the trans-Golgi network (TGN), where
cargo sorting and processing may occur (Brandizzi and Barlowe, 2013; Glick and
Nakano, 2009; Guo et al., 2014). The degradative route, on the other hand, commences at
the plasma membrane with an endocytic event (Doherty and McMahon, 2009). The
endocytosed cargo is then shuttled through a succession of endosomes (Huotari and
Helenius, 2011) before it is delivered to lysosomes, where final degradation occurs
(Luzio et al., 2007). Endocytosed cargo may also be recycled in one of two predominant
ways: in rapid recycling, the cargo returns back to the plasma membrane directly from an
early endosome; in slow recycling, the cargo first travels to a specialized recycling
endosome, from where it can then return to the plasma membrane (Grant and Donaldson,
2009; Ren et al., 1998). Importantly, none of these pathways functions in isolation. For
example, the last steps of recycling perform a function similar to that of the late secretory
pathway, namely delivery of cargo to the plasma membrane. Indeed, some biosynthetic
cargoes may traverse the recycling endosome during their secretion (Ang et al., 2004).
The interconnectedness of the major intracellular transport pathways is also evident in the
delivery of biosynthetic cargo to the endolysosomal degradative or related compartments
(Anitei et al., 2010; Bonifacino and Traub, 2003; Raposo et al., 2007).
While this simplified description introduces some of the major players and
functions that occur at various stages of vesicular transport, the structural and functional
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details of this system are much more complex. More minute functional and structural
divisions of the vesicular transport system exist. For example, ER-derived vesicles may
fuse together to form an ER-Golgi intermediate compartment (ERGIC) before they reach
the Golgi system (Appenzeller-Herzog and Hauri, 2006; Xu and Hay, 2004). Similarly,
the transition from endocytic vesicles to lysosomes may include several functionally and
structurally distinct stages, from early to late endosomes and then to lysosomes (Huotari
and Helenius, 2011). Post-Golgi secretory intermediates may include specialized vesicles,
such as those loaded with neurotransmitters, endocrine hormones, or cytotoxic immune
cell products, whose release is tightly regulated (de Saint Basile et al., 2010; Sudhof,
2004). Conceptually, the progression from one compartment to another may be viewed as
delivery of cargo to a pre-existing target compartment. The same process may be also
described as the transformation, or maturation, of a given vesicular compartment. For
example, transport vesicle fusion may lead to the formation of the compartment, as in the
case of ERGIC formation following fusion of ER-derived vesicles (Appenzeller-Herzog
and Hauri, 2006; Xu and Hay, 2004) or of early endosome formation following
homotypic fusion of endocytic vesicles (Bucci et al., 1992; Gorvel et al., 1991). Because
they lose certain vesicle-specific markers and properties, and acquire new ones, such
intermediate compartments may be viewed as being formed by maturation of the original
carriers. Regardless of whether membrane transport occurs through cargo shuttling from
one compartment to another, through maturation of the cargo transport carrier, or through
a mix of these two processes, the dynamically regulated essence of the transport process
remains unchanged.
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1.3. Vesicular transport in polarized cells
The simplified eukaryotic transport system described above assumes that all sides
of a cell are identical. Often this is not true, as many cells have a polar structural and
functional organization. An intensely studied type of polarity is that found across
columnar epithelia (Rodriguez-Boulan and Macara, 2014), but neurons (Namba et al.,
2015) and migrating cells (Petrie et al., 2009) are also the focus of extensive
investigation. In columnar epithelia, such as those lining the digestive or respiratory
tracts, a sheet of cells separates two distinct environments: the tissue-facing side of the
epithelial sheet, which comprises the juxtaposed basal surfaces of individual cells, and
the outside- or lumen-facing side of the epithelial sheet, which comprises the juxtaposed
apical surfaces of individual cells (Figure 1.2A). The apical surface of a cell is separated
from the contiguous basolateral surface by tight junctions (Farquhar and Palade, 1963).
These tight junctions (Figure 1.2B) simultaneously restrict trans-epithelial diffusion and
prevent mixing of apical and basolateral membrane components (Madara, 1998; Shin et
al., 2006). The tight junctions alone would likely not be able to maintain polarity if the
cells did not possess mechanisms that allow them to concentrate basolateral and apical
components at the appropriate poles (Goldenring, 2013; Rodriguez-Boulan and Macara,
2014). Such mechanisms include polarized secretion (Figure 1.2B), by which apical
markers are transported from the TGN directly to the apical surface, and basolateral
markers are transported directly to the basolateral surface. Cells may also target cargo to
the correct surface by transcytosis (Preston et al., 2014; Rojas and Apodaca, 2002). In
this case, cargo initially delivered to one surface is endocytosed and transported across
the cell to the opposite surface (Figure 1.2C-D). The presence of polar surfaces
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complicates endocytic recycling the most, and several partly interconnected endosometype compartments have been identified and shown to control recycling and, in some
cases, biosynthetic transport at both poles (Goldenring, 2013, 2015). Thus, basal early
endosomes function in recycling and some secretory transport to the basolateral surface,
apical early endosomes and apical recycling endosomes function at the apical pole, and
common recycling endosomes function in both recycling and transcytosis (Figure 1.2CE). The recycling endosome system may be composed of separate membrane
compartments, or may consist of a contiguous compartment with specific functions
performed by distinct domains (Goldenring, 2015; Sonnichsen et al., 2000).

Figure 1.2. Polarized transport. (A) Schematic representation of a columnar epithelium.
Cells are packed tightly in a monolayer, with the apical surfaces (top, green) facing a
lumenal or exterior space, and the basolateral surfaces (bottom) facing the interior. Figure
adapted from (Treyer and Musch, 2013), with the permission from Wiley-Blackwell.
Copyright © American Physiological Society. (B-E) Selected types of post-Golgi
vesicular transport occurring in polarized cells. Figures adapted by permission from
Macmillan Publishers Ltd: Nature Rev. Cancer (Goldenring, 2013) ©2013 (B) Apical
and basolateral secretion from the Golgi compartment. (C) Apical to basolateral
transcytosis. (D) Basolateral to apical transcytosis. (E) Apical and basolateral recycling;
TJ, tight junction; AJ, adherens junction; AEE, apical early endosome; BEE, basolateral
early endosome; ARE, apical recycling endosome; CRE, common recycling endosome.
7

1.4. Regulation of vesicular transport
The vesicular transport steps that connect the major organelles of the secretory
pathway are regulated according to well-established principles. The process encompasses
cargo sorting at the donor compartment into a budding vesicle, vesicle scission, transport,
tethering to the target compartment, and fusion of the vesicle and target compartment
membranes (Figure 1.3).
Vesicle budding, accompanied by recruitment of a vesicle coat complex to the
nascent transport carrier, is followed by scission of the vesicle membrane form the donor
compartment membrane (Figure 1.3a-b). Transmembrane cargoes may be recognized by
the sorting machinery due to specific amino acid sorting signals that they possess in their
cytosolic domains. Soluble cargoes, on the other hand, may bind to transmembrane
sorting receptors, such as the KDEL receptor (Lewis and Pelham, 1992) or the manose-6phosphate receptor (Guo et al., 2014). These receptors in turn possess cytosolic sorting
signals required for transport (Dancourt and Barlowe, 2010; Guo et al., 2014).
Recruitment of the vesicle coats to the site of vesicle budding may be initiated by
the GTP-loaded, active form of a small GTPase of the Sar/Arf family (Gillingham and
Munro, 2007). Sar1 GTPases recruit coat protein complex II, or COPII, at the ER to
mediate anterograde traffic to the Golgi (Aridor et al., 1995; Gillingham and Munro,
2007; Kuge et al., 1994; Nakano and Muramatsu, 1989; Stagg et al., 2006; Stagg et al.,
2008). The Arf1 (ADP ribosylation factor 1) GTPase recruits the coat protein complex I,
or COPI, at Golgi membranes to mediate intra-Golgi transport and retrograde ER-toGolgi transport (Aridor et al., 1995; Gillingham and Munro, 2007; Presley et al., 2002;
Stearns et al., 1990). Arf proteins may also recruit adaptor protein (AP) complexes and
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clathrin cages that mediate late exocytic transport out of the TGN compartment
(Gillingham and Munro, 2007; Guo et al., 2014). Lastly, several factors may induce
vesicle scission from the donor compartment, including the large GTPases of the
dynamin family (Campelo and Malhotra, 2012; Morlot and Roux, 2013; Schmid et al.,
2015). Some of these events may occur sequentially, while others may occur
simultaneously. Thus, vesicle scission from the donor compartment obligatorily occurs
after cargo sorting, but cargo sorting may occur concurrently and in conjunction with
vesicle coat formation (Macro et al., 2012), or cargo may be recruited to pre-existent
vesicle coats (Rappoport and Simon, 2009).
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Figure 1.3. Details of vesicular transport. Detailed depiction of the steps involved in
vesicular transport between a donor and a target organelle. (a) Cargo is sorted into a
budding vesicle while coat proteins promote budding. (b) After scission, the coat proteins
are released. (c) The vesicle travels along the cytoskeleton; (d) The vesicle tethers to a
target compartment. (e) SNARE proteins mediate vesicle fusion to the target
compartment. Throughout transport, the vesicle associated Rab protein is found in the
GTP-bound active form and is membrane associated. Upon GTPase activating protein
(GAP)-induced GTP hydrolysis, the inactive Rab-GDP binds a GDP-dissociation
inhibitor (GDI). The resulting complex is cytosolic. The Rab activity cycle resumes when
a GDI displacement factor (GDF) and a Rab guanine exchange factor (GEF) act to
promote release of GDP and loading of GTP onto the Rab, returning it to a membranebound active state. Figure adapted by permission from Macmillan Publishers Ltd: Nature
Rev. Mol. Cell. Biol. (Stenmark, 2009) ©2009.
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Transport carrier formation is followed by its movement towards and fusion to a
target compartment (Figure 1.3c-d). This process is regulated by the Rab family of small
Rab GTPases (Hutagalung and Novick, 2011; Stenmark, 2009; Takai et al., 2001). Their
functional cycle will be described in greater detail in the next section. It is sufficient to
note here that an active, GTP-loaded Rab protein becomes associated with the budding or
budded transport carrier. The active Rab protein will then recruit various types of effector
molecules that directly influence vesicle behavior. For example, Rabs may recruit motor
proteins of the dynein, kinesin, or myosin families (Hutagalung and Novick, 2011),
which will determine whether the transport carriers utilize actin fibers or microtubules for
their movement, and whether this movement is directed towards the (+) end or (-) end of
microtubules. Similarly, Rabs may recruit tethering and vesicle fusion factors, which will
recognize the appropriate target compartment, tether the transport carrier to that
compartment, and mediate the fusion of the two membranes and delivery of the cargo
(Figure 1.3d-e). For example, Rab1 on ER-to-Golgi transport vesicles recruits p115
(Allan et al., 2000), which tethers anterograde transport vesicles to the Golgi, while Rab8
recruits the exocyst complex to post-Golgi vesicles (Mazelova et al., 2009b). Various
SNARE systems control vesicle fusion at various subcellular locations (Martens and
McMahon, 2008; Rizo and Rosenmund, 2008; Rizo and Xu, 2015; Wickner and
Schekman, 2008).
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1.5. The Rab GTPases
While the major regulators of transport carrier formation at the donor
compartment are the Sar/Arf GTPases, the major regulators of transport carrier behavior
are the Rab GTPases (Hutagalung and Novick, 2011; Stenmark, 2009). They form the
largest family of small GTPase in eukaryotes, with over 60 encoded by the human
genome (Diekmann et al., 2011; Gurkan et al., 2005). They are somewhat specifically
associated with discrete steps of vesicular trafficking (Figure 1.4). Rab1, for example,
regulates early anterograde traffic, from the ER to the Golgi (Plutner et al., 1991), while
Rab5 regulates the initial steps of endocytic traffic (Bucci et al., 1992; Gorvel et al.,
1991). Several Rabs may act together within a given pathway, such as Rab11 and Rab8 in
post-Golgi transport to the primary cilium (Knodler et al., 2010; Westlake et al., 2011),
while several isoforms may be differentially expressed in various tissues and regulate
related but distinct processes (Diekmann et al., 2011; Gurkan et al., 2005).
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Figure 1.4. Subcellular localization of Rab GTPase functions. The major organelles of
a polarized eukaryotic cells are depicted, together with vesicular traffic pathways that
connect them. The many Rab GTPases are depicted at their site of function or
localization. Figure adapted by permission from Macmillan Publishers Ltd: Nature Rev.
Mol. Cell. Biol. (Stenmark, 2009) ©2009. For detailed references, please see the original
review article (Stenmark, 2009).
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The Rabs amino-terminal domain is the best conserved and contains the GTPase
domain. This domain is related to the GTPase domains of other small GTPases of the
Rho, Rac and Sar/Arf families (Takai et al., 2001; Wittinghofer and Vetter, 2011), and is
involved in GTP or GDP binding and GTP hydrolysis. Sequences connected to the
GTPase domain change conformation depending on the nucleotide load of the GTPase
and are involved in effector molecule recognition and binding (Takai et al., 2001). The
carboxyl-terminal domain of the Rabs has a more divergent primary sequence and may
be involved in the localization of the Rab to a given organelle or vesicle (Chavrier et al.,
1991). Lastly, conserved cysteines at or very near to the carboxyl-terminus of the Rabs
are prenylated with prenyl (usually geranylgeranyl) lipid tails (Khosravi-Far et al., 1991;
Leung et al., 2006). These lipid tails mediate the association of the Rabs with target
membranes and are essential for function (Khosravi-Far et al., 1991; Nuoffer et al.,
1994).
The Rab nucleotide exchange and hydrolysis cycle (Figures 1.3 and 1.5) is similar
to that of other small GTPases (Hutagalung and Novick, 2011; Stenmark, 2009; Takai et
al., 2001). The active form is the GTP-bound form; active Rab-GTP complexes are
membrane bound and mediate effector recruitment (Figure 1.3a-d). Intrinsic Rab GTPase
activities are generally slow (Ingmundson et al., 2007), ensuring that inactivation of the
Rabs does not occur prematurely. When Rab function needs to cease, however, a Rab
GTPase activating protein, or GAP, will bind to the active Rab and stimulate its GTPase
activity (Barr and Lambright, 2010). The resulting Rab GDP is inactive, and it detaches
from the membrane, creating a cytosolic, inactive, GDP-bound pool of Rab molecules. A
GDP dissociation inhibitor, or GDI, accelerates the extraction of prenylated, GDP-loaded,
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inactive Rabs from the membrane (Gavriljuk et al., 2013), and, in the process, shields the
hydrophobic Rab prenyl moiety in the otherwise hydrophilic cytoplasm (Pylypenko et al.,
2006; Rak et al., 2003). The Rabs are returned to their active by exchange of the GDP for
a GTP. This is facilitated by proteins called guanine nucleotide exchange factors, or
GEFs, which may also ensure recruitment and activation of a given Rab at the
appropriate membrane compartment (Barr and Lambright, 2010; Blumer et al., 2013).
The Rabs are thus recycled back into a new round of activity.

Figure 1.5. The Rab GDP-GTP cycle. An inactive GDP-bound Rab releases GDP and
binds GTP, a process promoted by a GEF. The active Rab-GTP is membrane bound and
recruits effector molecules. Upon stimulation by a GAP, GTP hydrolysis occurs and the
Rab returns to the inactive GDP-bound state. Figure adapted by permission from
Macmillan Publishers Ltd: Nature Rev. Mol. Cell. Biol. (Stenmark, 2009) ©2009.
An ongoing debate focuses on which factors determine membrane identity. It is
clear by now that the Rabs, due to their somewhat specific association with discrete
subcellular compartments, are obvious membrane identity marker candidates, but they are
not the only ones (Barr, 2013; Pfeffer, 2013). Other factors that establish membrane
identity include the lipid and protein composition of an organelle and vesicle. As traffic is
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by necessity continuously dynamic, it is likely that membrane identity is too. Indeed, one
Rab may direct the recruitment of another Rab's GEF, which in turn activates the latter
onto the membrane and therefore changes membrane identity (Blumer et al., 2013). Rabs
may also recruit phosphoinositide kinases or phosphatases, which modify the lipid head
groups on a membrane and therefore change the nature of that membrane (Shin et al.,
2005). Regardless of the spatio-temporally, morphologically and compositionally
dynamic nature of vesicular transport networks, the generally specific functional
association between a given Rab and a given organelle or transport carrier render the
Rabs obvious targets during investigations aimed at defining a specific cargo's transport
pathway(s).
1.6. Selected methods to study Rab function
Study of Rab GTPase involvement in vesicular transport is facilitated by the
availability of several well-established experimental approaches. These include, but are
not limited to, expression of DN Rab mutants, expression of fluorescent protein-tagged
Rab constructs, and overexpression of Rab GAPs and GEFs, including bacterial effectors
that have evolved to target specific Rabs.
Introducing any one of several mutations into the Rab protein sequence can
abrogate the Rab functional cycle. This is most commonly done using mutations that
interfere with the guanine nucleotide exchange and hydrolysis cycle. Shown in Table 1.1
below are these three major mutant classes, along with references to publications where
the noted Rab1 mutations have been characterized in greater detail. The amino acids
mutated are indicated on a crystal structure of Rab1b in Figure 1.6. The mutations mirror
those used in the study of the prototypic small GTPase, H-Ras.
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Figure 1.6. Rab1b crystal structure. Crystal structure of Rab1b at 1.7 Å resolution
(Protein Data Bank structure 3NKV). Structure initially published in (Muller et al., 2010).
Shown is the Rab1b backbone (in gray), together with several features highlighted. The
GTP analog GppNHp (guanosine 5’-β,γ-imidotriphosphate, is in cyan. The guanine ring
is at the right, and the alpha, beta and gamma phosphates are indicated at the left. The
Gln67 residue involved in GTP hydrolysis is in red. The Ser22 residue involved in Mg2+
coordination is in green, while the Mg2+ ion is in orange. The Asn121 residue involved in
guanine ring binding is in blue. Original structure was processed using PyMOL.

A conserved asparagine residue in the guanine ring binding site of the Rab
proteins (Figure 1.6, equivalent to H-RasN116) may be mutated and replaced with the
bulkier and hydrophobic isoleucine residue. This change prevents the resulting mutant
protein from stably binding GDP or GTP (Pind et al., 1994; Walter et al., 1986). Indeed,
it is thought that this mutant may exchange GDP and GTP too rapidly and in an
unregulated manner (Pind et al., 1994; Walter et al., 1986). This mutation may induce
unregulated recruitment of GTPase effectors, possibly at ectopic locations, thus affecting
their dynamics and function. Expression of this nucleotide-binding Rab1 mutant affected
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the dynamics of Rab1 effector (p115, GBF1) association with membranes (Alvarez et al.,
2003; Brandon et al., 2006; Garcia-Mata et al., 2003; Monetta et al., 2007).
A conserved serine or threonine residue of the nucleotide binding pocket is
located close to the β- and γ-phosphates of GTP (Figure 1.6) and is involved in Mg2+
coordination in H-Ras (Farnsworth and Feig, 1991). Replacement of the equivalent Rab
residue, for example Rab1aS25, with an asparagine residue does not allow GTP binding,
but permits GDP binding (Nuoffer et al., 1994). As such, this GTP-binding mutant is
locked in the inactive GDP-bound form. Rab1aS25N (or Rab1bS22N) has been proposed to
compete with the WT Rab1a or Rab1b for binding of either a Rab1 GEF or a Rab1 GDI
(Nuoffer et al., 1994), in a model mirroring that proposed to explain H-RasS17N activity
(Farnsworth and Feig, 1991). This mutant may be interchangeably referred to either as a
GTP-binding or as a GDP-restricted mutant; throughout this work, I will refer to it as a
GDP-restricted mutant. Both it, and the above-mentioned nucleotide-binding mutant, are
widely referred to in the literature as DN mutants.
A third, well conserved glutamine residue also close to the γ-phosphate of GTP
(Figure 1.6) performs intrinsic GTPase activity of the Rabs, and at times also the
stimulated GTPase activity (Gavriljuk et al., 2012; Mihai Gazdag et al., 2013; Mishra et
al., 2013; Yu et al., 2013). Its mutation to a leucine (or another hydrophobic residue)
abrogates intrinsic Rab GTPase activity, resulting in a mutant that becomes locked in the
GTP-bound, active form (Mishra et al., 2013). This GTP-restricted/GTPase mutant is at
times referred to as dominant active mutant. Since the expression of these mutants may
result in abrogation of the normal Rab function, albeit at a different stage within the GTP
cycle, I will refer to the GTPase mutants as DN mutants as well.
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Table 1.1 Widely used Rab mutations
Rab process
Nucleotide
Activity
inhibited
load
Normal
Normal
None (WT)
exchange
activity cycle
GDP-GTP
Nucleotide-free Inactive
Nucleotide
binding
GDP-restricted Inactive
GTP-binding
GTPase
activity

GTP-restricted

Active

Rab1(a or b)
mutation
None

Reference

Rab1aN124I
Rab1bN121I
Rab1aS25N
Rab1bS22N
Rab1aQ70L
Rab1bQ67L

(Pind et al.,
1994)
(Nuoffer et al.,
1994)
(Gavriljuk et
al., 2012)

The general effectiveness of these mutants in inhibiting Rab function in transport
is in part due to their ability to interfere with the normal dynamics of the Rab functional
GTP/GDP exchange and hydrolysis cycle. The Rab regulators GEF and GAP also
interfere with the dynamics of this cycle by skewing the Rab-GDP/Rab-GTP ratio
towards the active form (the Rab GEFs) or the inactive form (the Rab GAPs).
Overexpression of either has been successfully used to modulate and investigate Rab
function (Fuchs et al., 2007; Udayar et al., 2013; Yoshimura et al., 2010). Proteins with
GEF or GAP activity have also evolved in some bacterial pathogens that replicate
intracellularly, in vesicles derived from the cellular organelles (Hicks and Galan, 2013).
Legionella pneumophila is an extensively studied example, and has been shown to inject
into the host cell cytoplasm several proteins that modulate Rab1 function (Hardiman et
al., 2012). Other examples of bacteria that have evolved capabilities to control
intracellular vesicular transport include Coxiella burnetii (Campoy et al., 2011; Hardiman
et al., 2012), Salmonella typhi (Spano and Galan, 2012), Shigella flexneri and
Escherichia coli (Dong et al., 2012). That the activities of these bacterial effectors have
been fine-tuned over many cycles of evolution informs both their specificity and their
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efficacy, and recommends them for use in experiments aimed at modulating Rab
function.
Lastly, Rab proteins have generally been proven to tolerate fluorescent proteintagging very well. Many fluorescent protein-Rab fusions have been shown to retain the
localization patterns of the parental Rab, as well as its function (Chen and WandingerNess, 2001; Feng et al., 2001; Moyer et al., 2001b; Peranen and Furuhjelm, 2001). This is
however not true across the board, since examples exist where attachment of even a small
epitope tag has resulted in a non-functional Rab chimera (Tisdale and Balch, 1996).
However, the general usefulness of such fusions remains uncontested, since the many
functional fusions allow detailed spatial and temporal analyses of Rab involvement in
traffic (Huang et al., 2010; Rzomp et al., 2003; Sonnichsen et al., 2000), as well as a
means for monitoring expression levels.
1.7. A case study in complex transport regulation: the hepatocyte
This work specifically focuses on analyzing the secretion pathways utilized by
hepatic lipoproteins and HCV, a hepatotropic virus. In order to properly contextualize
any experimental findings regarding the regulation of transport of these cargoes, one
must consider the function and architecture of the hepatocyte. I therefore introduce here a
few notions regarding liver function, architecture and how the hepatocyte functional and
structural polarization relate to these.
1.8. Liver function and architecture
The liver carries out a number of complex and often essential functions in the
animal body (Strain and Neuberger, 2002; Treyer and Musch, 2013). Among these are
energy storage, excretion, drug processing, and the synthesis of numerous serum
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components, such as albumin, alpha-1-antitrypsin, complement, coagulation factors, and
lipoproteins. The convergence of these functions in one organ is informed by the liver's
complex architecture (Figure 1.7). Blood enters the organ through the portal vein, which
collects nutrient-rich venous blood from most of the intestine, and through the hepatic
artery, which brings in oxygenated blood from the heart. The blood intake supply divides
and bathes the liver cells in a system of sinusoids, then reunites to exit the organ through
the hepatic vein, and thus re-enters into the general circulation. As such, the liver serves
as one of several filters of the circulatory system: it takes up components from the
afferent blood supply and releases its own products into efferent blood. The other major
liver function, excretion, is achieved through the bile canaliculi system, which converges
into the bile ducts and transports the bile (which includes digestive aids and waste
products) to the proximal intestine (Boyer, 2013). The function of the organ is predicated
on the separation of the blood-related functions of the liver from its excretory function,
resulting in an architecture of inter-weaved biliary duct tree branches and afferent and
efferent blood vessel tree branches.
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Figure 1.7. Liver architecture. Schematic of liver structural organization. Shown at the
top in blue and red are the blood vessels. Blood flows from branches of the portal vein
and the hepatic artery, into the hepatic sinusoids, and then into the central veins, which
return the blood into general circulation. Shown in green is the bile duct system, which
collects bile from the bile canaliculi. The hepatocytes (in purple) separate the biliary
(apical) compartment and the sinusoidal (basolateral) compartment. Other liver-resident
cell types (endothelial, Kupffer and stellate cells) are indicated, but discussion of their
function is beyond the scope of this work. Figure adapted from (Bhatia et al., 2014).
Reprinted with permission from AAAS.
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1.9. Hepatocyte organization
The separation between the blood-related and bile-related functions of the liver
occurs at the level of the hepatocyte (Figure 1.8), which is the functional unit of this
organ. Hepatocytes are polarized cells with apical (biliary) and basolateral (sinusoid)
surfaces (Gissen and Arias, 2015; Musch, 2014; Treyer and Musch, 2013). While this
structural and functional division of the hepatocyte is related to the organization of the
cells of simpler, columnar epithelia, such as those of the lung or of the intestine
(Marchiando et al., 2010; Rodriguez-Boulan and Macara, 2014), the hepatic cells display
a more complex architecture. Thus, at contact sites between hepatocytes, rows of tight
junctions delineate narrow apical intercellular lumens, called bile canaliculi (Gissen and
Arias, 2015; Musch, 2014; Treyer and Musch, 2013). These canals converge to form the
bile duct system and transport the bile, which contains the excretory and digestive
products of the hepatocytes (Boyer, 2013). Several canaliculi may flank a given
hepatocyte, while the rest of the hepatocyte surface, outside the tight junctions which
delineate the bile canaliculi, forms basolateral surfaces oriented towards other
hepatocytes or towards the sinusoidal space (Gissen and Arias, 2015; Musch, 2014;
Ogawa et al., 1979; Treyer and Musch, 2013). Given the cell's essential role in so many
aspects of animal life, it is important to understand how hepatocytes regulate secretion in
the context of their architecture and of their other functions.
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Figure 1.8. Hepatocyte polarity. (A) Three-dimensional schematic of spatial
relationships between hepatocytes, bile canaliculi, and hepatic sinusoids. The narrow
apical (biliary) domains, in green, are sequestered between adjacent hepatocytes and form
a complex network of canaliculi, while the basolateral domains encompass the remaining
hepatocyte

surfaces.

Figure

from

(Gissen

and

Arias,

2015),

DOI

10.1016/j.jhep.2015.06.015, reproduced under the Creative Commons Attribution
License (CC BY, http://creativecommons.org/licenses/by/4.0/, accessed on February 10,
2016). (B) Simplified depiction of a sheet of hepatocytes surrounded by apical
canalicular domains (in green) sequestered between adjacent cells. Top and bottom
surfaces are formed by basolateral domains. (C) Schematic section, perpendicular on the
apical lumen, through a hepatocyte-like polarity system. The apical lumen (red) is found
between adjacent cells, while basolateral domains (top and bottom) sandwich the cells.
(B) and (C) images adapted from (Treyer and Musch, 2013), with the permission from
Wiley-Blackwell. Copyright © American Physiological Society.
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1.10. Hepatic secretory cargoes of interest
My interest has long been in studying biological phenomena related to disease. In
the context of hepatic secretion, the lipoproteins and HCV have stood out as ideal study
candidates. I have also included albumin in this analysis, since its physico-chemical
properties diverge from those of the lipoproteins and of HCV. This work therefore
focuses on identifying the transport pathways involved in the secretion of a model
monomeric protein, albumin, and of the larger and more complex macromolecular
assemblies that are the lipoproteins and the HCV particles. I now describe some relevant
known features of these cargoes.
1.11. Albumin
I selected serum albumin as a model for the secretion of small, monomeric
proteinaceous cargo. Albumin is the most abundant protein in plasma, where it helps
maintain homeostasis of the circulatory system while also binding to and transporting
various small molecules throughout the body (Ha and Bhagavan, 2013; Quinlan et al.,
2005; Rothschild et al., 1988; Yamasaki et al., 2013). The albumin mRNA is translated
by ER-associated ribosomes. The amino-terminal signal peptide directs translocation of
the nascent protein into the lumen of the ER, resulting in a form termed proalbumin
(Judah et al., 1973; Quinn et al., 1975), which is then transported by the vesicular
secretory system. During transport, proalbumin is further proteolytically processed into
the mature form, albumin (Bathurst et al., 1987; Brennan and Peach, 1988). No
glycosylation sites are predicted in the primary amino-acid sequence of albumin; it is
secreted mainly in a non-glycosylated form (Struck et al., 1978).
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1.12. Hepatic lipoproteins
Definition, general features and metabolic functions. Lipoproteins are large,
complex, macromolecular assemblies that employ the lipid-binding and amphipathic
properties of their protein components, the apolipoproteins, to solubilize and transport
otherwise poorly soluble lipids, such as triglycerides, sphingolipids, cholesterol and
cholesterol esters (Mahley et al., 1984). The major lipoproteins produced in the body are
the chylomicrons, the very low-density lipoproteins (VLDL) and the high-density
lipoproteins (HDL). Chylomicrons are produced by enterocytes and transport dietary
lipids from the intestine to the rest of the body. They are the largest of the lipoproteins
produced in the body, with diameters over 100 nm (Mahley et al., 1984). As they become
depleted of their lipid cargo, they become denser and are termed (chylomicron) remnants.
The VLDL fulfill similar lipid transport functions as the chylomicrons, but are produced
by hepatocytes. They have densities below 1.006 g/mL and are the largest among the
non-chylomicron lipoproteins, with diameters in the range of 30 to 90 nm (Mahley et al.,
1984). As VLDL deliver their lipid cargo to cells throughout the body, they too become
gradually denser and are therefore termed intermediate-density lipoproteins (IDL, with
densities in the range of 1.006 to 1.019 g/mL), or low-density lipoproteins (LDL, with
densities between 1.019 and 1.063 g/mL). Lipid loss by VLDL is accompanied by a
reduction in particle size, down to LDL diameters of about 20 nm (Mahley et al., 1984).
Lastly, HDL are the smallest (8-12 nm in diameter) and densest (densities in the range of
1.063 g/mL to 1.21 g/mL) of the plasma lipoproteins. HDL particles fulfill a major role in
a process termed reverse cholesterol transport, which consists of the shuttling of
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cholesterol from cells throughout the body to the liver, where cholesterol processing and
excretion occurs (Zannis et al., 2015).
The lipid transport function of the lipoproteins is facilitated by their structural
organization. At the core of the particle are neutral lipids such as triglycerides and
cholesterol esters. This hydrophobic core is similar to that of intracellular lipid droplets
(Welte, 2015; Wilfling et al., 2014), in which the hydrophobic fats are also segregated
from the aqueous cellular environment with which the neutral lipids are immiscible. The
lipid core is surrounded by a polar lipid monolayer, organized similarly to a single leaflet
of a membrane that has been wrapped around the neutral lipid center. Apolipoproteins
can also on the surface of lipoprotein particles (Mahley et al., 1984). These proteinaceous
components utilize lipid-binding domains, most commonly amphipathic helices (Segrest
et al., 1992), to associate with the lipid particle. Apolipoproteins are involved both in
lipoprotein formation and in their functional processing throughout the body.
Apolipoproteins and their disease associations. Serum lipoproteins contain
several proteins components, termed apolipoproteins. ApoB100 is expressed in
hepatocytes and is essential for VLDL formation, serving as its defining structural
component. It is a very large protein of over 4500 amino acids and contains hydrophobic
β-sheet domains involved in lipid binding (Chen et al., 1986; Cladaras et al., 1986; Law
et al., 1986; Yang et al., 1986). Apolipoprotein B48 (ApoB48) synthesis results from
citidine deamination of the ApoB100 mRNA by Apobec-1, which creates a premature
STOP codon in the sequence (Teng et al., 1993; Tennyson et al., 1989). ApoB48 is
produced in enterocytes in humans, and in both enterocytes and hepatocytes in rodents
(Davidson and Shelness, 2000). Enterocyte-made ApoB48 is involved in chylomicron
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biogenesis, while hepatic ApoB100 drives VLDL particle formation (Mansbach and
Siddiqi, 2010; Olofsson and Boren, 2005). Other apolipoproteins include those belonging
to the A, C and E classes (Kohan, 2015; Kohan et al., 2015; Mahley, 1988; Mahley et al.,
1984; Maiga et al., 2014; Norata et al., 2015; Phillips, 2014; Sacks, 2015; Sundaram and
Yao, 2012; Zannis et al., 2015). Some of these may undergo cycles of association with
and dissociation from the surface of the large ApoB-containing lipoproteins: the
chylomicrons, the VLDL and the LDL, and are therefore referred to as exchangeable
apolipoproteins. They may also participate in the formation of HDL particles (Zannis et
al., 2015). They have been shown to regulate, at least in part, ApoB-containing
lipoprotein biogenesis, receptor binding of the lipoproteins, and lipolysis (Kohan, 2015;
Kohan et al., 2015; Mahley, 1988; Mahley et al., 1984; Maiga et al., 2014; Norata et al.,
2015; Phillips, 2014; Sacks, 2015; Sundaram and Yao, 2012; Zannis et al., 2015).
Among the most extensively investigated apolipoproteins, and components of
both VLDL and HCV particles, are ApoB100 and ApoE. Since the work I present here
deals exclusively with these two lipoprotein components, I restrict myself to providing
detailed background information regarding only these two. The investigation principles
that I present throughout this work are nonetheless transferable to the analysis of the
secretion of other exchangeable apolipoproteins.
In humans, VLDL obligatorily contains ApoB100, a component that likely has a
structural function. VLDL also contains ApoE and other exchangeable apolipoprotein
components (Utermann, 1975). Proper regulation of VLDL formation (assembly),
secretion, and metabolism are tightly controlled; defects in these processes have been
associated with numerous metabolic disease syndromes. Such conditions include
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abetalipoproteinemia (Berriot-Varoqueaux et al., 2000; Wetterau et al., 1992), which
results from a defect in the lipidation of ApoB100, and hypobetalipoproteinemia
(Schonfeld, 2003; Schonfeld et al., 2005; Young et al., 1989), which results from
missense mutations in the ApoB100 sequence. These and other types of primary
lipoproteinemias may cause atherosclerosis and coronary artery disease (Lusis et al.,
2004).
ApoE, the other apolipoprotein I investigate here, occurs in humans as several
major isoforms, termed ApoE2, ApoE3 and ApoE4, respectively (Utermann et al., 1977;
Weisgraber et al., 1981). While ApoE3 is the most common isoform and is considered
"neutral" with respect to disease association, ApoE2 is associated with type III
hyperlipoproteinemia and ApoE4 is associated with type V hyperlipoproteinemia
(Ghiselli et al., 1982a; Ghiselli et al., 1982b; Utermann et al., 1977). Furthermore, the
minor isoform ApoE3-Leiden is a dominant predictor of type III hyperlipoproteinemia
(Havekes et al., 1986). Type III disease association is correlated with low clearance rate
of ApoE-containing lipoproteins due to defects in LDL receptor (LDLR) binding (Gregg
et al., 1981); indeed, ApoE contains a well defined LDLR-binding domain (Wilson et al.,
1991). The absence of ApoE expression, or expression of LDLR-binding defective ApoE
isoforms, results in accumulation of VLDL, triglycerides, and cholesterol in plasma
(Mahley et al., 1999; Plump et al., 1992; Zhang et al., 1992), and increases the likelihood
of developing atherosclerosis and coronary artery disease. In these conditions, large
amounts of plasma LDL, including its oxidized forms, are deposited in arterial walls. The
arterial wall thus accumulates plaque, loses elasticity, and the arterial lumen narrows,
eventually leading to cardiovascular morbidity (Breslow, 2000, 2001).
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Besides its role in cholesterol transport and metabolism, ApoE has many other
functions. Some of these functions are related to its expression by a wide variety of cells
in many tissues. For example, macrophages express ApoE and may use it to deliver
necessary lipids at sites of nerve regeneration (Ignatius et al., 1986; Snipes et al., 1986).
Similarly, astrocytes express ApoE (Murakami et al., 1988; Pitas et al., 1987), which may
be involved in sustaining proper neuronal physiology. Indeed, ApoE has been implicated
in neurodegenerative disease conditions (Corder et al., 1994; Corder et al., 1993;
Greenberg et al., 1995; Martinez et al., 2005; Vance and Hayashi, 2010), with ApoE4
being associated with higher risk of developing late onset Alzheimer's disease, while
ApoE2 protecting against the same condition (Corder et al., 1994; Corder et al., 1993).
ApoE has also been shown to modulate cell activation and migration (Ali et al., 2005;
Kelly et al., 1994; Kothapalli et al., 2004; van den Elzen et al., 2005), and just recently,
increased ApoE expression by melanoma cells was shown to increase aggressive tumor
behavior and metastatic potential (Pencheva et al., 2012). ApoE-dependent modulation of
cell activation may be achieved through direct transcriptional control (Theendakara et al.,
2016) or through cell-surface receptor-mediated signaling (Pencheva et al., 2012).
1.13. Lipoprotein assembly and secretion
VLDL assembly and secretion. VLDL assembly commences with the translation
of the ApoB100 mRNA and the concurrent translocation of the resulting protein (Chen et
al., 1986; Cladaras et al., 1986; Law et al., 1986; Yang et al., 1986) into the lumen of the
ER. Efficient translocation requires concomitant loading of lipids onto the nascent
polypeptide; this lipidation process is catalyzed by the microsomal triglyceride transport
protein (Boren et al., 1992; Wetterau et al., 1992). From the ER, ApoB100-containing
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VLDL transits the Golgi system (Ehrenreich et al., 1973) en route to the basolateral
plasma membrane, where it is secreted. The complex processes of assembly and
maturation of the VLDL particle that occur during its journey through the secretory
pathway may include further lipidation, association with exchangeable apolipoproteins,
including ApoE, and various post-translational modifications (Olofsson and Boren, 2005;
Sundaram and Yao, 2010, 2012; Tiwari and Siddiqi, 2012). VLDL progression through
the secretory pathway is also controlled by at least two degradative processes (Ginsberg
and Fisher, 2009; Rutledge et al., 2010). When lipid sources are insufficient to achieve
proper initial lipidation or if the microsomal triglyceride transport protein activity is
reduced or abolished, ApoB100 translocation stalls. The nascent polypeptide then
becomes exposed to the cytoplasm and is ubiquitinylated and targeted for proteasomemediated ER-associated degradation (Benoist and Grand-Perret, 1997; Fisher et al., 2011;
Fisher et al., 1997; Zhou et al., 1998). When pre-VLDL formation is completed, but the
nascent lipoprotein becomes exposed to poly-unsaturated fatty acids or is oxidized, then
the particle is targeted for degradation by the autophagosome (Pan et al., 2008a). Only
VLDL molecules that survive this strict quality control process are secreted.
ApoE secretion in the presence or absence of VLDL. Secreted VLDL particles
also contain ApoE, a 299-amino-acid, O-glycosylated exchangeable apolipoprotein (Rall
et al., 1982; Utermann, 1975; Wernette-Hammond et al., 1989; Zanni et al., 1989). ApoE
can be secreted on its own from many cell types, including hepatocytes (Dashti et al.,
1980), macrophages (Basu et al., 1981), and astrocytes (Pitas et al., 1987), and can form
HDL particles involved in cholesterol transport. Indeed, a major function of lipoproteinassociated ApoE is to tightly bind LDLR family receptors and to promote clearance of
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cholesterol-rich lipoprotein particles from circulation (Mahley, 1988; Plump et al., 1992;
Zhang et al., 1992). ApoE isoforms or mutants with low LDLR-binding affinity are
associated with type III hyperlipoproteinemia and coronary artery disease (Breslow,
2000; Mahley et al., 1999). ApoE is synthesized on ER-associated ribosomes, is
translocated into the lumen of the ER, and is transported through the Golgi to the cell
surface in secretory vesicles that travel along microtubules (Kockx et al., 2007). A
fraction of newly-synthesized ApoE is degraded intracellularly in a post-ER compartment
(Deng et al., 1995; Ye et al., 1993). Once secreted, ApoE may associate with the cell
surface (Lilly-Stauderman et al., 1993), and may become re-internalized and recycled
(Heeren et al., 2003; Laatsch et al., 2012). Lastly, beyond simply being associated with
VLDL particles, ApoE was also shown to promote their secretion (Kuipers et al., 1997;
Mensenkamp et al., 2001). Various lipoprotein components thus display a complex
functional interplay during the assembly and egress of VLDL, with major implications
for human disease.
1.14. Hepatitis C virus
Another known cargo of the secretory pathway in hepatocytes is HCV. Infection
with HCV may be the cause of several very serious disease conditions, and it was, until
recently, very difficult to cure (Thomas, 2013). Furthermore, HCV is peculiar in that it
very closely associates with host lipoproteins, including ApoE and ApoB100
(Lindenbach, 2013; Lindenbach and Rice, 2013). HCV has thus become an obvious
target in our investigation into how hepatocytes regulate cargo secretion. I provide here a
summary of relevant aspects of the HCV life cycle that I hope will inform the
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understanding of the investigations I have commenced into the regulation of HCV
particle secretion.
1.15. Hepatitis C
Hepatitis - the inflammation of the liver - can have widely varied etiologies, with
viral infections being a major cause (Protzer et al., 2012). Several hepatotropic viruses
have been identified and shown to be etiologic agents of viral hepatitis. Hepatitis A virus
(Matheny and Kingery, 2012) and hepatitis E virus (Khuroo and Khuroo, 2016; PerezGracia et al., 2014; Sayed et al., 2015) generally cause self-limiting acute hepatitis, while
hepatitis B virus, HCV and the hepatitis B virus-dependent hepatitis delta virus, in turn,
often establish chronic infections that may remain active over several decades
(MacLachlan and Cowie, 2015; MacLachlan et al., 2015; Rizzetto, 2015; Thomas, 2013).
The usual progression of HCV infection is depicted in Figure 1.9. While some patients
clear HCV infections spontaneously, the virus often causes chronic infection, which may
further progress through the following stages: liver fibrosis, liver cirrhosis, and
hepatocellular carcinoma (Hoofnagle, 1997; Thomas, 2000). Liver failure secondary to
advanced chronic viral hepatitis remains a major indication for liver transplantation
(Neuberger, 2016). Given the severity of HCV-dependent pathologies, HCV infection
remains a major health burden worldwide, with over 185 million people (or almost 3% of
the world population) thought to be chronically infected with the virus (Mohd Hanafiah
et al., 2013). This problem is exacerbated by the failure to develop a protective anti-HCV
vaccine (Honegger et al., 2014; Walker and Grakoui, 2015), and by the high costs of
effective and well tolerated treatments that have only recently become available (Ayoub
and Tran, 2015; Holmes and Thompson, 2015; Scheel and Rice, 2013).
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Figure 1.9. HCV disease progression. Symptoms associated with the successive stages
of HCV infection. ALT, alanine aminotransferase plasma levels; HCC, hepatocellular
carcinoma. Figure adapted by permission from Macmillan Publishers Ltd: Nature Med.
(Thomas, 2013) ©2013.

1.16. The HCV virion: structure and composition
HCV is an enveloped virus and has a single-stranded, positive-sense RNA
genome; it belongs to the genus Hepacivirus within the Flaviviridae family
(Bartenschlager et al., 2011; Moradpour et al., 2007; Scheel and Rice, 2013). Notable
related viruses include the recently identified hepaciviruses (Kapoor et al., 2011; Kapoor
et al., 2013; Pybus and Theze, 2015), as well as the more distantly related flaviviruses,
pestiviruses, and pegiviruses (Knipe and Howley, 2013).
The HCV particle contains the positive polarity RNA genome, virus-encoded
proteins, namely the capsid protein Core and the glycoproteins E1 and E2, and host cell
derived proteins and lipid membranes (Bartenschlager et al., 2011; Lindenbach, 2013;
Lindenbach and Rice, 2013; Scheel and Rice, 2013). Of the host-cell derived viral
particle protein components, most notable are ApoE and ApoB100. The virus association
with hepatocyte-derived lipoproteins confers it light, lipoprotein-like densities,
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particularly in vivo (Andre et al., 2002; Lindenbach, 2013; Lindenbach et al., 2006;
Lindenbach and Rice, 2013; Nielsen et al., 2006). The HCV-lipoprotein chimeric entity is
called a lipoviroparticle (Andre et al., 2002).
Unlike the more highly and uniformly organized flavivirus particles (Kuhn et al.,
2002; Mukhopadhyay et al., 2003; Mukhopadhyay et al., 2005; Zhang et al., 2003a;
Zhang et al., 2003b), HCV presents a more amorphous structure, not easily resolved by
conventional structural techniques (Catanese et al., 2013). This may be due in part to
lipoprotein association, the nature of which has not been unambiguously described as of
yet (Lindenbach, 2013; Lindenbach and Rice, 2013). Highly purified infectious particles
are about 70 nm (40-100 nm range) in diameter (Catanese et al., 2013), although earlier
reports have described a significantly more heterogeneous (both in size and shape)
particle population found in more crude viral preparations (Gastaminza et al., 2010; Merz
et al., 2011; Yu et al., 2007).
1.17. HCV life cycle
The HCV life cycle follows the classical paradigm of virus propagation, as
depicted in Figure 1.10. At a cellular level, the infectious HCV particle enters a host cell,
primarily the human hepatocyte, where the virus replicates its genome, and assembles
and releases new infectious particles that further propagate the cycle (Scheel and Rice,
2013). To survive inside the host, the virus has developed mechanisms to counteract the
host's antiviral defenses, both innate and adaptive (Dustin et al., 2014; Dustin and Rice,
2007; Horner and Gale, 2013). Lastly, to spread within the human population, the virus
must be able to infect new hosts. A major driving force for the ongoing epidemic was
transmission through non-sterile medical procedures and the lack of screening blood for
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transfusion, organs for transplant, and similar other human donor-derived biomedical
products (Thomas, 2000, 2013). More recently, injection drug habits in conjunction with
use of non-sterile paraphernalia has constituted a major cause of new transmissions
(Thomas, 2013), and reports have emerged linking HCV transmission with unsafe sexual
practices in at-risk populations (Danta et al., 2007; Schmidt et al., 2011; Thomas, 2013;
Urbanus et al., 2009; van de Laar et al., 2009; van de Laar et al., 2010; van de Laar et al.,
2007). The mode of HCV transmission prior to the modern medicine-facilitated and
relatively recent spread remains unclear (Pybus and Theze, 2015).
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Figure 1.10. The HCV life cycle. The cycle of cellular infection by HCV: (1) The
lipoprotein-associated virus binds a series of co-receptors, then undergoes receptormediated endocytosis (2), to mediate entry into the target cells. Acid mediated fusion of
the viral and host cell membrane within an endosomal compartment leads to release of
the viral capsid into the cytosol and uncoating of the genome (3). The genome is
translated on ER-associated ribosomes (4), then undergoes replication (5) via a (-) strand
RNA intermediate. Virion morphogenesis (6) occurs in an ER-related compartment. The
newly formed viruses mature (7) as they are secreted by the host cell vesicular transport
system (8), to be released into the extracellular space. LDLR, LDL receptor; GAG,
glucosaminoglycans; SCARB1, scavenger receptor B1, CLDN1, claudin1; OCLN,
occludin. Figure adapted by permission from (Ploss and Rice, 2009), ©2009 European
Molecular Biology Organization.
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HCV Entry. The virus enters the target hepatocytes via receptor-mediated
endocytosis, followed by acid-mediated fusion of viral and cellular membranes
(Lindenbach and Rice, 2013; Scheel and Rice, 2013). Binding to hepatocytes is mediated
by several cell-surface co-receptors and may involve a cascade of binding and transport
events before the virus is internalized (Lindenbach and Rice, 2013; Scheel and Rice,
2013). Ligands on the surface of the viral particles include the E2 envelope glycoprotein
and potentially the associated host lipoproteins, while the cellular receptors include:
glucosaminoglycans, LDLR (Andre et al., 2002; Monazahian et al., 1999), the tetraspanin
membrane proteins CD81 (Pileri et al., 1998), and scavenger receptor B1 (Bartosch et al.,
2003), the tight junction proteins claudin-1 (Evans et al., 2007) and occludin (Ploss et al.,
2009), the epidermal growth factor receptor and the ephrin type-A receptor 2 (Lupberger
et al., 2011), and the Niemann-Pick C1-like 1 cholesterol absorption receptor (Sainz et
al., 2012). Following receptor-mediated endocytosis, acidification of virus-containing
endosomal compartments is thought to mediate conformational changes within the viral
glycoproteins, which mediate virus-host membrane fusion (Takikawa et al., 2000),
leading to release of the RNA genome into the target cell’s cytoplasm, thus initiating
HCV infection.
Translation and polyprotein processing. The HCV protein is encoded by the
positive sense viral genome, in which the protein-coding region is flanked by highly
structured 5'- and 3'- end untranslated regions, or UTRs (Figure 1.11A). The HCV
genome is translated on ER-associated ribosomes (Hijikata et al., 1991), which recognize
the 5'-UTR-contained HCV internal ribosome entry site (IRES) structure (TsukiyamaKohara et al., 1992). Translation of the viral RNA results in the synthesis of a single
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precursor polyprotein (Figure 1.11B). This HCV polyprotein contains, in order of
translation, the following viral proteins (Figure 1.11B-C): the capsid protein Core, the
envelope glycoproteins E1 and E2, the viroporin p7, and the nonstructural proteins (NS)
2, 3, 4A, 4B, 5A and 5B (Grakoui et al., 1993c; Lin et al., 1994). These 10 mature HCV
proteins are released from the precursor polyprotein by four proteases (Figure 1.11B),
two expressed by the host cell and two by the virus. The host cell proteases involved in
HCV polyprotein processing are the signal peptidase, which cleaves the viral polyprotein
at the junctions between Core and E1, between E1 and E2, between E2 and p7, and
between p7 and NS2 (Hijikata et al., 1991; Lin et al., 1994; Mizushima et al., 1994a;
Mizushima et al., 1994b), and the signal peptide peptidase, which removes the E1 signal
peptide from the carboxyl terminus of the Core protein (McLauchlan et al., 2002). The
virus encodes the remaining protease activities required for the processing of its
polyprotein, namely a cysteine protease formed by NS2 and the amino terminus of NS3
(Grakoui et al., 1993b; Hijikata et al., 1993a; Lorenz et al., 2006), and a serine protease
formed by NS3 and its cofactor NS4A (Bartenschlager et al., 1995; Hijikata et al., 1993a;
Kim et al., 1996; Lin et al., 1995; Love et al., 1996; Tomei et al., 1993). The NS2-3
cysteine protease cleaves the NS2/3 junction (Grakoui et al., 1993b; Hijikata et al.,
1993a), while the NS3-4A serine protease cleaves the NS3/4A, 4A/4B, 4B/5A and 5A/5B
junctions (Bartenschlager et al., 1993; Grakoui et al., 1993a; Hijikata et al., 1993a;
Hijikata et al., 1993b; Tomei et al., 1993). The resulting mature HCV proteins are then
involved in viral genome replication, virion assembly, and release of assembled progeny
virus particles, as well as modulation of host innate immune responses (Scheel and Rice,
2013).
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Figure 1.11. The HCV genome and the encoded proteins. (A) Depiction of the HCV
RNA genome. The open reading frame is flanked by 5’ and 3’ UTRs. The 5’UTR
contains an IRES. (B) IRES-mediated translation results in the synthesis of a large
polyprotein, which undergoes proteolytic processing. Arrows indicate the sites of
cleavage by the two viral proteases. Filled diamonds indicate the sites of cleavage by the
host signal peptidase, while the empty diamond indicates the site of cleavage by the host
signal peptide peptidase. (C) The 10 major HCV proteins are shown. Known selected
functions are listed under each protein. Figure adapted by permission from Macmillan
Publishers Ltd: Nature Rev. Microbiol. (Moradpour et al., 2007) ©2007.
The replication organelle and genome replication. A characteristic of many
cytoplasm-replicating RNA viruses is that they reorganize host cell membranes to create
new functional entities dedicated to the replication of the viral genome (Romero-Brey
and Bartenschlager, 2014). This adaptation may serve several purposes. For example, by
concentrating the enzymatic activities in a small volume or on a small surface, the
efficiency of the genome replication process would also be increased. Since many of
these viruses are enveloped viruses, the final stages of particle assembly, namely the
envelopment of the capsid and the concurrent loading of the envelope glycoproteins,
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would also benefit from the spatial coupling of genome replication with the membranedependent particle envelopment step on an organelle of the vesicular secretory pathway.
Lastly, by segregating, to some extent, the viral replication process from the rest of the
cytoplasm, the viruses may have achieved a spatial separation of the genome and its
replication intermediates - both potent activators of cytoplasmic innate immune signaling
pathways - and the cytosolic innate immune sensor molecules, such as those belonging to
the RIG-I family of cytoplasmic innate immune receptors. The creation of a specialized
membranous organelle to perform viral genome replication would thus shield the virus
and the virus-infected cell from the immediate and long-term anti-viral effects of an
activated innate immune system.
HCV, like other flaviviruses, replicates its genome on an ER-derived membranous
formation, which has been described as a network of small, interconnected vesicular
structures, also called a membranous web (Egger et al., 2002; Romero-Brey and
Bartenschlager, 2014; Romero-Brey et al., 2012). The replication activities occurring
within it require the non-structural proteins NS3 through NS5B, the 5' and 3' viral
genome UTRs, as well as some RNA secondary structure-forming sequences present
within the HCV ORF (Lohmann, 2013). The NS3-5B proteins are the viral proteins both
necessary and sufficient for genome replication (Egger et al., 2002; Lohmann et al., 1999;
Moradpour et al., 2004; Moradpour et al., 2003). The NS3/4A dimer cleaves the
polyprotein and releases the other individual NS proteins such that they can perform their
respective functions (Kim et al., 1996; Love et al., 1996). NS3 also contains a helicase
domain, likely involved in RNA unwinding (Raney et al., 2010). NS4A targets NS3 to
membranes due to its amphipathic helix (Wolk et al., 2000). NS4B has a major function
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in organizing host membranes into the replication complex (Egger et al., 2002; RomeroBrey et al., 2012). NS5A has RNA binding properties and is essential for both replication
and assembly of the viral particle, but does not possess a known enzymatic activity
(Appel et al., 2008; Love et al., 2009; Tellinghuisen et al., 2008; Tellinghuisen et al.,
2004; Tellinghuisen et al., 2005). Lastly, NS5B is the RNA-dependent RNA polymerase
that replicates the viral genome (Behrens et al., 1996; Lesburg et al., 1999). This process
involves the synthesis of a complementary, negative sense copy of the viral genome,
which then serves as a template for the production of more copies of the positive sense
RNA genome. A major requirement for genome replication is the involvement of the host
cell microRNA miR-122, a tropism determinant that is also utilized by the virus to
modulate host cell gene expression (Jopling et al., 2005; Luna et al., 2015).
HCV assembly and lipoprotein association. Assembly of HCV particles is
currently believed to occur at or near cytoplasmic lipid droplets or on ER-derived
membranes (Bartenschlager et al., 2011; Lindenbach, 2013; Lindenbach and Rice, 2013).
This model is based on several observations. The HCV Core protein, which is required
for the formation of the HCV virion (Miyanari et al., 2007; Murray et al., 2007), localizes
onto lipid droplets and ER membranes (Boson et al., 2011; Miyanari et al., 2007; Murray
et al., 2007). The ability of Core to associate with the cytoplasmic surfaces of the lipid
droplets and of the ER membrane is required for viral particle assembly (Boulant et al.,
2007; Targett-Adams et al., 2008). Second, in pulse-chase time course experiments,
fluorescently labeled Core molecules were observed to relocate from their site of
synthesis (ER-bound ribosomes) to the surface of lipid droplets and then back to the ER
(Counihan et al., 2011). Furthermore, the E1/E2 glycoprotein heterodimer, required for
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particle production and entry, localizes specifically within the ER (Cocquerel et al., 1999;
Cocquerel et al., 1998), where it is presumably loaded onto the nascent viral particles
during particle envelopment. Particle assembly involves tight coordination of the
structural viral particle components (Core, E1 and E2) and some nonstructural HCV
proteins (p7, NS2, NS3, NS5A), as evidenced by their colocalization and interaction
networks, the later revealed both biochemically and genetically (Appel et al., 2008;
Gentzsch et al., 2013; Jirasko et al., 2010; Jones et al., 2011; Kim et al., 2011;
Lindenbach, 2013; Lindenbach and Rice, 2013; Ma et al., 2008; Masaki et al., 2008;
Miyanari et al., 2007; Murray et al., 2008; Popescu et al., 2011).
Production of infectious HCV also requires that cells express apolipoproteins,
such as ApoE and/or ApoB100 (Chang et al., 2007; Fukuhara et al., 2014; Gastaminza et
al., 2008; Hishiki et al., 2010; Huang et al., 2007; Hueging et al., 2014; Lee et al., 2014;
Long et al., 2011; Vogt et al., 2013). These apolipoproteins are incorporated into the
virus particles (Andre et al., 2002; Catanese et al., 2013; Chang et al., 2007; Nielsen et
al., 2006) and confer them lipoprotein-like properties, such as a light density (Andre et
al., 2002; Gastaminza et al., 2008; Gastaminza et al., 2006; Lindenbach et al., 2006;
Nielsen et al., 2006), resulting in the formation of lipoviroparticles (Andre et al., 2002).
Knockdown of ApoE or ApoB100, or inhibition of their lipidation, impairs HCV particle
production (Chang et al., 2007; Gastaminza et al., 2008; Jiang and Luo, 2009), and Core
punctate signals were shown to colocalize with ApoE punctate signals in infected cells
(Coller et al., 2012). Additionally, the E2 transmembrane domain was shown to interact
with ApoE (Lee et al., 2014). Association of ApoE and ApoB100 with HCV may serve
several functions in the viral life cycle: they may help prevent intracellular degradation of
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newly assembled HCV particles (Gastaminza et al., 2008), mediate transport of HCV
through the secretory pathway (Hishiki et al., 2010), and facilitate entry into target cells
through interactions with viral co-receptors, including LDLR (Agnello et al., 1999;
Monazahian et al., 1999), glucosaminoglycans (Germi et al., 2002) and scavenger
receptor B1 (Scarselli et al., 2002). Overall, the uniquely tight associations between HCV
and the liver-derived apolipoproteins ApoE and ApoB100, as well as the complex nature
of VLDL and HCV particle assembly and secretion from hepatocytes, invites the inquiry
of how the secretion routes of these entities are molecularly regulated.
1.18. Regulation of HCV and lipoprotein release
HCV and lipoprotein secretion has been characterized in broad terms, but
molecular details of the regulation of these processes remain somewhat sparse. Both
VLDL and HCV transit through the Golgi as they are being secreted, as both ApoB100
and HCV glycoproteins acquire glycan chain modifications that require Golgi-resident
enzyme activity (Tran et al., 2002; Vieyres et al., 2010). Furthermore, VLDL particles,
HCV and ApoE have each been colocalized or co-isolated with the Golgi (Coller et al.,
2012; Ehrenreich et al., 1973; Kockx et al., 2007). Brefeldin A, a potent and widely used
inhibitor of ER to Golgi traffic, has been shown to impair the secretion of HCV, ApoE
and ApoB100 (Deng et al., 1995; Gastaminza et al., 2008; Rustaeus et al., 1995; Ye et al.,
1992; Ye et al., 1993). Lastly, transport of ApoE and of HCV appears to occur along
microtubules, since the movement of fluorescently labeled HCV (Coller et al., 2012) or
ApoE (Kockx et al., 2007) is severely reduced by treatment with the microtubule poison
nocodazole.

44

Investigation into how HCV and lipoproteins are transported from the ER to the
Golgi remains an area of continued interest. Experiments in several systems have
documented that both HCV (Coller et al., 2012) and lipoprotein (Gusarova et al., 2003;
Jones et al., 2003; Siddiqi et al., 2003) transport depend on the activity of Sar1 GTPases.
This is consistent with the particles - at least initially - being transported by a COPII
membrane carrier, since Sar1 is the GTPase that specifically recruits COPII at the site of
vesicle formation at ER exit sites (Kuge et al., 1994; Nakano and Muramatsu, 1989).
There, VLDL may be loaded into a specialized transport vesicle, the VLDL transport
vesicle, which was found to be larger than a regular protein transport vesicle, and of a
lighter density (Siddiqi, 2008). Albumin has been shown to be transported by such
protein transport vesicles, and it was absent from the VLDL transport vesicle (Siddiqi,
2008). It is unclear at the moment whether exclusion of regular proteins from the VLDL
transport vesicle is due to passive phenomena (i.e. once a VLDL is sorted there is not
much room left in the nascent VLDL transport vesicle to package more cargo) or active
processes (i.e. the VLDL is actively concentrated into VLDL transport vesicles while the
regular proteins are actively excluded from VLDL transport vesicles and/or actively and
specifically concentrated into protein transport vesicles). Also intriguing is the finding
that ApoB100 and ApoE segregated into distinct subpopulations of in vitro-made ERderived vesicles, but were found in the same Golgi-derived vesicle population (Gusarova
et al., 2007). Since at least a fraction of the hepatic ApoE may be secreted as part of
VLDL particles (Dolphin, 1981; Reardon et al., 1998; Vance et al., 1984; Wilcox and
Heimberg, 1987), these findings suggest that ApoE-VLDL association occurs in the
Golgi, and that their transport from the ER to the Golgi occurs in separate carriers.
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Less is known about these cargoes' post-Golgi routes of secretion. They have been
shown to be partly degraded intracellularly in a post-Golgi compartment, since
degradation was sensitive to inactivation of ER to Golgi transport by brefeldin A
treatment (Deng et al., 1995; Gastaminza et al., 2008; Ye et al., 1993). Furthermore, this
post-ER degradation has been shown to be inhibited by treatment with protease inhibitors
that target endosomal cathepsin and calpain proteases (Deng et al., 1995; Gastaminza et
al., 2008; Hiwasa et al., 1990; Ye et al., 1993). It may be the case that some of these
cargoes are targeted for endolysosomal degradation, which may be reduced in the
presence of said protease inhibitors. It may also be the case that the secretion pathway(s)
of these cargoes passes through an endosomal compartment, where some cargo becomes
degraded. Indeed, release of HCV particles has been shown to be reduced when Rab11a
expression was impaired (Coller et al., 2012). Rab11a is a defining marker of recycling
endosomes (Ullrich et al., 1996), as I will more fully explain in Chapter 4. HCV secretion
was also reduced when Rab3d expression was knocked down (Coller et al., 2012). Rab3d
(also known as Rab16) is known to function at late exocytic steps (Fukuda, 2008) and
may thus regulate the final transport steps of HCV secretion. Differences nevertheless do
appear to exist between post-Golgi HCV and VLDL transport, since HCV transport was
impaired when expression of the γ-1 subunit of the clathrin adaptor protein complex AP1 was knocked down, while VLDL secretion was unaffected (Benedicto et al., 2015).
Characterization in greater detail of the molecular basis of post-Golgi transport of
HCV and of lipoprotein particles is in order. Such work also needs to account for other
known aspects of intracellular transport of HCV and of lipoprotein components. A major
concern is the need to distinguish, particularly in imaging experiments, between secretory
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behavior of newly synthesized cargo and endocytic recycling of cargo up-taken from the
extracellular space. ApoE, for example, was shown to be a recycled cargo, although
ApoB was not, but was instead targeted for lysosomal degradation (Heeren et al., 2003;
Laatsch et al., 2012). HCV, in turn, enters cells through receptor mediated endocytosis
(Coller et al., 2009). It is unclear to what extent newly endocytosed particles may reach a
compartment that may also function in secretion, such as the recycling endosome (Coller
et al., 2012), and how transport of endocytosed infectious viruses differs, if at all, from
transport of endocytosed non-infectious viruses, which form the majority of the particles
even in some of the most enriched infectious virus preparations (Catanese et al., 2013;
Gastaminza et al., 2010).
Any interpretation of experimental findings documenting the involvement of one
pathway or the other in HCV or lipoprotein secretion must also account for the possibility
that one single pathway may not be exclusively or even primarily responsible for cargo
release.
1.19. Significance
As repeatedly emphasized above, the hepatic cargoes that are the focus of the
studies I present here serve essential functions in the human body. Maintenance of
circulatory system homeostasis and lipid transport are the most obvious of these functions
(Ha and Bhagavan, 2013; Olofsson and Boren, 2005; Yamasaki et al., 2013; Zannis et al.,
2015). The disease association of these cargoes is extensive. Atherosclerotic
cardiovascular disease is a leading cause of morbidity and mortality worldwide (Barquera
et al., 2015). The pathologies associated with HCV infection are also numerous and can
severely affect human life (Hoofnagle, 1997; Thomas, 2013). Understanding the
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processes involved in the production of these bioparticles is thus necessary, and may, in
the long run, provide avenues for therapeutic intervention.
From a cell biological perspective, this topic is of interest because it deals with a
particularly challenging question: how are large cargoes, such as VLDL or HCV
particles, transported by the secretory pathway, given that documented sizes of transport
vesicles appear to be insufficient to allow for packaging of these large cargoes (Miller
and Schekman, 2013)? Indeed, intensive recent research efforts have dealt with how such
cargoes are packaged into COPII-dependent ER-derived vesicles (Jin et al., 2012;
Mansbach and Siddiqi, 2010). While my work does not address the sorting of large
cargoes into the transport carriers per se, it nevertheless touches on the question of
whether there are any differences between the transport regulation of carriers that shuttle
regularly-sized proteins, such as albumin, and those that transport the large lipoprotein
and viral particles. This body of work also lays the groundwork for addressing the
question of how polarized transport of lipoproteins and of HCV is regulated by the
hepatocyte.
Lastly, the analysis of HCV and lipoprotein secretion must be undertaken while
considering the evolutionary history of the virus. That HCV has evolved to be so closely
associated with the hepatic lipoproteins is a testimony to how well the virus has "learned"
the cell biology of the hepatocyte (Lindenbach, 2013; Lindenbach and Rice, 2013; Scheel
and Rice, 2013). Delineating which transport pathways are common for HCV and
lipoproteins, and which are distinct, may well advance the understanding of both host and
pathogen cell biology. This line of inquiry conceptually mirrors the study of the exocytic
transport of the vesicular stomatitis virus glycoprotein (VSVg), which has helped define
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major features of secretory vesicular traffic (Bergmann, 1989), or the study of viral and
bacterial toxin entry, which have facilitated the investigation of important endocytic
processes (Pelkmans, 2005; Schiavo and van der Goot, 2001).
1.20. Aims
Given the biomedical importance of the lipoproteins and HCV alike, and given
the complex and interconnected cell biology that is involved in the production of these
cargoes by hepatocytes, I set out to define and characterize molecular, spatial and
temporal aspects of lipoprotein and HCV egress. My work aimed to: (i) identify the
transport regulators of HCV and lipoprotein particle secretion by means of performing a
screen using DN mutants of the Rab GTPases; (ii) confirm and describe the involvement
of specified members of the Rab family in these secretory processes,; and (iii) validate
fluorescent protein-tagged versions of the Rab GTPases and of cargoes as useful tools in
live-cell imaging analyses of hepatic cargo secretion. I now compile the work I have
performed to date, and describe some avenues of investigation that I believe future work
could successfully pursue. This thesis will thus describe at length the methodology used
to advance this project. I will then present the design and the results of the DN Rab
GTPase screen that I used to unbiasedly identify regulators of hepatic cargo secretion. I
will describe ongoing investigations into how Rab11 and Rab8 GTPases may control
lipoprotein and HCV secretion, and the characterization of Rab1 involvement in the same
processes. I will also describe the tests I performed to determine whether fluorescent
protein-tagged ApoE might be used in the study of hepatic lipoprotein and HCV
secretion. Throughout the pages, I will also discuss how the approaches and the assays
that I have utilized may be improved and adapted to other lines of investigation.
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Chapter 2.
Materials and Methods.

2.1. DNA manipulations
Standard molecular biology protocols were used to construct or modify the
plasmids used in this work, as described below. Polymerase chain reaction (PCR) using
Platinum PCR Supermix (Life Technologies) or Takara polymerase (Clontech) was
performed to amplify DNA fragments, which were then digested using New England
Biolabs restriction endonucleases and ligated (Quick Ligase, New England Biolabs) into
target vectors. Alternatively, the In-Fusion HD kit (Clontech) was employed, according
to the manufacturer's instructions, to insert DNA fragments into target vectors. Sitedirected mutagenesis (SDM) was performed using the Quick Change Lightning Site
Directed Mutagenesis kit (Agilent) according to the manufacturer's instructions. Plasmids
were transformed and grown in the DH5α E. coli strain at 30°C (retroviral and lentiviral
vectors) or at 37°C (all other vectors) in LB medium or terrific broth (Difco). Ampicillin
was used at 100 μg/mL and kanamycin was used at 50 μg/mL for selection. DNA was
isolated using Purelink Quick Plasmid Miniprep, Quick Gel Extraction or HiPure Plasmid
Maxiprep kits (Life Technologies). Plasmids and some of their relevant features are listed
in Table 2.1, while the text below also describes the steps undertaken to make these
constructs. Table 2.1 also includes a series of plasmids that were used as templates for
amplification of various DNA sequences, or as vector backbones. The references or
commercial sources for the various plasmids used in this work are also listed in Table
2.1. For the Rab-encoding plasmids that I used in the DN Rab screen part of this work, I
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also list in Table 2.1 the NCBI reference sequence number of the respective WT human
Rab proteins. The nucleotide sequences of the DNA primers employed during the
plasmid construction process are listed in Table 2.2, and the primers are referred to in the
text by their names. They were chemically synthesized by IDT. The nucleotide sequences
of the relevant features of both intermediate and final constructs were confirmed using
DNA sequencing by Genewiz or Macrogen.
Table 2.1. Plasmids
Construct

Relevant Features

Non-viral plasmids
pCR3.1 SynGag

HIV-1 Gag

pMLV GagPol

MLV GagPol

pVSVg
pHCMV-VSVg

VSVg
VSVg

pVSVgtsO45-GFP

PCMV VSVgtsO45-GFP Retained in the ER
at 39.5°C
PCMV MCS-mEGFP
EGFPA206K
PCMV MCS-mCherry
PCMV GFP-DrrA61-647 L. pneumophila
effector
Rab10
Rab12
Calnexin
Rab1a
Rab1b
Rab1c/35
Rab3d/16
Rab5b
Rab5c
Rab13
Rab21
Rab22a
Rab23
Rab27a
Rab27b
Rab38
Rab2a

pmEGFP-N1
pmCherry-N1
pGFP-DrrA61-647
pCMV-XL5 Rab10
pCMV-XL5 Rab12
pCMV-XL5 Calnexin
pCMV-SPORT6 Rab1a
pCMV-SPORT6 Rab1b
pCMV-SPORT6 Rab1c/35
pCMV-SPORT6 Rab3d/16
pCMV-SPORT6 Rab5b
pCMV-SPORT6 Rab5c
pCMV-SPORT6 Rab13
pCMV-SPORT6 Rab21
pCMV-SPORT6 Rab22a
pCMV-SPORT6 Rab23
pCMV-SPORT6 Rab27a
pCMV-SPORT6 Rab27b
pCMV-SPORT6 Rab38
pOTB7-Rab2a
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Notes

Retrovirus
packaging vector
Pseudotyping
vectors

Source or
Reference
(Graf et al.,
2000)
(Jouvenet et
al., 2009)
Clontech
(Beyer et
al., 2002)
(Presley et
al., 1997)
Lab plasmid
Clontech
(Murata et
al., 2006)
Origene

Mammalian
Gene
Collection,
Open
Biosystems

Table 2.1. Plasmids
Construct

Relevant Features

pOTB7-Rab3b
pOTB7-Rab4b
pOTB7-Rab6a
pOTB7-Rab7a
pOTB7-Rab8a
pOTB7-Rab11c/25
pOTB7-Rab22b/31
pOTB7-Rab24
pOTB7-Rab33a
pOTB7-Rab43
pDNR-LIB-Rab2b
pDNR-LIB-Rab8b
pDNR-LIB-Rab32
pBlueScriptR-Rab15
pBlueScriptR-Rab33b
pCR-TOPO-Rab11b
pCR-TOPO-Rab36
pCDNA5 Flag3-Rab5a

Rab3b
Rab4b
Rab6a
Rab7a
Rab8a
Rab11c/25
Rab22b/31
Rab24
Rab33a
Rab43
Rab2b
Rab8b
Rab32
Rab15
Rab33b
Rab11b
Rab36
Rab5a

pEGFP-Rab11aWT

Rab11a

pEGFP-Rab18
HCV plasmids
pFL J6/JFH1

Rab18

Lentiviral plasmids
pCR/V1 NL GagPol
pLX304 Rab3a
pLX304 Rab3c
pLX304 Rab4a
pLX304 Rab6b
pLX304 Rab6c
pLX304 Rab7b
pLX304 Rab9a
pLX304 Rab9b
pLX304 Rab14
pLX304 Rab17
pLX304 Rab19b
pLX304 Rab20
pLX304 Rab26
pLX304 Rab7L1/29
pLX304 Rab30

Notes

Obtained from
Addgene

Source or
Reference

(Sun et al.,
2010a)
(Choudhury
et al., 2002)
Lab plasmid

PT7 HCV J6/JFH1
cDNA

For in vitro
transcription

(Lindenbach
et al., 2005)

HIV-1 GagPol +
accessory genes
Rab3a
Rab3c
Rab4a
Rab6b
Rab6c
Rab7b
Rab9a
Rab9b
Rab14
Rab17
Rab19b
Rab20
Rab26
Rab7L1/29
Rab30

Lentivirus
packaging vector

(Zennou et
al., 2004)
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(Yang et al.,
2011)

Table 2.1. Plasmids
Construct
pLX304 Rab34
pLX304 Rab37
pLX304 Rab39a
pLX304 Rab39b
pLX304 Rab40a
pLX304 Rab40al
pLX304 Rab40b
pLX304 Rab40c
pLX304 Rab41
pLVX Puro
pLenti4/V5-Dest
pLVX Bhi3
pLVX Hhi3
pLVX Nhi3
pLVX Phi3
pLVX Zhi3
pLVX Che-hi3
pLVX Hhi3 ApoE3
pLVX Hhi3 ApoE3mEGFP
pLVX Bhi3 mEGFPApoE3
pLVX Phi3 mCherry
pLVX Phi3 FLuc
pLVX Bhi3 FLuc
OL135 pLVX Phi3
mCherry-Rab1b
OL115 pLVX Phi3
mCherry-Rab1bQ67L
OL142 pLVX Phi3
mCherry-Rab1bS22N
OL143 pLVX Phi3
mCherry-Rab1bN121I
OL177 pLVX Che-hi3
Rab1b

Relevant Features
Rab34
Rab37
Rab39a
Rab39b
Rab40a
Rab40al
Rab40b
Rab40c
Rab41
PCMV MCS;
PPGK PuroR
ZeoR
PCMV MCS;
PPGK BlastR
PCMV MCS;
PPGK HygroR
PCMV MCS; PPGK
NeoR
PCMV MCS;
PPGK PuroR
PCMV MCS; PPGK
ZeoR
PCMV MCS;
PPGK mCherry
PCMV ApoE3
PCMV ApoE3mEGFP
PCMV SP-mEGFPApoE3
PCMV mCherry

Notes

Clontech
Invitrogen
This study
Improved MCS
and varied
eukaryotic
antibiotic selection
markers
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This study
This study
This study
This study

mCherry reporter
vector
ApoE3 engineered
to be knockdown resistant

This study
This study
This study
This study

mCherry control
expression vector

PCMV FLuc
PCMV mCherryRab1b
PCMV mCherryRab1bQ67L
PCMV mCherryRab1bS22N
PCMV mCherryRab1bN121I
PCMV hab1b

Source or
Reference

This study
This study
This study
This study
This study
This study
This study

NP_112243.1

This study

Table 2.1. Plasmids
Construct
OL178 pLVX Che-hi3
Rab1bN121I
OL249 pLVX Che-hi3
Rab1bQ67L
OL250 pLVX Che-hi3
Rab1bS22N
OL 175 pLVX Che-hi3
Rab1a
OL 176 pLVX Che-hi3
Rab1aN124I
OL179 pLVX Che-hi3
Rab1c/35
OL180 pLVX Che-hi3
Rab1c/35N120I
OL181 pLVX Che-hi3
Rab2a
OL182 pLVX Che-hi3
Rab2aN119I
OL183 pLVX Che-hi3
Rab3a
OL184 pLVX Che-hi3
Rab3aN135I
OL185 pLVX Che-hi3
Rab3b
OL186 pLVX Che-hi3
Rab3bN135I
OL187 pLVX Che-hi3
Rab3c
OL188 pLVX Che-hi3
Rab3cN143I
OL189 pLVX Che-hi3
Rab3d/16
OL190 pLVX Che-hi3
Rab3d/16N135I
OL191 pLVX Che-hi3
Rab4a
OL192 pLVX Che-hi3
Rab4aN126I
OL193 pLVX Che-hi3
Rab5a
OL194 pLVX Che-hi3
Rab5aN133I

Relevant Features
PCMV Rab1bN121I

Source or
Reference
This study

PCMV Rab1bQ67L

This study

PCMV Rab1bS22N

This study

PCMV Rab1a

Notes

NP_004152.1

PCMV Rab1aN124I
PCMV Rab1c/35

This study
NP_006852.1

PCMV Rab1c/35N120I
PCMV Rab2a

NP_002856.1

NP_002857.1

NP_002858.2

NP_612462.1

NP_004274.1

PCMV Rab5aN133I
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This study
This study

NP_004569.2

PCMV Rab4aN126I
PCMV Rab5a

This study
This study

PCMV Rab3d/16N135I
PCMV Rab4a

This study
This study

PCMV Rab3cN143I
PCMV Rab3d/16

This study
This study

PCMV Rab3bN135I
PCMV Rab3c

This study
This study

PCMV Rab3aN135I
PCMV Rab3b

This study
This study

PCMV Rab2aN119I
PCMV Rab3a

This study

This study
This study

NP_004153.2

This study
This study

Table 2.1. Plasmids
Construct
OL195 pLVX Che-hi3
Rab6a
OL196 pLVX Che-hi3
Rab6aN126I
OL197 pLVX Che-hi3
Rab7b
OL198 pLVX Che-hi3
Rab7bN124I
OL199 pLVX Che-hi3
Rab8a
OL200 pLVX Che-hi3
Rab8aN121I
OL319 pLVX Che-hi3
Rab8aQ67L
OL320 pLVX Che-hi3
Rab8aT22N
OL201 pLVX Che-hi3
Rab8b
OL202 pLVX Che-hi3
Rab8bN121I
OL321 pLVX Che-hi3
Rab8bQ67L
OL322 pLVX Che-hi3
Rab8bT22N
OL203 pLVX Che-hi3
Rab9a
OL204 pLVX Che-hi3
Rab9aN124I
OL205 pLVX Che-hi3
Rab10
OL206 pLVX Che-hi3
Rab10N122I
OL207 pLVX Che-hi3
Rab11a
OL208 pLVX Che-hi3
Rab11aN124I
OL313 pLVX Che-hi3
Rab11aQ70L
OL314 pLVX Che-hi3
Rab11aS25N
OL209 pLVX Che-hi3
Rab11b

Relevant Features

Notes

PCMV Rab6a

NP_002860.2

PCMV Rab6aN126I
PCMV Rab7b

This study
NP_796377.3

PCMV Rab7bN124I
PCMV Rab8a

Source or
Reference
This study

This study
This study

NP_005361.2

This study

PCMV Rab8aN121I

This study

PCMV Rab8aQ67L

This study

PCMV Rab8aT22N

This study

PCMV Rab8b

NP_057614.1

This study

PCMV Rab8bN121I

This study

PCMV Rab8bQ67L

This study

PCMV Rab8bT22N

This study

PCMV Rab9a

NP_004242.1

PCMV Rab9aN124I
PCMV Rab10

This study
NP_057215.3

PCMV Rab10N122I
PCMV Rab11a

This study

This study
This study

NP_004654.1

This study

PCMV Rab11aN124I

This study

PCMV Rab11aQ70L

This study

PCMV Rab11aS25N

This study

PCMV Rab11b
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NP_004209.2

This study

Table 2.1. Plasmids
Construct
OL210 pLVX Che-hi3
Rab11bN124I
OL315 pLVX Che-hi3
Rab11bQ70L
OL316 pLVX Che-hi3
Rab11bS25N
OL211 pLVX Che-hi3
Rab11c/25
OL212 pLVX Che-hi3
Rab11c/25N125I
OL213 pLVX Che-hi3
Rab12
OL214 pLVX Che-hi3
Rab12N155I
OL215 pLVX Che-hi3
Rab13
OL216 pLVX Che-hi3
Rab13N121I
OL217 pLVX Che-hi3
Rab14
OL218 pLVX Che-hi3
Rab14N124I
OL219 pLVX Che-hi3
Rab18
OL220 pLVX Che-hi3
Rab18N122I
OL221 pLVX Che-hi3
Rab19b
OL222 pLVX Che-hi3
Rab19bN130I
OL223 pLVX Che-hi3
Rab22b/31
OL224 pLVX Che-hi3
Rab22b/31N119I
OL225 pLVX Che-hi3
Rab23
OL226 pLVX Che-hi3
Rab23N121I
OL227 pLVX Che-hi3
Rab26
OL228 pLVX Che-hi3
Rab26N177I

Relevant Features
PCMV Rab11bN124I

Source or
Reference
This study

PCMV Rab11bQ70L

This study

PCMV Rab11bS25N

This study

PCMV Rab11c/25

Notes

NP_065120.2

PCMV Rab11c/25N125I
PCMV Rab12

This study
NP_001020471.2

PCMV Rab12N155I
PCMV Rab13

NP_002861.1

NP_057406.2

NP_067075.1

NP_001008749.2

NP_006859.2

PCMV Rab26N177I
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This study
This study

NP_057361.3

PCMV Rab23N121I
PCMV Rab26

This study
This study

PCMV Rab22b/31N119I
PCMV Rab23

This study
This study

PCMV Rab19bN130I
PCMV Rab22b/31

This study
This study

PCMV Rab18N122I
PCMV Rab19b

This study
This study

PCMV Rab14N124I
PCMV Rab18

This study
This study

PCMV Rab13N121I
PCMV Rab14

This study

This study
This study

NP_055168.2

This study
This study

Table 2.1. Plasmids
Construct
OL229 pLVX Che-hi3
Rab27a
OL230 pLVX Che-hi3
Rab27aN133I
OL231 pLVX Che-hi3
Rab27b
OL232 pLVX Che-hi3
Rab27bN133I
OL233 pLVX Che-hi3
Rab32
OL234 pLVX Che-hi3
Rab32N143I
OL235 pLVX Che-hi3
Rab33a
OL236 pLVX Che-hi3
Rab33aN151I
OL237 pLVX Che-hi3
Rab39a
OL238 pLVX Che-hi3
Rab39aH127I
OL239 pLVX Che-hi3
Rab40a
OL240 pLVX Che-hi3
Rab40aN126I
OL251 pLVX Che-hi3
Rab2b
OL252 pLVX Che-hi3
Rab2bN119I
OL253 pLVX Che-hi3
Rab4b
OL254 pLVX Che-hi3
Rab4bN121I
OL255 pLVX Che-hi3
Rab5b
OL256 pLVX Che-hi3
Rab5bN133I
OL257 pLVX Che-hi3
Rab5c
OL258 pLVX Che-hi3
Rab5cN134I
OL259 pLVX Che-hi3
Rab6b

Relevant Features

Notes

PCMV Rab27a

NP_004571.2

PCMV Rab27aN133I
PCMV Rab27b

This study
NP_004154.2

PCMV Rab27bN133I
PCMV Rab32

NP_006825.1

NP_004785.1

NP_059986.1

NP_543155.2

NP_116235.2

NP_057238.3

NP_002859.1
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This study
This study

NP_004574.2

PCMV Rab5cN134I
PCMV Rab6b

This study
This study

PCMV Rab5bN133I
PCMV Rab5c

This study
This study

PCMV Rab4bN121I
PCMV Rab5b

This study
This study

PCMV Rab2bN119I
PCMV Rab4b

This study
This study

PCMV Rab40aN126I
PCMV Rab2b

This study
This study

PCMV Rab39aH127I
PCMV Rab40a

This study
This study

PCMV Rab33aN151I
PCMV Rab39a

This study
This study

PCMV Rab32N143I
PCMV Rab33a

Source or
Reference
This study

This study
This study

NP_057661.3

This study

Table 2.1. Plasmids
Construct
OL260 pLVX Che-hi3
Rab6bN126I
OL261 pLVX Che-hi3
Rab6c
OL262 pLVX Che-hi3
Rab6cN126I
OL263 pLVX Che-hi3
Rab7a
OL264 pLVX Che-hi3
Rab7aN125I
OL265 pLVX Che-hi3
Rab9b
OL266 pLVX Che-hi3
Rab9bN124I
OL267 pLVX Che-hi3
Rab15
OL268 pLVX Che-hi3
Rab15T22N
OL269 pLVX Che-hi3
Rab17
OL270 pLVX Che-hi3
Rab17N132I
OL271 pLVX Che-hi3
Rab20
OL272 pLVX Che-hi3
Rab20N113I
OL274 pLVX Che-hi3
Rab21
OL274 pLVX Che-hi3
Rab21N132I
OL275 pLVX Che-hi3
Rab22a
OL276 pLVX Che-hi3
Rab22aN118I
OL277 pLVX Che-hi3
Rab24
OL278 pLVX Che-hi3
Rab24T120I
OL279 pLVX Che-hi3
Rab28
OL280 pLVX Che-hi3
Rab28N129I

Relevant Features

Notes

Source or
Reference
This study

NP_115520.2

This study

PCMV Rab6bN126I
PCMV Rab6c
PCMV Rab6cN126I
PCMV Rab7a

This study
NP_004628.4

PCMV Rab7aN125I
PCMV Rab9b

This study
NP_057454.1

PCMV Rab9bN124I
PCMV Rab15

NP_941959.1

NP_071894.1

NP_060287.1

NP_055814.1

NP_065724.1

PCMV Rab28N129I
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This study
This study

NP_570137.2

PCMV Rab24T120I
PCMV Rab28

This study
This study

PCMV Rab22aN118I
PCMV Rab24

This study
This study

PCMV Rab21N132I
PCMV Rab22a

This study
This study

PCMV Rab20N113I
PCMV Rab21

This study
This study

PCMV Rab17N132I
PCMV Rab20

This study
This study

PCMV Rab15T22N
PCMV Rab17

This study

This study
This study

NP_004240.2

This study
This study

Table 2.1. Plasmids
Construct
OL281 pLVX Che-hi3
Rab29/7L1
OL282 pLVX Che-hi3
Rab29/7L1N125I
OL283 pLVX Che-hi3
Rab30
OL284 pLVX Che-hi3
Rab30N122I
OL285 pLVX Che-hi3
Rab33b
OL286 pLVX Che-hi3
Rab33bN148I
OL287 pLVX Che-hi3
Rab34
OL288 pLVX Che-hi3
Rab34S166I
OL289 pLVX Che-hi3
Rab36
OL290 pLVX Che-hi3
Rab36T237I
OL291 pLVX Che-hi3
Rab37
OL292 pLVX Che-hi3
Rab37N143I
OL293 pLVX Che-hi3
Rab38
OL294 pLVX Che-hi3
Rab38N127I
OL295 pLVX Che-hi3
Rab39b
OL296 pLVX Che-hi3
Rab39bH123I
OL297 pLVX Che-hi3
Rab40al
OL298 pLVX Che-hi3
Rab40alN126I
OL299 pLVX Che-hi3
Rab40b
OL300 pLVX Che-hi3
Rab40bN126I
OL301 pLVX Che-hi3
Rab40c

Relevant Features

Notes

PCMV Rab29/7L1

NP_003920.1

PCMV Rab29/7L1N125I
PCMV Rab30

This study
NP_055303.2

PCMV Rab30N122I
PCMV Rab33b

NP_112586.1

NP_114140.4

NP_004905.2

NP_001006639.1

NP_071732.1

NP_741995.1

NP_001027004.1
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This study
This study

NP_006813.1

PCMV Rab40bN126I
PCMV Rab40c

This study
This study

PCMV Rab40alN126I
PCMV Rab40b

This study
This study

PCMV Rab39bH123I
PCMV Rab40al

This study
This study

PCMV Rab38N127I
PCMV Rab39b

This study
This study

PCMV Rab37N143I
PCMV Rab38

This study
This study

PCMV Rab36T237I
PCMV Rab37

This study
This study

PCMV Rab34S166I
PCMV Rab36

This study
This study

PCMV Rab33bN148I
PCMV Rab34

Source or
Reference
This study

This study
This study

NP_066991.3

This study

Table 2.1. Plasmids
Construct
OL302 pLVX Che-hi3
Rab40cN126I
OL303 pLVX Che-hi3
Rab41
OL304 pLVX Che-hi3
Rab41N143I
OL305 pLVX Che-hi3
Rab42
OL306 pLVX Che-hi3
Rab42H129I
OL307 pLVX Che-hi3
Rab43
OL308 pLVX Che-hi3
Rab43N131I
Lentiviral shRNA plasmids
pLKO.1
pLKO.1 shApoE

Relevant Features

Notes

Source or
Reference
This study

NP_001027898.2

This study

PCMV Rab40cN126I
PCMV Rab41
PCMV Rab41N143I
PCMV Rab42

This study
NP_001180461.1

PCMV Rab42H129I
PCMV Rab43

This study
NP_940892.1

PCMV Rab43N131I

shApoE,
NM_000041

Retroviral plasmids
LMNI

IRES-BlastR

pLHCX
pLNCX2
pRetroX Tet3G

HygroR
NeoR
PCMV-TetON3G

pRetroX TRE3G

PTRE3G-MCS

pRetroX TRE3G-FLuc
pRetroX TRE3G-mCherry
OR161 pRetroX TRE3G
mCherry-Rab1b
OR162 pRetroX TRE3G
mCherry-Rab1bQ67L
OR163 pRetroX TRE3G
mCherry-Rab1bS22N
OR164 pRetroX TRE3G
mCherry-Rab1bN121I
OR366 pRetroX TRE3G
mEGFP
OR367 pRetroX TRE3G
GFP-DrrA61-647

PTRE3G-FLuc
PTRE3G mCherry
PTRE3G mCherryRab1b
PTRE3G mCherryRab1bQ67L
PTRE3G mCherryRab1bS22N
PTRE3G mCherryRab1bN121I
PTRE3G mEGFP
PTRE3G
GFP-DrrA61-647
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This study

This study
This study

Clone ID
TRCN0000010913

Expresses TetON
3G reverse
transactivator
For Dox-inducible
expression

Dharmacon
Broad
Institute
(Jouvenet et
al., 2009)
Clontech
Clontech
Clontech
Clontech
Clontech
This study
This study
This study
This study
This study
This study
This study

Table 2.1. Plasmids
Construct

Relevant Features

Notes

Source or
Reference
This study

PTRE3G mCherryOR332 pRetroX TRE3G
Rab11a
mCherry-Rab11a
PTRE3G mCherryThis study
OR333 pRetroX TRE3G
Rab11aN124I
mCherry-Rab11aN124I
PTRE3G mCherryThis study
OR334 pRetroX TRE3G
Rab11aQ70L
mCherry-Rab11aQ70L
PTRE3G mCherryThis study
OR336 pRetroX TRE3G
Rab11aS25N
mCherry-Rab11aS25N
This study
PTRE3G mCherryOR337 pRetroX TRE3G
Rab11b
mCherry-Rab11b
PTRE3G mCherryThis study
OR338 pRetroX TRE3G
Rab11bN124I
mCherry-Rab11bN124I
PTRE3G mCherryThis study
OR340 pRetroX TRE3G
Rab11bQ70L
mCherry-Rab11bQ70L
PTRE3G mCherryThis study
OR341 pRetroX TRE3G
Rab11bS25N
mCherry-Rab11bS25N
This study
PTRE3G mCherryOR342 pRetroX TRE3G
Rab8a
mCherry-Rab8a
PTRE3G mCherryThis study
OR344 pRetroX TRE3G
Rab8aN121I
mCherry-Rab8aN121I
PTRE3G mCherryThis study
OR345 pRetroX TRE3G
Rab8aQ67L
mCherry-Rab8aQ67L
PTRE3G mCherryThis study
OR346 pRetroX TRE3G
Rab8aT22N
mCherry-Rab8aT22N
PTRE3G mCherryThis study
OR348 pRetroX TRE3G
Rab8b
mCherry-Rab8b
PTRE3G mCherryThis study
OR349 pRetroX TRE3G
Rab8bN121I
mCherry-Rab8bN121I
PTRE3G mCherryThis study
OR350 pRetroX TRE3G
Rab8bQ67L
mCherry-Rab8bQ67L
PTRE3G mCherryThis study
OR356 pRetroX TRE3G
Rab8bT22N
mCherry-Rab8bT22N
Abbreviations: MLV, murine leukemia virus; HIV-1, human immunodeficiency virus 1;
PCMV, cytomegalovirus (CMV) promoter; PPGK, phosphoglycerate kinase (PGK)
promoter; PTRE3G, third generation tetracycline response element (TRE) promoter; MCS,
multicloning site; SP, signal peptide; FLuc, firefly luciferase; BlastR, blasticidin
resistance gene, blasticidin S deaminase, bsd; HygroR, hygromycin resistance gene,
hygromycin B phosphotransferase, hph; NeoR, neomycin/kanamycin resistance gene,
neomycin phosphotransferase, npt; PuroR, puromycin resistance gene, puromycin Nacetyl-transferase, pac; ZeoR, zeocin/bleomycin/phleomycin resistance gene, ble.
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2.2. Modified lentivirus expression vectors
To allow for versatile expression of multiple constructs in the same cell, a palette
of lentiviral expression vectors was constructed. The vectors are listed in Table 2.1 and
some of their relevant features are depicted in Figure 2.1. These vectors were derived
from pLVX Puro, and were engineered to carry antibiotic resistance markers that allowed
transduced cells to be selected with one of the following antibiotics: puromycin (P),
blasticidin (B), hygromycin (H), neomycin or its substitute, G418, (N) , zeocin (Z) or the
fluorescent protein reporter mCherry (Che). The multicloning site (MCS) was also
expanded in steps. The name of each vector includes all the relevant information about
the vector. For example, in the case of pLVX Phi3: pLVX signifies that the backbone of
the vector was derived from Clontech's pLVX Puro; P in Phi3 signifies that the
resistance/reporter gene is the puromycin resistance gene; hi in Phi3 signifies that gene
expression from the MCS is controlled by the high expression cytomegalovirus (CMV)
promoter; and, lastly, 3, in Phi3 signifies that the 3rd generation of expanded MCS can
be found in this vector. Since all these vectors contain the same MCS, transfer of genes
among them can be easily achieved by a simple "cut/paste" reaction: cutting the insert
from the donor vector with suitable restriction enzymes followed by ligation between the
same sites in the target vector. Here follow the cloning steps that I used to make these
vectors. I thank Brenna Flatley and Rachel Belote for performing some of these steps.
pLVX Phi3. An improved MCS DNA, containing sequences cleaved, in order, by
the following restriction endonucleases: 5'-ClaI-BlpI-BclI-AgeI-AfeI-HindIII-BglIIXhoI-EcoRI-NotI-BspEI-MluI-SalI-MfeI-PspOMI-ApaI-NsiI-SphI-AvrII-NgoMIVNaeI-HpaI-AsiSI-SbFI-BamHI-ClaI-3', was custom synthesized into the pUC57-Amp
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vector (Genewiz). The improved MCS was excised as a ~100 base-pair (bp) AfeI/BamHI
fragment from pUC57-Amp-MCS and ligated into the AfeI/BamHI backbone of pLVX
Puro to form pLVX Phi. A modified pSL1180 cloning vector, named pSL1180.1, was
obtained by digesting pSL1180 with AfeI and SmaI followed by re-ligation of the
purified vector backbone. The ~1.9 kbp XbaI/KpnI fragment of pLVX Puro was ligated
into XbaI/KpnI-cut pSL1180.1. In this vector, the BsiWI site within the PuroR gene was
mutated by SDM using primers NT430 and NT431. The mutation is silent. The resulting
XbaI/KpnI fragment was reinserted into the XbaI/KpnI sites of pLVX Phi. Primers
NT454 and NT455 were annealed to each other and then ligated into the XbaI/BamHI
sites of the vector to further improve the MCS.

Figure 2.1. Organization of lentiviral and retroviral vectors. (A) pLVX-based vectors
expressing an antibiotic selection marker; (B) pLVX Che-hi3 vector expressing an
mCherry fluorescent protein reporter in lieu of the antibiotic resistance; (C and D)
retroviral vectors used to make inducible expression cell lines. (C) pRetroX Tet3G vector
used to generate Huh-7.5 TetON clonal cell lines. It constitutively expresses a TetON3G
reverse transactivator. (D) pRetroX TRE3G-based vectors used to transduce the Huh-7.5
TetON clonal cell lines. The TetON3G reverse transactivator binds to the Tetracycline
Response Element TRE3G in the presence of doxycycline and induces gene expression.
LTR, long terminal repeat; ψ, packaging signal; PCMV, CMV promoter; MCS,
multicloning site; GOI, gene of interest; PPGK, phosphoglycerate kinase promoter; AbR,
antibiotic resistance marker; IRES, internal ribosome entry site; NeoR, neomycin
resistance; PTRE3GV, virus-adapted TRE3G promoter; PuroR, puromycin resistance.
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pLVX Bhi3. The PGK promoter sequence of pLVX Puro was amplified using
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) sequence was
PCR amplified from pLVX Puro using primers NT189 and NT190, then digested with
AbsI and KpnI. The Blasticidin resistance gene BlastR was PCR amplified from LMNI
using primers NT197 and NT198, then digested with AbsI and XmaI. These three
fragments were assembled between the XbaI and KpnI sites of pSL1180.1 to form PPGKBlastR-WPRE. In this construct, the XhoI site at the 5’ end of BlastR was mutated by
SDM using primers NT438 and NT439, and the XmaI site at the 3’ end of BlastR was
mutated by SDM using primers NT440 and NT441. The resulting ~1.7 kilobase-pair
(kbp) XbaI/KpnI fragment was ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX
Phi. Primers NT454 and NT455 were annealed to each other and then ligated into the
XbaI/BamHI sites of the vector to further improve the MCS.
pLVX Hhi3. The PGK promoter sequence of pLVX Puro was amplified using
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then
digested with AbsI and KpnI. The Hygromycin resistance gene HygroR was PCR
amplified from pLHCX using primers NT195 and NT196, then digested with AbsI and
XmaI. These three fragments were assembled between the XbaI and KpnI sites of
pSL1180.1 to form PPGK-HygroR-WPRE. The EcoRI site within the HygroR gene was
mutated by SDM using primers NT432 and NT433. The AsiSI site within the HygroR
gene was mutated by SDM using primers NT434 and NT435. The mutations are silent.
The XhoI site at the 5’ end of the HygroR gene was mutated by SDM using primers
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NT442 and NT443. The XmaI site at the 3’ end of the HygroR gene of was mutated by
SDM using primers NT444 and NT445. The resulting ~2.3 kbp XbaI/KpnI fragment was
ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX Phi. Primers NT454 and NT455
were annealed to each other and then ligated into the XbaI/BamHI sites of the vector to
further improve the MCS.
pLVX Nhi3 The PGK promoter sequence of pLVX Puro was amplified using
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then
digested with AbsI and KpnI. The Neomycin resistance gene NeoR was PCR amplified
from pLNCX2 using primers NT193 and NT194 and digested with AbsI and XmaI.
These three fragments were assembled between the XbaI and KpnI sites of pSL1180.1 to
form PPGK-NeoR-WPRE. The XhoI site at the 5’ end of the NeoR gene of was mutated
by SDM using primers NT446 and NT447. The XmaI site at the 3’ end of the NeoR gene
was mutated by SDM using primers NT448 and NT449. The resulting ~2.1 kbp
XbaI/KpnI fragment was ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX Phi.
Primers NT454 and NT455 were annealed to each other and then ligated into the
XbaI/BamHI sites of the vector to further expand the MCS.
pLVX Zhi3. The PGK promoter sequence of pLVX Puro was amplified using
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then
digested with AbsI and KpnI. The Zeocin resistance gene ZeoR of pLenti4/V5-Dest was
PCR amplified using primers NT321 and NT322, then digested with AbsI and AgeI.
These three fragments were assembled between the XbaI and KpnI sites of pSL1180.1 to
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form PPGK-ZeoR-WPRE. The XmaI site within the ZeoR gene was mutated by SDM
using primers NT436 and NT437. The mutation is silent. The XhoI site at the 5’ end of
the ZeoR gene was mutated by SDM using primers NT452 and NT453. The resulting
~1.6 kbp XbaI/KpnI fragment of pSL1180 PPGK -ZeoR-WPRE was ligated into the ~6.3
kbp XbaI/KpnI backbone of pLVX Phi. Primers NT454 and NT455 were annealed to
each other and then ligated into the XbaI/BamHI sites of the vector to further expand the
MCS.
pLVX Che-hi3. The PGK promoter sequence of pLVX Puro was amplified using
primers NT191 and NT192, then digested with AbsI (Sibenzyme) and XbaI. The WPRE
sequence was PCR amplified from pLVX Puro using primers NT189 and NT190, then
digested with AbsI and KpnI. The two fragments were assembled between the XbaI and
KpnI sites of pSL1180.1 to form PPGK-WPRE. Next mCherry was amplified from
pmCherry-N1 using primers Inf-For and Inf-Rev and inserted into the XmaI-digested site
of the PPGK-WPRE fragment using an InFusion reaction. The ~2.0 kbp XbaI/KpnI
resulting fragment was ligated into the ~6.3 kbp XbaI/KpnI backbone of pLVX Phi3.
Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT117
NT189
NT190
NT191
NT192
NT193
NT194
NT195
NT196
NT197
NT198
NT321
NT322
NT344
NT356
NT357
NT358

TATATAGGTACCGCCACCATGGTCAAGGTTCTGTGGGCTGCGTTG
CCCGGTACCTGAGGTGTGACTGGAAAACCC
TATATACCTCGAGGCCCGGGTCTGGAACAATCAACCTCTGGATTAC
TATATACCTCGAGGCAGGTCGAAAGGCCCGGAGATG
GGGGTCTAGATAATTCTACCGGGTAGGGGAGG
CACACCTCGAGGATGATTGAACAAGATGGATTGC
TATACCCGGGTCAGAAGAACTCGTCAAGAAGGCG
CACACCTCGAGGATGGATAGATCCGGAAAGCC
TATACCCGGGCTATTCCTTTGCCCTCGGACG
CACACCTCGAGGATGGCCAAGCCTTTGTCTCAAG
CACACCCGGGTTAGCCCTCCCACACATAACC
TATACCTCGAGGATGGCCAAGTTGACCAGTGC
TATAACCGGTTCAGTCCTGCTCCTCGGCCACG
TATACGGCCGATGGTGAGCAAGGGCGAGG
TATATACGCGTGCCACCATGGAAGGGAAGTGGTTGC
CAGACGGCCGATCATGAGCCTCAACAATAGC
CGACGCCTAGGCTTGTACAGCTCGTCCATGC
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT430
NT431
NT432
NT433
NT434
NT435
NT436
NT437
NT438
NT439
NT440
NT441
NT442
NT443
NT444
NT445
NT446
NT447
NT448
NT449
NT452
NT453
NT454
NT455
NT458
NT459
NT461
NT463
NT465
NT466
NT467
NT468
NT469
NT471
NT472
NT473
NT475
NT477
NT478
NT479
NT481
NT483
NT484
NT485
NT487
NT489
NT491
NT493
NT495
NT514
NT515
NT516
NT517

CGACGTCCCCAGGGCAGTACGCACCCTCGCC
GGCGAGGGTGCGTACTGCCCTGGGGACGTCG
CTTGACATTGGGGAATTTAGCGAGAGCCTGACC
GGTCAGGCTCTCGCTAAATTCCCCAATGTCAAG
GGAGGCCATGGATGCAATCGCTGCGGCCGATC
GATCGGCCGCAGCGATTGCATCCATGGCCTCC
GCTCGGGTTCTCCCGAGACTTCGTGGAGGAC
GTCCTCCACGAAGTCTCGGGAGAACCCGAGC
GGCCTTTCGACCTGCATCGAGGATGGCCAAG
CTTGGCCATCCTCGATGCAGGTCGAAAGGCC
GTGGGAGGGCTAACCCAGGTCTGGAACAATCAACC
GGTTGATTGTTCCAGACCTGGGTTAGCCCTCCCAC
GGCCTTTCGACCTGCATCGAGGATGGATAGATC
GATCTATCCATCCTCGATGCAGGTCGAAAGGCC
GGCAAAGGAATAGCCTGGGTCTGGAACAATC
GATTGTTCCAGACCCAGGCTATTCCTTTGCC
GGCCTTTCGACCTGCATCGAGGATGATTGAAC
GTTCAATCATCCTCGATGCAGGTCGAAAGGCC
CGAGTTCTTCTGACCCAGGTCTGGAACAATCAACC
GGTTGATTGTTCCAGACCTGGGTCAGAAGAACTCG
CCTTTCGACCTGCCTTGAGGATGGCCAAGTTGACC
GGTCAACTTGGCCATCCTCAAGGCAGGTCGAAAGG
GATCCGGCGCGCCCGGGTTCGAATGTACACGTACGTTAATTAAT
CTAGATTAATTAACGTACGTGTACATTCGAACCCGGGCGCGCCG
TATACCTAGGTCAGGTGGAGGATCTATGATGGCGAAGACGTACGATTATC
GATGGATCCTCATCAAAGTAGCGAGCAACGAAAGAAACTGG
CGACGAGGATCCTCAGCAACACTGGGATTTGTTCTCTGC
CGAGGATCCTTAGCACCAGCACGTCATTGC
TATAGGATCCTCAACAGCAGCCGCCCCCAGC
TATACCTAGGTCAGGTGGAGGATCTATGGCGCAGCCCATCCTGG
GGCGGAGAATTCGGATCCTCAACAAGGACAGGAAGTTTTACTG
GAACCTAGGTCAGGTGGAGGATCTATGTTGGAGGAAGATATGG
CGATGTCGACGGATCCTTAGGGTATGCTACAGCTGC
CACAGGATCCTCAACAGCCACATGCCCCTTTC
CACACCTAGGTCAGGTGGAGGATCTATGAACCCCGAATATGACTACC
TATAGGATCCCTAGCAACAGCCACCGCCAGC
CACAGGATCCTCAGTTGCTGCAGCACTGGCTCC
GAGAGGATCCTCAGCCCAGGGAGCACTTGTTGG
TATACCTAGGTCAGGTGGAGGATCTATGGGGACCCGGGACGACG
CACAGGATCCTCACAGGTTCTGGCAGCACTGC
GGAGAGGATCCTCAGTTGCTACAACACTGGCTCTTG
CCGGTGGATCCTTAGTTACTACAACACTGATTCCTGG
TATACCTAGGTCAGGTGGAGGATCTATGGGTACCCGCGACGACGAGTACG
CCGGTGGATCCTTAGATGTTCTGACAGCACTGCACC
GAGAGGATCCTTAGCAGCAACCTCCACCTGAC
GAGAGGATCCTCAGCAGCAGCCAGAGTTGG
GAGAGGATCCTCAGAGGCTGATGCAACAGG
TATAGGATCCTCAACAGCACCGGCGGCTGG
GAGAGGATCCCTAGCAGATACATTTCTTCTCTGGTGGC
CCAACCTCAAAATGTGGATTCAAGAATGCAATGGGCATGC
GCATGCCCATTGCATTCTTGAATCCACATTTTGAGGTTGG
CTCAAACAACAAATAGCTGAAGATCCAGAACTAACGCATTCAAG
CTTGAATGCGTTAGTTCTGGATCTTCAGCTATTTGTTGTTTGAG
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT567
NT628
NT635
NT636
NT637
NT644
NT653
NT654
NT667
NT668
NT669
NT670
NT671
NT672
NT693
NT698
NT699
NT700
NT701
NT702
NT703
NT729
NT731
NT755
NT756
NT775
NT776
NT781
NT782
NT783
NT784
NT785
NT786
NT787
NT788
NT789
NT790
NT791
NT792
NT793
NT794
NT795
NT796
NT797
NT798
NT799
NT800
NT801
NT802
NT803
NT804
NT805
NT806

TATAGGATCCCTAGCAGCTGCAGCTGCTGGG
TATAACGCGTGCCACCATGGTCAAGGTTCTGTG
TATACCTAGGGGAGGAGGTAAGGTGGAGCAAGCGGTGG
GAGAGGATCCTATTAGTGATTGTCGCTGGGCACAGGG
ATAGGATCCGCGTGATTGTCGCTGGGCACAGG
GTGGTATGGCTGATTATGATCTAGAGTCGCGGC
GGGACACAGCGGGCCTGGAACGGTTCCGGACC
GGTCCGGAACCGTTCCAGGCCCGCTGTGTCCC
GGGACACAGCGGGTCTTGAAAGATTCCGAACAATCACG
CGTGATTGTTCGGAATCTTTCAAGACCCGCTGTGTCCC
GCACAGATATGGGACACAGCAGGGCTGGAGCGATATCGAGCTATAACATCAGC
GCTGATGTTATAGCTCGATATCGCTCCAGCCCTGCTGTGTCCCATATCTGTGC
GCAGATCTGGGACACCGCTGGCCTGGAGCGCTACCGCGCCATCACC
GGTGATGGCGCGGTAGCGCTCCAGGCCAGCGGTGTCCCAGATCTGC
TATATACGCGTTGCCACCATGGTGAGCAAGGGCGAGG
GTCAACAAATTGTTGGTAGGGATTAAATGTGATCTGACCACAAAGAAAG
CTTTCTTTGTGGTCAGATCACATTTAATCCCTACCAACAATTTGTTGAC
CGACTCAGGCGTGGGCAAGAACTGCCTGCTCCTGCGGTTTGCTG
CAGCAAACCGCAGGAGCAGGCAGTTCTTGCCCACGCCTGAGTCG
CGTCAATAAGCTCCTGGTGGGCATTAAGAGCGACCTCACCACCAAGAAGG
CCTTCTTGGTGGTGAGGTCGCTCTTAATGCCCACCAGGAGCTTATTGACG
CGAAGGATCCGCCACCATGGTGAGCAAGGGCG
TATAGCGGCCGCCTAGCAACAGCCACCGCCAGCCG
TAGCTTTATCGGGAATTAAGGCCGACCTAGCA
TGCTAGGTCGGCCTTAATTCCCGATAAAGCTA
TATACGCGTGCCACCATGGAAGACGCCAAAAACATAAAGAAAGG
GCGCGGATCCTTACAATTTGGACTTTCCGCCCTTC
TATACGCGTGCCACCATGTCCAGCATGAATCCCGAATATG
TATACGCGTGCCACCATGAACCCCGAATATGACTACC
TATACGCGTGCCACCATGGCCCGGGACTACGACC
GCGGGATCCTAGCAGCAGCGTTTCTTTCGTTTACTG
TATACGCGTGCCACCATGGCGTACGCCTATCTCTTCAAG
TATACGCGTGCCACCATGGCATCCGCCACAGACTCG
TATGGATCCTTAGCAGGCGCAGTCCTGGTGCGG
GACGAATTCGCCACCATGGCTTCAGTGACAGATGG
TATGGATCCTAGCATGAGCAGTTCTGCTGCAGC
TATACGCGTGCCACCATGAGACACGAAGCGCCCATGC
TATGGATCCTTAGCAGGCACAGTTGGGCTGCGGTGG
TATACGCGTGCCACCATGGCATCAGCTGGAGACACC
TATACGCGTGCCACCATGTCGCAGACGGCCATGTCC
GAGAGGATCCTTAACAACCACACTCCTGAGCGTTCG
TATACGCGTGCCACCATGGCTAGTCGAGGCGCAACAAG
TATACGCGTGCCACCATGTCCACGGGCGGAGACTTCG
GAGAGGATCCTTAGCAGAACAGCCTCCTTCACTGAC
TATACGCGTGCCACCATGAATCCCCGGAAGAAGG
TATGGATCCTAGCAGCATCTGCTCCTTGACTGG
TATACGCGTGCCACCATGGCGAAGACCTACGATTACC
GAGAGGATCCTACAGAAGAACACATCGGAAAAAGCTGC
TATACGCGTGCCACCATGATGGCGAAGACGTACGATTATCTC
TATACGCGTGCCACCATGGCAGGAAAATCATCAC
GAGAGGATCCTAACAGCAAGATGAGCTAGGC
TATACGCGTGCCACCATGGCGAAGAAGACGTACGACC
GGAGGATCCTAGCAGCATTTGCTCTTCCAGCC
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT807
NT808
NT809
NT810
NT811
NT812
NT813
NT814
NT815
NT816
NT817
NT818
NT819
NT820
NT821
NT822
NT823
NT824
NT825
NT826
NT827
NT828
NT829
NT830
NT832
NT833
NT834
NT835
NT836
NT837
NT838
NT839
NT840
NT841
NT842
NT843
NT844
NT845
NT846
NT847
NT848
NT849
NT850
NT851
NT852
NT853
NT854
NT855
NT856
NT857
NT858
NT859
NT860

TATACGCGTGCCACCATGGGTACCCGCGACGACG
TATACGCGTGCCACCATGGGGACCCGGGACGACGAG
TATACGCGTGCCACCATGGGGAATGGAACTGAGGAAG
TATACGCGTGCCACCATGGCCAAAGCCTACGACCACC
TATACGCGTGCCACCATGGCAACTGCACCATACAAC
TATGGATCCTAGCAGCCACAGCCTTCTCTCTGGGGTTGGGG
TATACGCGTGCCACCATGGACGAGGACGTGCTAACC
GCGGGATCCTATAACACAGAGCAATAACCACCACAG
TATACGCGTGCCACCATGCACTTCTCGAGCTCAGCC
GAGAGGATCCTAGCAAGTGCAGTGGGTCTTTTCAC
TATACGCGTGCCACCATGATGGCGATACGGGAGCTC
TATACGCGTGCCACCATGTTGGAGGAAGATATGGAAG
TATACGCGTGCCACCATGTCCAGGAAGAAGACCCCCAAG
TATGGATCCTAAGGGCGGCAGCAGGAGGCCC
TATACGCGTGCCACCATGTCTGATGGAGATTATGATTACC
TATACGCGTGCCACCATGACCGATGGAGACTATGATTATCTG
TATATACGCGTGCCACCATGGCGGGCGGAGGAGCC
TATACGCGTGCCACCATGGCGCAGCCCATCCTGG
TATACGCGTGCCACCATGGAGACCATCTGGATCTACC
GAGAGGATCCTAGCAGAAGCATTCTTTCCTGGGC
TATATTACGCGTGCCACCATGAGCGCCCCGGGCAGCC
CGCGCGGATCCTAAGAAATTTTGCAGCTGTTTCTGGTGCAG
TATAGAATTCGCCACCATGGATCCGGGCGCCGCGC
GAGCCTAGGCTAACAGCATCGGACATGTGGTCTTGG
GCCGAATATTAGTGGGTATAAAGAATGACGACCCTGAGC
GCTCAGGGTCGTCATTCTTTATACCCACTAATATTCGGC
GGTCATTATGCTTATTGGAATAAAAAGTGATTTAGAATCTAGAAG
CTTCTAGATTCTAAATCACTTTTTATTCCAATAAGCATAATGACC
GGTGCTGCTGGTAGGAATTAAGTGTGACATGGAGG
CCTCCATGTCACACTTAATTCCTACCAGCAGCACC
GCACAAGTTATTCTGGTGGGGATTAAGTGTGACATGGAGG
CCTCCATGTCACACTTAATCCCCACCAGAATAACTTGTGC
CCAAGTTATTCTGGTTGGGATTAAGTGTGACATGGAAGACG
CGTCTTCCATGTCACACTTAATCCCAACCAGAATAACTTGG
GGTCATCCTGGTGGGGATTAAGTGTGACCTGGAGG
CCTCCAGGTCACACTTAATCCCCACCAGGATGACC
GTGATCATCCTTTGTGGAATTAAGAAGGACCTGGATGC
GCATCCAGGTCCTTCTTAATTCCACAAAGGATGATCAC
CATCATGCTAGTAGGAATCAAAACAGATCTTGCTGACAAG
CTTGTCAGCAAGATCTGTTTTGATTCCTACTAGCATGATG
CCATGGTGTTGTTGGGGATTAAGATCGATCTGGCAGACC
GGTCTGCCAGATCGATCTTAATCCCCAACAACACCATGG
CGAAAAGATGATACTCGGGATTAAGTGTGATGTGAATGACAAG
CTTGTCATTCACATCACACTTAATCCCGAGTATCATCTTTTCG
CGAAAGAATGATCCTGGGTATTAAATGTGATATGAATGAC
GTCATTCATATCACATTTAATACCCAGGATCATTCTTTCG
CCTTTTGTGATTCTGGGTATTAAGATTGACATAAGCGAACG
CGTTCGCTTATGTCAATCTTAATACCCAGAATCACAAAAGG
GGAAAGAATGTTACTAGGAATTAAGTGTGATATGGACGAC
GTCGTCCATATCACACTTAATTCCTAGTAACATTCTTTCC
GTTATCATGCTTGTGGGCATCAAGAGTGATCTACGTCATC
GATGACGTAGATCACTCTTGATGCCCACAAGCATGATAAC
CGTCATCATGCTGGTGGGCATTAAGAGTGACCTGCGCCACC
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT861
NT862
NT863
NT866
NT867
NT868
NT869
NT870
NT871
NT872
NT873
NT874
NT875
NT876
NT877
NT878
NT879
NT880
NT881
NT882
NT883
NT884
NT885
NT886
NT887
NT888
NT889
NT890
NT891
NT892
NT893
NT894
NT895
NT899
NT900
NT901
NT902
NT903
NT904
NT905
NT906
NT907
NT908
NT909
NT910
NT911
NT912
NT913
NT914
NT915
NT916
NT917
NT918

GGTGGCGCAGGTCACTCTTAATGCCCACCAGCATGATGACG
CGTCGTCATGCTCGTGGGTATTAAAAGTGACCTCAGCCAGG
CCTGGCTGAGGTCACTTTTAATACCCACGAGCATGACGACG
GAGCTTCTCTTAGTTGGAATCAAGTTGGACTGTGAAACGG
CCGTTTCACAGTCCAACTTGATTCCAACTAAGAGAAGCTC
CGCCTCTTGCTGGGGATTAAATGTGACATGGAGG
CCTCCATGTCACATTTAATCCCCAGCAAGAGGCG
CTGTAATAATTCTCATAGGAATCAAAGCAGATTTGGAGGCAC
GTGCCTCCAAATCTGCTTTGATTCCTATGAGAATTATTACAG
GACATAGTAAACATGCTAGTTGGAATCAAAATCGATAAGGAAAATCGTG
CACGATTTTCCTTATCGATTTTGATTCCAACTAGCATGTTTACTATGTC
GGTCATTATGCTGATTGGAATCAAATGTGACCTCTGGG
CCCAGAGGTCACATTTGATTCCAATCAGCATAATGACC
GTAATGGCCATCGCTGGAATTAAGTGCGACCTCTCAG
CTGAGAGGTCGCACTTAATTCCAGCGATGGCCATTAC
CCAACTGTACTTGTGCAAATTAAGATTGATCTTCTGG
CCAGAAGATCAATCTTAATTTGCACAAGTACAGTTGG
GCTCATGCTGCTGGGGATTAAGGTGGACTCTGCCC
GGGCAGAGTCCACCTTAATCCCCAGCAGCATGAGC
CCAGATATAGTGCTGTGTGGAATTAAGAGTGATCTGGAGG
CCTCCAGATCACTCTTAATTCCACACAGCACTATATCTGG
CCAGATATAGTATTAATTGGCATTAAGGCAGACCTACCAG
CTGGTAGGTCTGCCTTAATGCCAATTAATACTATATCTGG
CCTGCTGTCCTCTTGGCTATTAAATGTGACCAGAACAAGG
CCTTGTTCTGGTCACATTTAATAGCCAAGAGGACAGCAGG
CCAAAGTGCTTGTGGGCATTAAGTGTGACTTGAGGG
CCCTCAAGTCACACTTAATGCCCACAAGCACTTTGG
GGATTGTATTTCTGCTAGTGGGAATAAAATGTGATTTAGCTTCACAACG
CGTTGTGAAGCTAAATCACATTTTATTCCCACTAGCAGAAATACAATCC
CCCTAAAATCCTGGTGGGGATACGCCTACATCTGGCATTC
GAATGCCAGATGTAGGCGTATCCCCACCAGGATTTTAGGG
GCTCAGCCAGGGCAGCAGATGAGAACTTTGACTATTTGTTCAAG
CTTGAACAAATAGTCAAAGTTCTCATCTGCTGCCCTGGCTGAGC
GAGACGCGTGCCACCATGACTTATGCTTATCTCTTCAAG
TATACGCGTGCCACCATGACTAGCAGAAGCACAGCTAGG
ATATACGCGTGCCACCATGGCGGGTCGGGGAGGC
TATACGCGTGCCACCATGGCTGAGGAGATGGAGTCG
TATGAATTCGCCACCATGGCTGAGACCTACGACTTCC
TATCCTAGGTTAGCAGCCACACGGCTGAGGGG
TATACGCGTGCCACCATGTCCGCAGGGGGAGATTTTGG
TATGGATCCTAGCAGGAGCAGCCGCCCTCG
TATACGCGTGCCACCATGTCCGCGGGCGGAGACTTCG
GACGGATCCTACCTCCACGAGACAGGCAGC
TATACGCGTGCCACCATGACCTCTAGGAAGAAAGTGTTGCT
TATGGATCCTCAGCAACTGCAGCTTTCTGCCGAGG
TATACGCGTGCCACCATGAGTGGGAAATCCCTGCTC
TATGGATCCTAACAGCACGAAGACCCTGCTTTGG
TATGAATTCGCCACCATGGCGAAGCAGTACGATGTGC
CGCGGATCCTAGACGCGTGAATGACTCTTTAATG
TATACGCGTGCCACCATGGCACAGGCACACAGGACC
GAAGGATCCTAGTGGGCGCAGCATTTGGCCTGC
TATACGCGTGCCACCATGAGGAAGCCCGACAGCAAG
CGCGGATCCTAGGCACAACACCCAGATCTGG
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT919
NT920
NT921
NT922
NT923
NT924
NT927
NT928
NT929
NT930
NT931
NT932
NT933
NT934
NT935
NT936
NT937
NT938
NT939
NT940
NT941
NT942
NT943
NT944
NT945
NT946
NT947
NT948
NT951
NT952
NT960
NT961
NT964
NT965
NT966
NT967
NT968
NT969
NT972
NT973
NT974
NT975
NT978
NT979
NT980
NT981
NT982
NT983
NT991
NT996
NT997
NT998
NT999

TATACGCGTGCCACCATGGCTGCGGCCGGCGG
GCGCCGGATCCTTATCCAGAAGAACAGCACCCTCC
TATACGCGTGCCACCATGGCGCTGAGGGAGCTCAAAGTG
TATGGATCCTCAGCAGCAGCTCCGCTTTGGCTCTG
TATACGCGTGCCACCATGAGCGGGCAGCGCGTGGACG
GCGCCGGATCCTCAGTGATGACAACAGCTGTAGAAGTAGG
TATACGCGTGCCACCATGGGCAGCCGCGACCACC
GACGGATCCTAGCAGCAGGACCAGCTGGAGGAC
TATACGCGTGCCACCATGAGTATGGAAGATTATGATTTCC
GACGGATCCTAGTTGAAATTACAACAAGTCAAATAGC
TATACGCGTGCCACCATGAACATTCTGGCACCCGTGC
GACGGATCCTATGGGCAACATGTGGGCTTCTTC
TATACGCGTGCCACCATGGTGATCGCCGGTGCAAGC
TATGGATCCTTAGCAGCAGCCCAGGCTGGAGGG
TATACGCGTGCCACCATGACGGGCACGCCAGGCG
CACGGATCCTACATGAAGGAGCAGCAGCTGGAGC
TATACGCGTGCCACCATGCAGGCCCCGCACAAGGAGC
CGCCGGATCCCTAGGATTTGGCACAGCCAGAGC
TATACGCGTGCCACCATGGAGGCCATCTGGCTGTACC
GCCGGATCCTAGCACAAACATCTCCTCTCTG
TATACGCGTGCCACCATGAGCGCCCCGGGCAGCC
CGCCGGATCCTAAGAAATTTTGCAGCTGTTTCTGGTGC
TATACGCGTGCCACCATGAGCGCCCTGGGCAGCCC
CGCCGGATCCTAAGAAATTTTGCAGCTGTTTCTGGTGC
TAAGAATTCGCCACCATGGGCTCGCAGGGCAGTCC
GCCCCTAGGCTAGGAGATCTTGCAGTTACTCC
TATACGCGTGCCACCATGTCTGCCTTTGGTCACGACG
CGCCGGATCCTAACAATAGCTTCTGTTGCCTGAC
TATACGCGTGCCACCATGGCAGGGCCGGGCCCAGG
GACGGATCCTAGCACCCGCAGCCCCAGCCTTCTCC
CGTGTGGCTTCTGCCCTTCTTTCCACAAGGACTTCACCTCCACC
GGTGGAGGTGAAGTCCTTGTGGAAAGAAGGGCAGAAGCCACACG
GTTACGTTTATTGAAACTAGGGCAAAAGCTGGATACAATGTAAAGCAGC
GCTGCTTTACATTGTATCCAGCTTTTGCCCTAGTTTCAATAAACGTAAC
GGATGGCGCGGCCGAGTCCCCGTACGGCCACCCGGCGG
CCGCCGGGTGGCCGTACGGGGACTCGGCCGCGCCATCC
GCTGGACGGCCGGCGCGTGAAGCTGGAGCTCTGGGACACG
CGTGTCCCAGAGCTCCAGCTTCACGCGCCGGCCGTCCAGC
GGAGATTCTGGTGTTGGAAAGAATAATCTCCTGTCTCGATTTACTCG
CGAGTAAATCGAGACAGGAGATTATTCTTTCCAACACCAGAATCTCC
GGACTCAGGCGTGGGCAAGAACAACCTGCTGTCGCGCTTCACC
GGTGAAGCGCGACAGCAGGTTGTTCTTGCCCACGCCTGAGTCC
GCAGATATGGGACACAGCCGGTCTGGAACGGTTTCGGACGATC
GATCGTCCGAAACCGTTCCAGACCGGCTGTGTCCCATATCTGC
CTCGGGGGTGGGGAAGAACTGTGTCCTGTTCCGC
GCGGAACAGGACACAGTTCTTCCCCACCCCCGAG
CTCGGGGGTAGGCAAGAACTGCCTCCTGTTCCGCTTCTC
GAGAAGCGGAACAGGAGGCAGTTCTTGCCTACCCCCGAG
TATCCTAGGTCAGGTGGAGGATCTATGGCGAAGACCTACGATTACC
GGTTATCATGCTCATTGGGATTAAGAGTGACCTAGAGTCCC
GGGACTCTAGGTCACTCTTAATCCCAATGAGCATGATAACC
GGTCATCCTCTGTGGCATCAAGAAGGACCTGGACC
GGTCCAGGTCCTTCTTGATGCCACAGAGGATGACC
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT1000
NT1001
NT1002
NT1003
NT1004
NT1005
NT1006
NT1007
NT1008
NT1009
NT1010
NT1011
NT1012
NT1013
NT1014
NT1015
NT1016
NT1017
NT1018
NT1019
NT1020
NT1021
NT1022
NT1023
NT1024
NT1025
NT1026
NT1027
NT1028
NT1029
NT1030
NT1031
NT1032
NT1033
NT1034
NT1035
NT1036
NT1037
NT1038
NT1039
NT1040
NT1041
NT1042
NT1043
NT1044
NT1045
NT1046
NT1047
NT1048
NT1049
NT1050
NT1051
NT1052

CGTTATTGCCCTGGCAGGGATCAAAGCTGACCTGGCCAAC
GTTGGCCAGGTCAGCTTTGATCCCTGCCAGGGCAATAACG
CGTCATTGCACTCGCGGGTATCAAGGCAGACCTGGCCAGC
GCTGGCCAGGTCTGCCTTGATACCCGCGAGTGCAATGACG
CATCATGCTGGTGGGCATCAAGACGGACCTGGCTG
CAGCCAGGTCCGTCTTGATGCCCACCAGCATGATG
GTTATCATCACGCTAGTAGGAATTAGAACAGATCTTGCTGAC
GTCAGCAAGATCTGTTCTAATTCCTACTAGCGTGATGATAAC
CCCATTTGTTGTGTTGGGAATCAAGATTGACCTCGAAAACAG
CTGTTTTCGAGGTCAATCTTGATTCCCAACACAACAAATGGG
CCTTTGTAGTTCTGGGTATCAAGGTAGACAAAGAGG
CCTCTTTGTCTACCTTGATACCCAGAACTACAAAGG
CCGGGGTGGGCAAGAACTGCCTGCTGTGCCGC
GCGGCACAGCAGGCAGTTCTTGCCCACCCCGG
CCTGGTGATGCTGGTGGGCATCAAGACGGACCTCAGCCAGG
CCTGGCTGAGGTCCGTCTTGATGCCCACCAGCATCACCAGG
CTTCGCCATCGTGGGGATCAAAGTGGACCTCACTG
CAGTGAGGTCCACTTTGATCCCCACGATGGCGAAG
CTGTTTATGTATAGTTGGTATTAAAATAGACTTGGAAAAGG
CCTTTTCCAAGTCTATTTTAATACCAACTATACATAAACAG
GTAGTTGCCATTGCAGGAATTAAATGTGATCTTATCGATG
CATCGATAAGATCACATTTAATTCCTGCAATGGCAACTAC
CCAAATCTACTTATGTGGCATCAAGAGTGACCTGCTGGAAG
CTTCCAGCAGGTCACTCTTGATGCCACATAAGTAGATTTGG
CTGGTTGCCTTGGTAGGCATTAAAATTGATTTGGAGCATATGC
GCATATGCTCCAAATCAATTTTAATGCCTACCAAGGCAACCAG
CCTGCCTGCTCTTGGCCATCAAGTGTGATCTGTCCCC
GGGGACAGATCACACTTGATGGCCAAGAGCAGGCAGG
CACTGTGTTAGTGGGCATCAAGATTGACCTGGCTG
CAGCCAGGTCAATCTTGATGCCCACTAACACAGTG
CCACGGATTCTTGTTGGAATTAAATGTGACTTGAGAAGTGC
GCACTTCTCAAGTCACATTTAATTCCAACAAGAATCCGTGG
GCTTCTCTTCCTTGTAGGTATCAAGAAGGATCTGAGTACC
GGTACTCAGATCCTTCTTGATACCTACAAGGAAGAGAAGC
CATCTTCCTCGTGGGAATCAAGAAGGACCTTCTGTC
GACAGAAGGTCCTTCTTGATTCCCACGAGGAAGATG
GGTGATCATGCTGCTAGGCATCAAGGCGGATATGAGCAGC
GCTGCTCATATCCGCCTTGATGCCTAGCAGCATGATCACC
CAGTGGTTTTGTTGGCCATCAAATGTGACCAGGGG
CCCCTGGTCACATTTGATGGCCAACAAAACCACTG
GTATTTGTTCTGGTGGGTATCAAGTGTGACCTGGATACAC
GTGTATCCAGGTCACACTTGATACCCACCAGAACAAATAC
CCTAAAATCCTGGTGGGGATTCGCCTACATCTGGCATTC
GAATGCCAGATGTAGGCGAATCCCCACCAGGATTTTAGG
CCAAGATCCTGGTGGGGATTCGCCTGCACCTGGCGTTC
GAACGCCAGGTGCAGGCGAATCCCCACCAGGATCTTGG
CCGGATCTTGGTTGGAATCCGGCTGCACCTGGCC
GGCCAGGTGCAGCCGGATTCCAACCAAGATCCGG
GTCATCATGTTGTTGGGTATCAAGATTGATTTGGATAAC
GTTATCCAAATCAATCTTGATACCCAACAACATGATGAC
CATCTTCCTGCTGGTTGGCATCAAGAGTGACCTGCAGAGC
GCTCTGCAGGTCACTCTTGATGCCAACCAGCAGGAAGATG
GTGCAGCTGCTGATCGGGATCAAGTCAGACCTCAGCGAGC
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Table 2.2 DNA oligonucleotide primer sequences
Primer Nucleotide sequence (5' to 3')
NT1053
NT1054
NT1055
NT1069
NT1123
NT1124
NT1125
NT1126
Inf-For
Inf-Rev

GCTCGCTGAGGTCTGACTTGATCCCGATCAGCAGCTGCAC
GCATCAACAGTGATGACAGCAACCTCTACCTAACTGC
GCAGTTAGGTAGAGGTTGCTGTCATCACTGTTGATGC
GCGCGAATTCTTATTTTATCTTAATGGTTTGTCTTTCTTG
TATAGCGGCCGCTAGATGTTCTGACAGCACTGCACC
TATAGCGGCCGCTACAGGTTCTGGCAGCACTGCAGC
TATAGCGGCCGCTACAGAAGAACACATCGGAAAAAGC
TATAGCGGCCGCTAAAGTAGCGAGCAACGAAAGAAACTGG
TGCCTCGAGGCCCGGGCCACCATGGTGAGC
TTGTTCCAGACCCGGTTACTTGTACAGCTC

2.3. Lentiviral constructs for constitutive expression
I wish to acknowledge the help that I received in making some of these
constructs, primarily from Caroline Gleason, but also from Colin Belanger. Some of the
lentiviral vectors listed below and in Table 2.1 were given an identifier starting with the
letters "OL". These two letters stand for "Organelle Lentivirus" and signify that these
vectors need to be packaged into lentiviral particles using a human immunodeficiency
virus 1 (HIV-1)-based packaging system.
pLVX Phi3 FLuc and pLVX Bhi3 FLuc The firefly (Photinus pyralis) luciferin
4-monooxygenase (FLuc) was amplified using primers NT775 and NT776 from pRetroX
TRE3G-Luc, digested with MluI and BamHI and ligated into the MluI/BamHI sites of
pLVX Phi3 or pLVX Bhi3, respectively.
pLVX Phi3 mCherry. The ~0.7 kbp EcoRI/NotI fragment from pmCherry-N1
was ligated into the EcoRI/NotI sites of pLVX Phi3.
OL135 pLVX Phi3 mCherry-Rab1b. Rab1b cDNA was amplified from pCMVSPORT6 Rab1b using primers NT472 and NT473 and digested with AvrII and BamHI;
mCherry was amplified from pmCherry-N1 using primers NT358 and NT693 and
digested with MluI and AvrII). The fragments were assembled within the MluI/BamHI
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sites of pLVX Phi3. OL115 pLVX Phi3 mCherry-Rab1bQ67L. Primers NT653 and
NT654 were used to introduce the Q67L mutation into the Rab1b sequence by SDM.
OL142 pLVX Phi3 mCherry-Rab1bS22N. Primers NT700 and NT701 were used to
introduce the S22N mutation into the Rab1b sequence by SDM. OL143 pLVX Phi3
mCherry-Rab1bN121I. Primers NT702 and NT703 were used to introduce the N121I
mutation into the Rab1b sequence by SDM.
pLVX Hhi3 ApoE3. A DNA sequence encoding an shRNA-resistant version of
ApoE3 was chemically synthesized, PCR-amplified using NT628 and NT636, digested
with MluI and BamHI and inserted into the MluI/BamHI sites of pLVX Hhi3. The silent
mutations present in this ApoE3 cDNA created a mismatch with the shRNA sequence
encoded by pLKO.1 shApoE (Clone ID TRCN0000010913, Broad Institute's Genetic
Perturbation Platform).
pLVX Hhi3 ApoE3-mEGFP. ApoE3 (shRNAres) was amplified with NT117
and NT637, digested with KpnI and BamHI and inserted into the KpnI/BamHI sites of
pmEGFP-N1. ApoE3-mEGFP was then amplified using NT628 and NT644, digested
with MluI and XbaI and cloned into the MluI/XbaI sites of pLVX Hhi3.
pLVX Phi3 mEGFP-ApoE3. The following fragments were assembled into the
cloning vector pSL1180: a sequence encoding amino acids 1-22 of calnexin (its signal
peptide) was amplified using NT356

and NT357 from pCMV6-XL5 Calnexin and

digested with MluI and EagI; mEGFP (monomeric enhanced green fluorescent protein)
was amplified from pmEGFP-N1 using primers NT344 and NT358 and digested with
EagI and AvrII; mature ApoE3 coding sequence (amino acids 1 through 299) was
amplified with NT635 and NT636 and digested with AvrII and BamHI. The resulting
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signal peptide-mEGFP-ApoE3 was excised using MluI and BamHI and inserted into the
MluI/BamHI sites of pLVX Phi3.
OL175 pLVX Che-hi3 Rab1a. Rab1a sequence (obtained from pCMV-Sport6
Rab1a) was PCR amplified using primers NT487 and NT781, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL 176 pLVX Che-hi3
Rab1aN124I. SDM was performed on OL175 using primers NT698 and NT699.
OL177 pLVX Che-hi3 Rab1b. Rab1b was amplified from OL135 using primers
NT473 and NT782, digested with MluI and BamHI and ligated into the MluI/BamHI
sites of pLVX Che-hi3. OL178 pLVX Che-hi3 Rab1bN121I. Rab1bN121I was amplified
from OL143 using primers NT473 and NT782, digested with MluI and BamHI and
ligated into the MluI/BamHI sites of pLVX Che-hi3. OL249 pLVX Che-hi3 Rab1bQ67L.
Rab1bQ67L was amplified from OL115 using primers NT473 and NT782, digested with
MluI and BamHI and ligated into the MluI/BamHI sites of pLVX Che-hi3. OL250
pLVX Che-hi3 Rab1bS22N. Rab1bS22N was amplified from OL142 using primers NT473
and NT782, digested with MluI and BamHI and ligated into the MluI/BamHI sites of
pLVX Che-hi3.
OL179 pLVX Che-hi3 Rab1c/35. Rab1c sequence was PCR amplified from
pCMV-Sport6/Rab1c/35 using primers NT783 and NT784, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL180 pLVX Che-hi3
Rab1c/35N120I. SDM was performed on OL179 using primers NT832 and NT833.
OL181 pLVX Che-hi3 Rab2A. Rab2a sequence (obtained from pOTB7-Rab2a)
was PCR amplified using primers NT465 and NT785, digested with MluI and BamHI
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and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL182 pLVX Che-hi3
Rab2aN119I. SDM was performed on OL181 using primers NT834 and NT835.
OL183 pLVX Che-hi3 Rab3a. Rab3a sequence was PCR amplified from
pLX304 Rab3a using primers NT786 and NT787, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL184 pLVX Che-hi3 Rab3aN135I.
SDM was performed on OL183 using primers NT836 and NT837.
OL185 pLVX Che-hi3 Rab3b. Rab3b sequence was PCR amplified from
pOTB7-Rab3b using primers NT788 and NT789, digested with EcoRI and BamHI and
cloned into the EcoRI/BamHI sites of pLVX Che-hi3. OL186 pLVX Che-hi3
Rab3bN135I. SDM was performed on OL185 using primers NT838 and NT839.
OL187 pLVX Che-hi3 Rab3c. Rab3c sequence was PCR amplified from
pLX304 Rab3c using primers NT790 and NT791, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL188 pLVX Che-hi3 Rab3cN143I.
SDM was performed on OL187 using primers NT840 and NT841.
OL189 pLVX Che-hi3 Rab3d/16. Rab3d/16 sequence (from pCMV-Sport6
Rab3d) was PCR amplified using primers NT567 and NT792, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL190 pLVX Che-hi3
Rab3d/16N135I. SDM was performed on OL189 with primers NT842 and NT843.
OL191 pLVX Che-hi3 Rab4a. Rab4a sequence was PCR amplified from
pLX304 Rab4a using primers NT793 and NT794, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL192 pLVX Che-hi3 Rab4aN126I.
SDM was performed on OL191 using primers NT844 and NT845.
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OL193 pLVX Che-hi3 Rab5a. Rab5a sequence (obtained from pCDNA5 Flag3Rab5a) was PCR amplified using primers NT483 and NT795, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL194 pLVX Che-hi3
Rab5aN133I. SDM was performed on OL193 using primers NT755 and NT756.
OL195 pLVX Che-hi3 Rab6a. Rab6a sequence was PCR amplified from
pOTB7-Rab6a using primers NT796 and NT797, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL196 pLVX Che-hi3 Rab6aN126I.
SDM was performed on OL195 using primers NT846 and NT847.
OL197 pLVX Che-hi3 Rab7b. Rab7b sequence was PCR amplified from
pLX304 Rab7b using primers NT798 and NT799, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL198 pLVX Che-hi3 Rab7bN124I.
SDM was performed on OL197 using primers NT848 and NT849.
OL199 pLVX Che-hi3 Rab8a. Rab8a sequence was PCR amplified from
pOTB7-Rab8a using primers NT800 and NT801, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL200 pLVX Che-hi3 Rab8aN121I.
SDM was performed on OL199 using primers NT850 and NT851. OL319 pLVX Chehi3 Rab8aQ67L. SDM was performed on OL199 using primers NT978 and NT979.
OL320 pLVX Che-hi3 Rab8aT22N. SDM was performed on OL199 using primers
NT980 and NT981.
OL201 pLVX Che-hi3 Rab8b. Rab8b sequence (obtained from pDNR-LIBRab8b) was PCR amplified using primers NT459 and NT802, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL202 pLVX Che-hi3
Rab8bN121I. SDM was performed on OL201 using primers NT852 and NT853. OL321
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pLVX Che-hi3 Rab8bQ67L. SDM was performed on OL201 using primers NT667 and
NT668. OL322 pLVX Che-hi3 Rab8bT22N. SDM was performed on OL201 using
primers NT982 and NT983.
OL203 pLVX Che-hi3 Rab9a. Rab9a sequence was PCR amplified from
pLX304 Rab9a using primers NT803 and NT804, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL204 pLVX Che-hi3 Rab9aN124I.
SDM was performed on OL203 using primers NT854 and NT855.
OL205 pLVX Che-hi3 Rab10. Rab10 sequence was PCR amplified from
pCMV-XL5/Rab10 using primers NT805 and NT806, digested with MluI and BamHI
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL206 pLVX Che-hi3
Rab10N122I. SDM was performed on OL205 using primers NT856 and NT857.
OL207 pLVX Che-hi3 Rab11a. Rab11a sequence (obtained from pEGFPRab11aWT) was PCR amplified using primers NT485 and NT807, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL208 pLVX
Che-hi3 Rab11aN124I. SDM was performed on OL207 using primers NT858 and NT859.
OL313 pLVX Che-hi3 Rab11aQ70L. SDM was performed on OL207 using primers
NT669 and NT670. OL314 pLVX Che-hi3 Rab11aS25N. SDM was performed on OL207
using primers NT972 and NT973.
OL209 pLVX Che-hi3 Rab11b. Rab11b sequence (obtained from pCR-BluntIITopo/Rab11b) was PCR amplified using primers NT479 and NT808, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL210 pLVX
Che-hi3 Rab11bN124I. SDM was performed on OL209 using primers NT860 and NT861.
OL315 pLVX Che-hi3 Rab11bQ70L. SDM was performed on OL209 using primers
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NT671 and NT672. OL316 pLVX Che-hi3 Rab11bS25N. SDM was performed on OL209
using primers NT974 and NT975.
OL211 pLVX Che-hi3 Rab11c/25. Rab11c/25 sequence (from pOTB7
Rab11c/25) was amplified using primers NT491 and NT809, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL212 pLVX Che-hi3
Rab11c/25N125I. SDM was performed on OL211 with primers NT862 and NT863.
OL213 pLVX Che-hi3 Rab12. Rab12 sequence was PCR amplified from
pCMV-XL5/Rab12 using primers NT829 and NT830, digested with EcoRI and AvrII and
cloned into the EcoRI/AvrII sites of pLVX Che-hi3. OL214 pLVX Che-hi3 Rab12N155I.
SDM was performed on OL213 using primers NT866 and NT867.
OL215 pLVX Che-hi3 Rab13. Rab13 sequence (obtained from pCMVSport6/Rab13) was PCR amplified using primers NT477 and NT810, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL216 pLVX
Che-hi3 Rab13N121I. SDM was performed on OL215 using primers NT868 and NT869.
OL217 pLVX Che-hi3 Rab14. Rab14 sequence was PCR amplified from
pLX304 Rab14 using primers NT811 and NT812, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL218 pLVX Che-hi3 Rab14N124I.
SDM was performed on OL217 using primers NT870 and NT871.
OL219 pLVX Che-hi3 Rab18. Rab18 sequence was PCR amplified from
pEGFP-Rab18 using primers NT813 and NT814, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL220 pLVX Che-hi3 Rab18N122I.
SDM was performed on OL219 using primers NT872 and NT873.
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OL221 pLVX Che-hi3 Rab19b. Rab19b sequence was PCR amplified from
pLX304 Rab19b using primers NT815 and NT816, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. The E12STOP mutation from the
template was reverted by SDM using primers NT894 and NT895. OL222 pLVX Chehi3 Rab19bN130I. SDM was performed on OL221 using primers NT874 and NT875.
OL223 pLVX Che-hi3 Rab22b/31. Rab22b/31 sequence (obtained from pOTB7Rab22b/31) was amplified using primers NT493 and NT817, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL224 pLVX Che-hi3
Rab22b/31N119I. SDM was performed on OL223 with primers NT876 and NT877.
OL225 pLVX Che-hi3 Rab23. Rab23 sequence (obtained from pCMV-Sport6
Rab23) was PCR amplified using primers NT468 and NT469, digested with AvrII and
SalI and cloned into the AvrII/SalI sites of pSL1180. The BamHI site within the Rab23
coding sequence was mutagenized using primers NT516 and NT517. The resulting
mutation is silent. The product was amplified with NT469 and NT818, digested with
MluI and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL226 pLVX
Che-hi3 Rab23N121I. SDM was performed on OL225 with primers NT878 and NT879.
OL227 pLVX Che-hi3 Rab26. Rab26 sequence was PCR amplified from
pLX304 Rab26 using primers NT819 and NT820, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL228 pLVX Che-hi3 Rab26N177I.
SDM was performed on OL227 using primers NT880 and NT881.
OL229 pLVX Che-hi3 Rab27a. Rab27a sequence (obtained from pCMVSport6/Rab27a) was PCR amplified using primers NT471 and NT821, digested with
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MluI and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL230 pLVX
Che-hi3 Rab27aN133I. SDM was performed on OL229 using primers NT882 and NT883.
OL231 pLVX Che-hi3 Rab27b. Rab27b sequence (obtained from pCMVSport6/Rab27b) was PCR amplified using primers NT495 and NT822, digested with
MluI and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL232 pLVX
Che-hi3 Rab27bN133I. SDM was performed on OL231 using primers NT884 and NT885.
OL233 pLVX Che-hi3 Rab32. Rab32 sequence (obtained from pDNRLIB/Rab32) was PCR amplified using primers NT461 and NT823, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL234 pLVX
Che-hi3 Rab32N143I. SDM was performed on OL233 using primers NT886 and NT887.
OL235 pLVX Che-hi3 Rab33a. Rab33a sequence (from pOTB7-Rab33a) was
PCR amplified using primers NT466 and NT467, digested with AvrII and EcoRI and
cloned into the AvrII/EcoRI sites of pSL1180. The BamHI site within the Rab33a coding
sequence was mutagenized using primers NT514 and NT515. The resulting mutation is
silent. The product was amplified using NT467 and NT824, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL236 pLVX Che-hi3
Rab33aN151I. SDM was performed on OL235 with primers NT888 and NT889.
OL237 pLVX Che-hi3 Rab39a. Rab39a sequence was PCR amplified from
pLX304 Rab39a using primers NT825 and NT826, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL238 pLVX Che-hi3
Rab39aH127I. SDM was performed on OL237 using primers NT890 and NT891.
OL239 pLVX Che-hi3 Rab40a. Rab40a sequence was PCR amplified from
pLX304 Rab40a using primers NT827 and NT828, digested with MluI and BamHI and
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cloned into the MluI/BamHI sites of pLVX Che-hi3. OL240 pLVX Che-hi3
Rab40aN126I. SDM was performed on OL239 using primers NT892 and NT893.
OL251 pLVX Che-hi3 Rab2b. Rab2b sequence (obtained from pDNRLIB/Rab2b) was PCR amplified using primers NT489 and NT899, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL252 pLVX
Che-hi3 Rab2bN119I. SDM was performed on OL251 using primers NT996 and NT997.
OL253 pLVX Che-hi3 Rab4b. Rab4b sequence (obtained from pOTB7-Rab4b)
was PCR amplified using primers NT903 and NT904, digested with AvrII and EcoRI and
cloned into the AvrII/EcoRI sites of pLVX Che-hi3. OL254 pLVX Che-hi3 Rab4bN121I.
SDM was performed on OL253 using primers NT998 and NT999.
OL255 pLVX Che-hi3 Rab5b. Rab5b sequence (obtained from pCMVSport6/Rab5b) was PCR amplified using primers NT481 and NT900, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL256 pLVX
Che-hi3 Rab5bN133I. SDM was performed on OL255 with primers NT1000 and NT1001.
OL257 pLVX Che-hi3 Rab5c. Rab5c sequence (obtained from pCMVSport6/Rab5c) was PCR amplified using primers NT475 and NT901, digested with MluI
and BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL258 pLVX
Che-hi3 Rab5cN134I. SDM was performed on OL257 with primers NT1002 and NT1003.
OL259 pLVX Che-hi3 Rab6b. Rab6b sequence was PCR amplified from
pLX304 Rab6b using primers NT905 and NT906, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL260 pLVX Che-hi3 Rab6bN126I.
SDM was performed on OL259 using primers NT1004 and NT1005.
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OL261 pLVX Che-hi3 Rab6c. Rab6c sequence was PCR amplified from
pLX304 Rab6c using primers NT907 and NT908, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. The A159T mutation from the
template was reverted by SDM using primers NT964 and NT965. OL262 pLVX Chehi3 Rab6cN126I. SDM was performed on OL261 using primers NT1006 and NT1007.
OL263 pLVX Che-hi3 Rab7a. Rab7a sequence was PCR amplified from
pOTB7-Rab7a using primers NT909 and NT910, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL264 pLVX Che-hi3 Rab7aN125I.
SDM was performed on OL263 using primers NT1008 and NT1009.
OL265 pLVX Che-hi3 Rab9b. Rab9b sequence was PCR amplified from
pLX304 Rab9b using primers NT911 and NT912, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL266 pLVX Che-hi3 Rab9bN124I.
SDM was performed on OL265 using primers NT1010 and NT1011.
OL267 pLVX Che-hi3 Rab15. Rab15 sequence was PCR amplified from
pBlueScriptR-Rab15 using primers NT913 and NT914, digested with EcoRI and BamHI
and cloned into the EcoRI/BamHI sites of pLVX Che-hi3. OL268 pLVX Che-hi3
Rab15T22N. SDM was performed on OL267 using primers NT1012 and NT1013.
OL269 pLVX Che-hi3 Rab17. Rab17 sequence was PCR amplified from
pLX304 Rab17 using primers NT915 and NT916, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL270 pLVX Che-hi3 Rab17N132I.
SDM was performed on OL269 using primers NT1014 and NT1015.
OL271 pLVX Che-hi3 Rab20. Rab20 sequence was PCR amplified from
pLX304 Rab20 using primers NT917 and NT918, digested with MluI and BamHI and
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cloned into the MluI/BamHI sites of pLVX Che-hi3. OL272 pLVX Che-hi3 Rab20N113I.
SDM was performed on OL271 using primers NT1016 and NT1017.
OL273 pLVX Che-hi3 Rab21. Rab21 sequence was PCR amplified from
pCMV-Sport6/Rab21 using primers NT919 and NT920, digested with MluI and BamHI
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL274 pLVX Che-hi3
Rab21N132I. SDM was performed on OL273 using primers NT1018 and NT1019.
OL275 pLVX Che-hi3 Rab22a. Rab22a sequence was PCR amplified from
pCMV-Sport6/Rab22a using primers NT921 and NT922, digested with MluI and BamHI
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL276 pLVX Che-hi3
Rab22aN118I. SDM was performed on OL275 using primers NT1020 and NT1021.
OL277 pLVX Che-hi3 Rab24. Rab24 sequence was PCR amplified from
pOTB7-Rab24 using primers NT923 and NT924, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL278 pLVX Che-hi3 Rab24T120I.
SDM was performed on OL277 using primers NT1022 and NT1023.
OL279 pLVX Che-hi3 Rab28. Rab28-coding sequence was synthesized
(Genewiz) in the pUC-Kan vector. Rab28 was excised using MluI and BamHI and cloned
into the MluI/BamHI sites of pLVX Che-hi3. OL280 pLVX Che-hi3 Rab28N129I. SDM
was performed on OL279 using primers NT1024 and NT1025.
OL281 pLVX Che-hi3 Rab29/7L1. Rab29/7L1 sequence was PCR amplified
from pLX304 Rab7L1 using primers NT927 and NT928, digested with MluI and BamHI
and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL282 pLVX Che-hi3
Rab29/7L1N125I. SDM was performed on OL281 using primers NT1026 and NT1027.
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OL283 pLVX Che-hi3 Rab30. Rab30 sequence was PCR amplified from
pLX304 Rab30 using primers NT929 and NT930, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL284 pLVX Che-hi3 Rab30N122I.
SDM was performed on OL283 using primers NT1028 and NT1029.
OL285 pLVX Che-hi3 Rab33b. Rab33b sequence (obtained from pBlueScriptRRab33b) was PCR amplified using primers NT463 and NT902, digested with MluI and
BamHI and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL286 pLVX Che-hi3
Rab33bN148I. SDM was performed on OL285 using primers NT1030 and NT1031.
OL287 pLVX Che-hi3 Rab34. Rab34 sequence was PCR amplified from
pLX304 Rab34 using primers NT931 and NT932, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. The S244N mutation from the
template was reverted by SDM using primers NT1054 and NT1055. OL288 pLVX Chehi3 Rab34S166I. SDM was performed on OL287 using primers NT1032 and NT1033.
OL289 pLVX Che-hi3 Rab36. Rab36 sequence was PCR amplified from pCRTOPO/Rab36 using primers NT933 and NT934, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL290 pLVX Che-hi3 Rab36T237I.
SDM was performed on OL289 using primers NT1034 and NT1035.
OL291 pLVX Che-hi3 Rab37. Rab37 sequence was PCR amplified from
pLX304 Rab37 using primers NT935 and NT936, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL292 pLVX Che-hi3 Rab37N143I.
SDM was performed on OL291 using primers NT1036 and NT1037.
OL293 pLVX Che-hi3 Rab38. Rab38 sequence was PCR amplified from
pCMV-Sport6/Rab38 using primers NT937 and NT938, digested with MluI and BamHI
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and cloned into the MluI/BamHI sites of pLVX Che-hi3. OL294 pLVX Che-hi3
Rab38N127I. SDM was performed on OL293 using primers NT1038 and NT1039.
OL295 pLVX Che-hi3 Rab39b. Rab39b sequence was PCR amplified from
pLX304 Rab39b using primers NT939 and NT940, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL296 pLVX Che-hi3
Rab39bH123I. SDM was performed on OL295 using primers NT1040 and NT1041.
OL297 pLVX Che-hi3 Rab40al. Rab40al sequence was PCR amplified from
pLX304 Rab40al using primers NT941 and NT942, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL298 pLVX Che-hi3
Rab40alN126I. SDM was performed on OL297 using primers NT1042 and NT1043.
OL299 pLVX Che-hi3 Rab40b. Rab40b sequence was PCR amplified from
pLX304 Rab40b using primers NT943 and NT944, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. The P42T mutation from the
template was reverted by SDM using primers NT966 and NT967. OL300 pLVX Chehi3 Rab40bN126I. SDM was performed on OL299 using primers NT1044 and NT1045.
OL301 pLVX Che-hi3 Rab40c. Rab40c sequence was PCR amplified from
pLX304 Rab40c using primers NT945 and NT946, digested with EcoRI and AvrII and
cloned into the EcoRI/AvrII sites of pLVX Che-hi3. The K64R mutation from the
template was reverted by SDM using primers NT968 and NT969. OL302 pLVX Chehi3 Rab40cN126I. SDM was performed on OL301 using primers NT1046 and NT1047.
OL303 pLVX Che-hi3 Rab41. Rab41 sequence was PCR amplified from
pLX304 Rab41 using primers NT947 and NT948, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. The S193P mutation from the
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template was reverted by SDM using primers NT960 and NT961. OL304 pLVX Chehi3 Rab41N143I. SDM was performed on OL303 using primers NT1048 and NT1049.
OL305 pLVX Che-hi3 Rab42. Rab42-coding sequence was synthesized
(Genewiz) in the pUC-Kan vector. Rab42 was excised using MluI and BamHI and cloned
into the MluI/BamHI sites of pLVX Che-hi3. OL306 pLVX Che-hi3 Rab42H129I. SDM
was performed on OL305 using primers NT1050 and NT1051.
OL307 pLVX Che-hi3 Rab43. Rab43 sequence was PCR amplified from
pOTB7-Rab43 using primers NT951 and NT952, digested with MluI and BamHI and
cloned into the MluI/BamHI sites of pLVX Che-hi3. OL308 pLVX Che-hi3 Rab43N131I.
SDM was performed on OL307 using primers NT1052 and NT1053.
2.4. Retroviral constructs for inducible expression
Some of the retroviral vectors listed below and in Table 2.1 were given an
identifier starting with the letters "OR". These two letters stand for "Organelle
Retrovirus" and signify that these vectors need to be packaged into retroviral particles
using a murine leukemia virus (MLV)-based packaging system.
pRetroX TRE3G-mCherry. The ~0.7 kbp BamHI/NotI fragment from
pmCherry-N1 was ligated into the BamHI/NotI sites of pRetroX TRE3G (Clontech).
OR366 pRetroX TRE3G-mEGFP. The ~0.7 kbp BamHI/NotI fragment from pmEGFPN1 was ligated into the BamHI/NotI sites of pRetroX TRE3G.
OR161 pRetroX TRE3G-mCherry-Rab1b. mCherry-Rab1b was amplified
from OL135 with primers NT729 and NT731, digested with BamHI/NotI, and ligated
into the BamHI/NotI sites of pRetroX TRE3G. OR162 pRetroX TRE3G-mCherryRab1bQ67L. mCherry-Rab1bQ67L was amplified from OL115 with primers NT729 and
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NT731, digested with BamHI/NotI, and ligated into the BamHI/NotI sites of pRetroX
TRE3G. OR163 pRetroX TRE3G-mCherry-Rab1bS22N. mCherry-Rab1bS22N was
amplified from OL142 with primers NT729 and NT731, digested with BamHI/NotI, and
ligated into the BamHI/NotI sites of pRetroX TRE3G. OR164 pRetroX TRE3GmCherry-Rab1bN121I. mCherry-Rab1bN121I was amplified from OL143 with primers
NT729 and NT731, digested with BamHI/NotI, and ligated into the BamHI/NotI sites of
pRetroX TRE3G.
OR332 pRetroX TRE3G mCherry-Rab11a. OR333 pRetroX TRE3G
mCherry-Rab11aN124I. OR334 pRetroX TRE3G mCherry-Rab11aQ70L. OR336
pRetroX TRE3G mCherry-Rab11aS25N. mCherry was amplified from pmCherry-N1
using NT358 and NT729 and digested with BamHI and AvrII. Rab11a (WT and mutant)
sequences were amplified from OL207, OL208, OL313 or OL314 using NT484 and
NT1123, and digested with AvrII and NotI. The resulting mCherry and Rab11a fragments
were assembled into the BamHI/NotI sites of pRetroX TRE3G.
OR337 pRetroX TRE3G mCherry-Rab11b. OR338 pRetroX TRE3G
mCherry-Rab11bN124I. OR340 pRetroX TRE3G mCherry-Rab11bQ70L. OR341
pRetroX TRE3G mCherry-Rab11bS25N. mCherry was amplified from pmCherry-N1
using NT358 and NT729 and digested with BamHI and AvrII. Rab11b (WT and mutant)
sequences were amplified from OL209, OL210, OL315 or OL316 using NT478 and
NT1124, and digested with AvrII and NotI. The resulting mCherry and Rab11b
fragments were assembled into the BamHI/NotI sites of pRetroX TRE3G.
OR342 pRetroX TRE3G mCherry-Rab8a. OR344 pRetroX TRE3G
mCherry-Rab8aN121I. OR345 pRetroX TRE3G mCherry-Rab8aQ67L. OR346
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pRetroX TRE3G mCherry-Rab8aT22N. mCherry was amplified from pmCherry-N1
using NT358 and NT729 and digested with BamHI and AvrII. Rab8a (WT and mutant)
sequences were amplified from OL199, OL200, OL319 or OL320 using NT991 and
NT1125, and digested with AvrII and NotI. The resulting mCherry and Rab8a fragments
were assembled into the BamHI/NotI sites of pRetroX TRE3G.
OR348 pRetroX TRE3G mCherry-Rab8b. OR349 pRetroX TRE3G
mCherry-Rab8bN121I. OR350 pRetroX TRE3G mCherry-Rab8bQ67L. OR356
pRetroX TRE3G mCherry-Rab8bT22N. mCherry was amplified from pmCherry-N1
using NT358 and NT729 and digested with BamHI and AvrII. Rab8b (WT and mutant)
sequences were amplified from OL201, OL202, OL321 or OL322 using NT458 and
NT1126, and digested with AvrII and NotI. The resulting mCherry and Rab8b fragments
were assembled into the BamHI/NotI sites of pRetroX TRE3G.
OR367 pRetroX TRE3G-GFP-DrrA61-647. L. pneumophila GFP-DrrA61-647 was
amplified from pGFP-DrrA61-647 using NT729 and NT1069, digested with BamHI/EcoRI
and ligated into the BamHI/EcoRI sites of pRetroX TRE3G.
2.5. Mammalian cell lines: derivation, selection and growth
The cell lines used in this work, the retroviral and lentiviral vectors used for their
construction and their antibiotic resistances are listed in Table 2.3. Briefly, human
hepatocellular carcinoma Huh-7.5 cells (Blight et al., 2002), Huh-7.5-derived cells,
human epithelial adenocarcinoma HeLa cells, and human embryonic kidney HEK293T
cells were grown in Dulbecco's Modified Eagle's Medium (DMEM, Gibco),
supplemented with L-glutamine, sodium pyruvate, 0.1 mM non-essential amino-acids
(from here-on referred to as DMEM+) and 10% fetal bovine serum (FBS, Sigma or
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HyClone) in humidified incubators at 37°C and in a 5% CO2 atmosphere. Antibiotic
selection of transduced Huh-7.5-derived cell lines employed puromycin (2 μg/mL),
G418/geneticin (500 μg/mL), hygromycin (150 μg/mL) or blasticidin (6 μg/mL). HeLa
cells were selected using puromycin (1 μg/mL) or hygromycin (250 μg/mL). The
antibiotics were from Sigma or Invivogen. Selection was started two days after
transduction and was maintained throughout subsequent growth. I wish to thank Caroline
Gleason and Jenna Lobby for their help in determining the antibiotic selection conditions
employed throughout this work.
Table 2.3. Cell lines
Cell line
Parental
Cell Line
N/A
HEK293T

Viral vector used for
construction
N/A

Antibiotic
Resistance
G418

Huh-7.5

N/A

N/A

none

Huh-7.5 FLuc
Huh-7.5 TetON
(Clone 9, Cl9)
Huh-7.5 TetON
(Clone 1, Cl1)
Huh-7.5 TetON
(Clone 2, Cl2)
Huh-7.5 TetON
(Clone 4, Cl4)
Huh-7.5 TetON
(Clone 12, Cl12)
Cl9 FLuc

Huh-7.5
Huh-7.5

pLVX Phi3 FLuc
pRetroX Tet3G

Puro
G418

Huh-7.5

pRetroX Tet3G

G418

Source /
Reference
P.
Bieniasz
(Blight et
al., 2002)
This Study
(Luna et
al., 2015)
This Study

Huh-7.5

pRetroX Tet3G

G418

This Study

Huh-7.5

pRetroX Tet3G

G418

This Study

Huh-7.5

pRetroX Tet3G

G418

This Study

Cl9

pLVX Bhi3 FLuc

Cl9 OR161

Cl9

Cl9 OR161 FLuc

Cl9
OR161

OR161 pRetroX TRE3GmCherry-Rab1B
pLVX Bhi3 FLuc

Blast;
This Study
G418
Puro; G418 This Study

Cl9 OR162

Cl9

Cl9 OR162 FLuc

Cl9
OR162

OR162 pRetroX TRE3GmCherry-Rab1BQ67L
pLVX Bhi3 FLuc

90

Puro;
This Study
G418;
Blast
Puro; G418 This Study
Puro;
G418;
Blast

This Study

Table 2.3. Cell lines
Cell line
Parental
Cell Line
Cl9
Cl9 OR163

Viral vector used for
construction
OR163 pRetroX TRE3GmCherry-Rab1BS22N
pLVX Bhi3 FLuc

Cl9 OR163 FLuc

Cl9
OR163

Cl9 OR164

Cl9

Cl9 OR164 FLuc

Cl9
OR164

Cl9 OR366 FLuc

Cl9 FLuc

OR366 pRetroX TRE3GmEGFP

Cl9 OR367 FLuc

Cl9 FLuc

OR367 pRetroX TRE3GGFP-DrrA61-647

Cl9 OR332

Cl9

Cl9 OR333

Cl9

Cl9 OR334

Cl9

Cl9 OR336

Cl9

Cl9 OR337

Cl9

Cl9 OR338

Cl9

Cl9 OR340

Cl9

Cl9 OR341

Cl9

Cl9 OR342

Cl9

Cl9 OR344

Cl9

Cl9 OR345

Cl9

Cl9 OR346

Cl9

Cl9 OR348

Cl9

OR332 pRetroX TRE3G
mCherry-Rab11a
OR333 pRetroX TRE3G
mCherry-Rab11aN124I
OR334 pRetroX TRE3G
mCherry-Rab11aQ70L
OR336 pRetroX TRE3G
mCherry-Rab11aS25N
OR337 pRetroX TRE3G
mCherry-Rab11b
OR338 pRetroX TRE3G
mCherry-Rab11bN124I
OR340 pRetroX TRE3G
mCherry-Rab11bQ70L
OR341 pRetroX TRE3G
mCherry-Rab11bS25N
OR342 pRetroX TRE3G
mCherry-Rab8a
OR344 pRetroX TRE3G
mCherry-Rab8aN121I
OR345 pRetroX TRE3G
mCherry-Rab8aQ67L
OR346 pRetroX TRE3G
mCherry-Rab8aT22N
OR348 pRetroX TRE3G
mCherry-Rab8b

OR164 pRetroX TRE3GmCherry-Rab1BN121I
pLVX Bhi3 FLuc
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Antibiotic Source /
Resistance Reference
Puro; G418 This Study
Puro;
This Study
G418;
Blast
Puro; G418 This Study
Puro;
G418;
Blast
Puro;
G418;
Blast
Puro;
G418;
Blast
Puro; G418

This Study
This Study
This Study
This Study

Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study
Puro; G418 This Study

Table 2.3. Cell lines
Cell line
Parental
Cell Line
Cl9
Cl9 OR349

Viral vector used for
construction
OR349 pRetroX TRE3G
mCherry-Rab8bN121I
OR350 pRetroX TRE3G
mCherry-Rab8bQ67L
OR356 pRetroX TRE3G
mCherry-Rab8bT22N
pLVX Hhi3

Antibiotic Source /
Resistance Reference
Puro; G418 This Study

Hygro

This Study

pLVX Hhi3 ApoE3mEGFP
pLKO.1 (EV)
pLVX Hhi3

Hygro

This Study

Puro
Puro;
Hygro
Puro;
Hygro
Puro
Puro;
Hygro
Puro;
Hygro
Puro;
Hygro
Puro
Puro;
Hygro
Puro;
Hygro
Puro;
Hygro
None

M. Scull
This Study

Cl9 OR350

Cl9

Cl9 OR356

Cl9

Huh-7.5/EV
Hygro
Huh-7.5/ApoEGFP
EVKD
EVKD/EV Hygro

Huh-7.5

EVKD/ApoEGFP
EKD1
EKD1/EV Hygro

EVKD
Huh-7.5
EKD1

pLVX Hhi3 ApoE3mEGFP
pLKO.1 shApoE
pLVX Hhi3

EKD1/ApoE

EKD1

pLVX Hhi3 ApoE3

Huh-7.5
Huh-7.5
EVKD

EKD1/ApoE-GFP EKD1
EKD2
EKD2/EV Hygro

Huh-7.5
EKD2

pLVX Hhi3 ApoE3mEGFP
pLKO.1 shApoE
pLVX Hhi3

EKD2/ApoE

EKD2

pLVX Hhi3 ApoE3

EKD2/ApoE-GFP EKD2
HeLa

N/A

pLVX Hhi3 ApoE3mEGFP
N/A

Puro; G418 This Study

This Study
M. Scull
This Study
This Study
This Study
M. Scull
This Study
This Study
This Study
P.
Bieniasz
This Study

pLVX Hhi3 ApoE3Hygro
mEGFP
pLVX Phi3 mEGFPPuro
This Study
HeLa/GFP-ApoE HeLa
ApoE3
Abbreviations: Blast, blasticidin S; Puro, puromycin; Hygro, hygromycin B; EV, empty
vector.
HeLa/ApoE-GFP

HeLa

Puro; G418 This Study
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Huh-7.5 TetON clonal cell lines. HCV-permissive Huh-7.5-derived clonal cell
lines were engineered to constitutively express the TetON3G transactivator protein via
transduction with retroviral particles generated using pRetroX Tet3G. Transduced cells
were selected with G418, then clonal cell lines were obtained by plating the selected
population in 96-well plates at 0.5-0.8 cells/well. Six weeks later, 12 Huh-7.5 TetON
single-clone-containing wells were expanded and characterized. The Huh-7.5 TetON
clones were tested for permissivity to HCV infection and spread using the reporter virus
Jc1 378-1-TagRFP (Christopher Jones). This HCV reporter is similar to Jc1 378-1-YPet
(Horwitz et al., 2013), but expresses a NS5A-TagRFP fusion instead of a NS5A-YPet
fusion. TagRFP is a red fluorescent protein (RFP) variant (Merzlyak et al., 2007), while
YPet is a yellow fluorescent protein variant (Nguyen and Daugherty, 2005). The clones,
alongside the parental Huh-7.5 cells, were infected with the RFP reporter HCV at a
multiplicity of infection (MOI) of 0.1 tissue culture infectious dose 50 (TCID50) per cell.
The cells were harvested at 30 h or at 72 h post infection, fixed, and the percentage of
infected (RFP-positive) cells was determined by flow cytometry. Clones 1, 2, 4, 9 and 12
were infected at levels comparable to the parental Huh-7.5 at both time points and were
chosen for further characterization. To determine expression induction properties, each
clone was transduced with retroviral particles made using pRetroX TRE3G-mCherry.
Transduced populations were selected with G418 and Puromycin. To determine a doseresponse induction curve for each TRE3G-mCherry-transduced TetON clone, decreasing
3-fold serial dilutions of doxycycline (Clontech) were used, starting from a high dose of
10 μg/mL. The cells were treated for 48 h then the mCherry fluorescence was quantified
by flow cytometry (Figure 2.2A). Since induction of mCherry expression in all the clones
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was found to near a plateau at about 3 μg/mL, this dose was used in all subsequent
experiments. To determine the time-course of induction, the reporter-transduced clones
were incubated with 3 μg/mL doxycycline for 0, 6, 12, 24, 36 or 48 h, and then the
mCherry fluorescence was quantified by flow cytometry (Figure 2.2A-B). Growth rates
were quantified using CyQuant NF Cell Proliferation Assay (Molecular Probes) for
several days after plating 15,000 or 5,000 cells/well in 96-well plates. All clones had
indistinguishable growth rates compared to the parental Huh-7.5, except for Clone 4,
which had a 30% lower growth rate as measured at 96 h after plating. Based on these
tests, Clone 9 was deemed to have the best properties in terms of permissivity to HCV
infection, tightness and magnitude of induction in response to doxycycline, was therefore
used in future studies, and was designated as Huh-7.5 TetON.
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Figure 2.2. Characterization of Huh-7.5 TetON clonal cell lines. The Huh-7.5 TetON
clones were transduced with a retrovirus expressing a doxycycline-inducible mCherry
fluorescent protein reporter and the induction of gene expression was characterized by
flow cytometry. (A) Doxycycline dose-response curve. Median fluorescence intensity
values of populations of cells treated for 48 h with the indicated concentrations of
doxycycline. A.U., arbitrary units. (B and C). Time course of induction. The cells were
treated with 3 μg/mL doxycycline for the indicated amounts of time, then the mCherry
fluorescence levels were quantified in single live cells by flow cytometry. (B) Data points
represent the median single-cell mCherry fluorescence intensity levels in each sample.
(C) Histograms of single cell mCherry fluorescence levels corresponding to the data
points from panel B.
Huh-7.5 ApoE knockdown cell clones. Stable clonal control knockdown and
ApoE knockdown Huh-7.5 cell lines were generated by Dr. Margaret A. Scull. I am
grateful to her for allowing me to use these cell lines. Huh-7.5 cells were transduced with
lentivirus particles generated using empty vector pLKO.1, or pLKO.1 shApoE, which
expresses an ApoE-targeting shRNA (clone ID=TRCN0000010913, Broad Institute's
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Genetic Perturbation Platform).

The cells were selected using puromycin before

undergoing single cell sorting into 96-well plates on a BD Aria2 Sorter at the Rockefeller
University Flow Cytometry Core Facility.

Individual cell clones were expanded in

DMEM+ supplemented with 10% FBS and 10 units/mL penicillin and 10 μg/mL
streptomycin (Gibco) and screened for HCV pseudoparticle entry and HCV replication
competence as well as ApoE knockdown by quantitative reverse transcription PCR (qRTPCR) and Western blotting. The empty vector-transduced clone was designated Huh-7.5
EV KD, while the two ApoE knockdown clones were designated Huh-7.5 EKD1 and
Huh-7.5 EKD2, respectively.
2.6. Plasmid transfections
Plasmid transfection of HEK293T cells was done by quickly vortexing plasmid
DNA and polyethyleneimine (Polysciences Inc, stock at 1 mg/mL in water) at a ratio of
1:4 in Optimem-I (Gibco, 10% of total media volume in the plate). The transfection mix
was kept at room temperature for 10 min, then the media on the cells was changed to
fresh media and the transfection mix was added. The media was again changed at 4-6 h.
Huh-7.5 cells were transfected with Lipofectamine-3000 (Invitrogen) according to the
manufacturer's instructions.
2.7. Lentivirus and retrovirus particle production
Low-passage HEK293T cells (60-80% confluent) were co-transfected using
polyethyleneimine and a 5:5:1 ratio of a retroviral or lentiviral plasmid, a suitable GagPol
plasmid, and a VSVg plasmid, respectively. To obtain virus for routine transductions, 11
μg of total DNA were used to transfect a 100-mm dish, in a total of 10 mL of media. To
produce high titer virus stocks, 88 μg of total DNA were used to transfect a 150-mm dish
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in a total of 20 mL of media. Virus-producing HEK293Ts were maintained in DMEM+
supplemented with 3% FBS. Virus-containing media was collected at 24 h, (and 48 h and
72 h, as needed) post transfection, filtered through a 0.45 μm filter, and used to transduce
target cells immediately, after short storage at 4°C, or frozen at -80°C with added 20 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco) and 4 μg/mL
Polybrene (Millipore). Fresh media was added to cells after each harvest, if further
collections were needed. For virus concentration, pooled virus-containing media was
mixed at a ratio of 3:1 with LentiX Concentrator (Clontech), cooled at 4°C, then
centrifuged for 45 min at 4°C and 1,500 x g. The viral pellet was resuspended into
DMEM+ supplemented with 3% FBS, 20 mM HEPES and 4 μg/mL Polybrene, to
achieve a 50 to 100-fold concentration, then aliquoted and stored at -80°C until used.
Infections of Huh-7.5-derived cell lines were done in DMEM+ supplemented with 3%
FBS, and 4 μg/mL Polybrene, for between 6 and 16 h, after which the media was changed
to DMEM+ containing 10% FBS.
2.8. Lentivirus titer determinations
Titers of lentiviruses expressing fluorescent protein (FP) markers were
determined using a flow cytometry-based assay as previously described (Sastry et al.,
2002). Briefly, Huh-7.5 cells were plated in 12-well plates at 105 cells/well. The
following morning, serial dilutions of lentivirus stocks were made in DMEM+
(supplemented with 3% FBS and 4 μg/mL Polybrene) and 1 mL of each dilution was
used to infect individual wells. The media was changed at 6-8 h to 1 mL DMEM+
supplemented with 10% FBS. At 48 h post infection, the cells were processed and
analyzed live by flow cytometry. Mock-transduced Huh-7.5 cells were used for gating.
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The percent of fluorescent protein-positive, single live cells was recorded. Dilutions
yielding a percent of fluorescent protein-positive cells between 1 and 20% were used to
calculate the titer of the original stock using the formula:
%

2.9. Flow cytometry
Cells were washed with phosphate-buffered saline (PBS) and trypsinized; trypsin
was inactivated using cold DMEM+ containing 10% FBS. The cells were then pelleted
for 2-3 min at 1,500 x g and 4°C, washed once with cold FACS buffer (PBS, 25 mM
HEPES, pH 7.4, 1% bovine serum albumin), resuspended in FACS buffer containing 50
ng/mL 4',6-diamidino-2-phenylindole (DAPI, Molecular Probes), and kept on ice until
analyzed on a BD-LSRII flow cytometer equipped with 405, 488, 561 and 640 nm lasers.
Gating and analysis was performed using BD FACSDiva and FlowJo software.
2.10. HCV
RNA transcripts of the infectious HCV clone J6/JFH1 were generated from
plasmids as previously described (Lindenbach et al., 2005). Briefly, plasmid DNA was
linearized by digestion with XbaI, templates were purified by Minelute column (Qiagen),
and 1 µg DNA was transcribed using the T7 RiboMAX™ Express Large Scale RNA
Production System (Promega). Template DNA was removed by digestion with 1 U
DNase I and RNA was cleaned up by RNeasy kit (Qiagen) with an additional on-column
DNase I digestion step (Qiagen). RNA was quantified by absorbance at 260 nm, its
integrity was verified by agarose gel electrophoresis, and 5 μg aliquots were stored at 80°C.
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HCV RNA was transfected into Huh-7.5 cells by electroporation as described
previously (Lindenbach et al., 2005). Briefly, Huh-7.5 cells were trypsinized, washed
twice with ice-cold Hanks' Balanced Salt Solution (HBSS, Ca2+/Mg2+-free, Gibco), and
resuspended to 1.5 x 107 cells/mL in cold PBS. For each electroporation, 5 µg of HCV
RNA were mixed with 6 x 106 cells and immediately pulsed using an ElectroSquare
Porator ECM 830 (BTX, Holliston, MA; 860 V, 99 µsec, five pulses). Electroporated
cells were diluted in 30 mL of DMEM+ supplemented with 10% FBS, and plated in 24well plates. Media was changed at 4-6 h, when a set of wells was further washed in cold
PBS and harvested in RLT buffer (Qiagen) containing 0.14 M 2-mercaptoethanol for
quantification of HCV RNA by qRT-PCR. When needed, cell supernatants were
harvested, clarified through a 0.45 µm filter and frozen at -80°C for assay of infectious
virus production by limiting dilution assay and tissue culture infectious dose 50
calculation by the method of Reed and Muench, as previously described (Lindenbach et
al., 2005). For quantification of intracellular infectious virus levels (Gastaminza et al.,
2006), the cells were trypsinized and pelleted at 1,500 x g for 3 min. Pellets were washed
and resuspended in DMEM+ supplemented with 10% FBS. The cells were lysed by four
freeze-thaw cycles, and the debris pelleted by twice centrifuging at 1,500 x g for 5 min.
The supernatant was collected and viral infectivity was quantified as described above.
2.11. Luciferase assay
For luciferase activity measurements in the cell lysates, cells expressing the firefly
luciferase were washed once in cold PBS, then 1 x Cell culture lysis reagent (Promega)
was added. The plates were immediately sealed with adhesive aluminum foil, and stored
at -80°C. On the day of the assay, the plates were thawed at 4°C and the cell lysates were
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transferred to 96-well plates. Protein concentration in the samples was determined when
needed using the Microplate BCA Protein Assay Kit, Reducing Agent Compatible
(Thermo Scientific). Activity (luminescence) in 20 μL of lysate was measured
immediately following injection of 50 μL of firefly luciferase assay buffer + substrate
(Promega) using a Synergy Neo plate reader (Bio-Tek).
2.12. Microscopy
Cells were imaged live in growth medium or in cell imaging media (Hanks'
balanced salts [Sigma], supplemented with 5% FBS, 0.1 mM non-essential amino acids,
10 mM HEPES, pH 7.5) or after fixation with 4% paraformaldehyde (Electron
Microscopy Sciences) solution in PBS and further PBS washes. Images were acquired on
the following systems: Olympus IX70/IX81 inverted microscopes equipped with 10X
UplanFL 0.3 numerical aperture air or 60X UPlanApo 1.2 numerical aperture water
objectives and Hamamatsu ORCA-ER cameras and Metamorph software (Molecular
Devices), or a Deltavision system (Applied Precision) equipped with a 60X 1.42
numerical aperture oil objective and SoftWoRx software (Applied Precision).
Deconvolution of fluorescence images using measured point-spread function was done in
the SoftWoRx software, Pearson's coefficient measurements were done in Imaris
(Bitplane), and final images were processed using FiJi (Schindelin et al., 2012) or
Metamorph software.
2.13. Transferrin uptake
The protocol to measure the uptake of transferrin was adapted from (Fielding et
al., 2012). Huh-7.5 cells were grown in 6-well plates. They were incubated for 1 h at
37°C in serum-free DMEM+, then washed with PBS and incubated in CellStripper
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(Corning) at room temperature until they became detached. The cells were immediately
moved into microcentrifuge tubes, cooled and subsequently processed on ice. The cells
were pelleted for 2 min at 1,500 x g and 4°C and resuspended in 250 μL cold serum-free
DMEM+, then 250 μL serum-free DMEM+ containing 100 μg/mL transferrin-Alexa
Fluor 647 (Molecular Probes) were added, mixed with the cells, and the entire volume
was split into two tubes and incubated for 5 min on ice to allow binding to the cell
surface, then pelleted as above. The cells from one set of tubes were washed twice each
with 1 mL ice-cold acid buffer (PBS, 1% bovine serum albumin, pH 5.0), then
resuspended in 100 μL FACS buffer, supplemented with 50 ng/mL DAPI as dead cell
exclusion stain and analyzed by flow cytometry to quantify the amount of transferrin
bound at 4°C. The cells from the second set of tubes were resuspended in serum-free
DMEM+, incubated at 37°C for 10 min to allow uptake, then cooled on ice for 5 min and
further acid-washed and analyzed as described above.
2.14. VSVg transport assays
VSVg transport was monitored biochemically by co-transfection of (per well of a
6-well plate) 2 μg of pVSVgtsO45-GFP (Presley et al., 1997) and 0.5 μg of a pLVX
plasmid expressing mCherry or mCherry-Rab1b constructs. The plates were placed in an
incubator set at 39.5°C. The media was changed at 4-6 h and the cells were returned to
39.5°C. At 24 h post-transfection, a plate containing one set of transfections was moved
to a 32°C incubator for 3 h. The plates were then rapidly cooled on ice, washed once with
cold PBS, scraped into PBS and moved into microcentrifuge tubes, on ice. The cells were
pelleted at 1,500 x g for 3 min at 4°C. The pellet was resuspended in 100 μL RIPA buffer
(Sigma) supplemented with Complete protease inhibitors (Roche), lysed on ice for 15
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min, then centrifuged at 20,000 x g for 15 min at 4°C. The lysates were moved to a new
tube and stored at -20°C. For endoglycosidase digestion, the lysates were thawed on ice
and divided into 3 aliquots. One aliquot was digested with EndoH, one with PNGase F,
and one was left untreated. Digestions were done for 2 h at 37°C according to New
England Biolabs instructions, and were stopped by boiling the samples in 2X sodium
dodecyl sulfate (SDS) sample buffer (containing protease inhibitors and 0.3 M 2mercaptoethanol)

and

followed

by

processing

for

SDS

Polyacrylamide

gel

electrophoresis (SDS-PAGE) and Western blotting experiments.
Huh-7.5 cells were plated in 35-mm glass-bottom MatTek dishes. The next day,
each dish was co-transfected with 1 μg of pVSVgtsO45-GFP and 0.5 μg of pLVX Phiderived plasmid expressing mCherry or mCherry-Rab1b constructs. The dishes were
immediately placed in an incubator set at 39.5°C. The media was changed at 4 h and the
cells were returned to 39.5°C. At 24 h post-transfection, one set of dishes was moved to a
32°C incubator for 3.5 h, while a second set was kept at 39.5°C, before all were fixed
with 4% paraformaldehyde in PBS for 15 min at room temperature, then washed with
PBS and imaged.
2.15. SDS-PAGE and Western blotting
Cells were lysed and boiled in reducing SDS sample buffer. The proteins were
separated on 4-12% Bis-Tris SDS-PAGE gels (Invitrogen), then transferred onto
nitrocellulose membranes using the iBlot system (Invitrogen). The membranes were
blocked in 5% non-fat milk in Tris-buffered saline supplemented with 0.1 % Tween-20)
for 1 h at room temperature, immunoblotted with primary antibodies (overnight at 4°C)
and matched horseradish peroxidase-conjugated secondary antibodies (1 h at room
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temperature), treated with chemiluminescence substrates (ECL Prime, Amersham or
West Pico or West Femto, Pierce), before being exposed to Amersham Hyperfilm MP
autoradiography film and developed.
2.16. Antibodies
The antibodies used throughout this work are listed in Table 2.4, alongside the
dilutions they were used at in each application. For immunoprecipitation, the amounts of
antibody used are described in the respective specific sections.
Table 2.4 Antibodies and usage conditions
Antibody
Type
Conjugation Usage
mouse
mAb
rabbit
mAb
rabbit pAb
mouse
mAb

WB 1:2000
IF 1:250
IP

α-ApoB
α-ApoB
α-ApoB
α-ApoE

goat pAb
goat pAb
rabbit pAb
rabbit
mAb

IP
WB 1:1000
IP
WB 1:1000
IF 1:250

α-ApoE

goat pAb

α-albumin

goat pAb

WB 1:1000
IP
IP

α-NS5A

mouse
mAb
goat pAb

HRP

α-rabbit
IgG

goat pAb

HRP

α-goat IgG

rabbit pAb

HRP

α-GFP
α-GFP
α-dsRed
α-(β)actin

α-mouse
IgG

WB 1:1000
WB 1:2000

IHC
1:25000
WB
1:80000 1:150000
WB
1:80000 1:150000
WB
1:80000 1:150000
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Source/Reference Catalog or
clone no.
Clontech
632381
Clone JL-8
(Cristea et al.,
N/A
2006)
Clontech
632496
Sigma
A5316
Clone
AC-74
Calbiochem
178467
Millipore
AB742
Abcam
50069
Abcam
52607
Clone
EP1374Y
Millipore
AB947
Midland
Bioproducts
????

71907

Sigma

Clone
9E10
A9917

Sigma

A0545

Sigma

A5420

Table 2.4 Antibodies and usage conditions
Antibody
Type
Conjugation Usage

Source/Reference Catalog or
clone no.
Jackson
115-035Immunoresearch
146
Jackson
011-000Immunoresearch
002
Molecular Probes A-11029

goat pAb
HRP
IHC 1:200
α-mouse
IgG
rabbit
IP
normal
IgG
goat pAb
AF488
IF 1:1000
α-mouse
IgG
goat pAb
AF594
IF 1:1000
Molecular Probes A-11037
α-rabbit
IgG
Abbreviations: IgG, immunoglobulin G; mAb, monoclonal antibody; pAb, polyclonal
antibody; IP, immunoprecipitation; IF, immunofluorescence; WB, Western blotting; IHC,
immunohistochemistry; HRP, horseradish peroxidase; AF, Alexa Fluor.
2.17. Secretion assays and cargo quantification
Cells were washed once with DMEM+ containing 1% FBS, and then were
allowed to secrete cargo in the same media for the indicated amounts of time (usually 6 h
for samples analyzed by ELISA, 5 h for samples subjected to lipoprotein immunoprecipitation, and 6 or 24 h for HCV infectivity assays, respectively, or otherwise as
indicated in the text or on the figures). For HCV secretion experiments, secretion was
performed in media containing 10% FBS. At the end of the secretion period, media and
cells were harvested and stored at -80°C until processed. If needed, cell lysates were
harvested at this time for luciferase activity assays. For ELISA-based quantification of
cell-associated cargo, cells were grown in 6-well plates, washed once in cold PBS
supplemented with 50 mM ethylenediaminotetraacetic acid (EDTA), then scraped on ice
in PBS supplemented with 50 mM EDTA. The cells were then pelleted and resuspended
in 500 μL RIPA buffer supplemented with protease inhibitors and lysed on ice for 15
min, then stored at -80°C. Cargo amounts in cell lysates and supernatants were quantified
using human-specific ELISA kits (Abcam: ApoE, ab108813; ApoB100, ab108807;
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albumin, ab108788). Unconditioned media containing 1% or 10% FBS contained
undetectable amounts of human albumin, ApoE, or ApoB100.
2.18. DN Rab GTPase screen
Huh-7.5 FLuc cells were plated at 42,000 cells/well in 12-well plates. After 7 h,
the cells were infected with pLVX Che-hi3-derived viruses expressing WT or DN
untagged Rab GTPases. The viruses, previously concentrated and titrated, were diluted in
DMEM+ supplemented with 3% FBS and 4 μg/mL Polybrene such that the final dose in
each target well was either 25 or 100 I.U./cell, and was contained in a total volume of 300
μL/well. The media was changed after 12 h to 500 μL/well of DMEM+ supplemented
with 10% FBS. At 48 h post transduction, the cells were washed with 250 μL/well of
DMEM+ containing 1% FBS, and then were incubated in the same media for 6 h at 37°C.
Finally, the media was harvested and stored at -80°C until ELISA assays were performed.
The cells were lysed on the plate in 100 μL/well of 1X cell culture lysis reagents, and
stored at -80°C until a luciferase assay was performed. Transductions and secretion
assays, ELISA assays and luciferase assays for paired WT-DN Rab samples were always
performed on the same plate to minimize technical variations.
2.19. Polarized induced hepatocyte-like cells
The yet unpublished differentiation protocol for human induced hepatocyte-like
cells (iHeps) from human embryonic stem cells has been developed by Dr. Xianfang Wu.
The conditions in which the iHeps may be differentiated and polarized in a monolayer
culture on trans-well filters has been developed by Dr. Wu and Dr. Viet Loan Dao Thi.
The details of these protocols will be described by Dr. Wu and Dr. Dao Thi in an article
currently in preparation. For the experiments presented in Chapter 4, trans-well filter-
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grown iHep monolayers were washed twice with HBM basal medium (Lonza) and
exposed to fresh media in both the apical and basolateral chambers for 6 h. The medium
added to the apical chamber (within the trans-well insert) was the HBM basal medium.
The medium added to the basolateral chamber (outside the trans-well insert) was the
same HBM medium supplemented with all the components of the HCM Bullet Kit
(Lonza) with the exception of the epidermal growth factor, EGF. The media was also
supplemented with 10 U/mL penicillin, 10 μg/mL streptomycin and 20 ng/mL
Oncostatin-M. At the end of the 6 h secretion assay, the media were harvested and stored
at -80°C. The cells were washed in cold PBS and then lysed at 4°C on the filter in 300 μL
cold RIPA buffer supplemented with protease inhibitors. The lysate was also stored at 80°C and the cargo amounts were measured in the media and in the lysates by ELISA
Unconditioned media did not yield an ELISA signal for either human albumin, ApoE or
ApoB100.
2.20. Co-immunoprecipitation of lipoproteins
Huh-7.5/EV Hygro or Huh-7.5/ApoE-GFP cells were washed once with DMEM+
containing 1% FBS, allowed to secrete cargo in the same media for 5 h, then media and
cells were harvested. Media was cleared by a 3 min, 500 x g spin, then an aliquot of the
media was mixed with SDS sample buffer, denatured, and stored at -20°C.
Immunoprecipitation of 1.8 mL of cleared media was done as follows. All tubes were
pre-coated with 1% bovine serum albumin, 0.1% Tween-20, PBS for 1 h, then washed 3
times with PBS. Media was incubated with 29 μg of rabbit α-GFP, rabbit α-ApoB100, or
normal rabbit IgG, overnight at 4°C. Protein G Dynabeads (50 μL, pre-washed with PBS)
were added and incubated 1 h at room temperature, then washed 4 times with PBS, then
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denatured in SDS sample buffer. Samples were then processed by SDS-PAGE and
Western blotting.
2.21. Radioactivity pulse-chases
This procedure was adapted from a previous study (Wang et al., 1993) as follows.
Huh-7.5/EV Hygro and Huh-7.5/ApoE-GFP cells were plated at 3 x 105 cells/well in 6well plates once day prior to the pulse chase assay. Clone 9 OR164 FLuc cells (inducibly
expressing mCherry-Rab1bN121I) were plated at 2.5 x 105 cells/well in 6-well plates 2
days before the pulse chase assay; the next day, half of the wells in each plate were
induced with 3 μg/mL doxycycline, and the rest were left uninduced. On the day of the
pulse chase assay, the cells were washed in PBS and then pulse labeled with 35S-cysteine
and 35S-methionine (120 μCi/well) in DMEM containing no cold cysteine or methionine,
and supplemented with 1% FBS and 0.1 mM non-essential amino acids for 20 min. The
cells were then washed twice in PBS and chased in DMEM containing cycloheximide
(Millipore, 50 μM) and excess of methionine (1.5 mg/mL) and cysteine (0.5 mg/mL). At
each time point, the media was removed and the cells were washed once with PBS. The
cells were lysed by rocking at 4°C for 30 min in 1 mL of Lysis buffer: 6.1 mM Na2HPO4,
4.5 mM NaH2PO4, 88.4 mM NaCl, 36.58 mM LiCl, 24.1 mM sodium deoxycholate, 1%
Triton X100, 1% SDS, pH 7.4, supplemented with 4 μL/mL phenylmethanesulfonylfluoride (Sigma, 0.1 M in ethanol) and Complete protease inhibitors. Total
protein-incorporated radioactivity in the samples collected at each time point was
determined

after

trichloroacetic

acid

precipitation,

using

scintillation

fluid.

Immunoprecipitation of ApoE, ApoB100 and albumin from media and cell lysates was
performed by incubation with 5 μL each of the anti-ApoE, anti-ApoB100 and anti-
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albumin antibodies and 50 μL protein A sepharose 4B beads (Invitrogen) in 1X NET
buffer (0.15 M NaCl, 5 mM EDTA, 50 mM Tris, pH 7.5) supplemented with 1% Triton
X100, overnight at 4°C. The beads were then washed 3 times in 1X NET buffer
supplemented with 1% Triton X100 and 1% SDS, then the bound protein was eluted in
1X NET buffer containing 1% SDS. Samples were resuspended in denaturing buffer: 125
mM Tris-HCl, pH 6.8, 6 M urea, 1 mM EDTA, 10 mM dithiothreitol, 4% SDS, 25 mM 2mercaptoethanol, and separated by SDS-PAGE on 4-12% Bis-Tris gels. The gels were
fixed for 15 min with a 50% methanol, 7% acetic acid aqueous solution, incubated with
Autofluor (National Diagnostic) for 15 min, and exposed in a Typhon 9400
phosphorimager. The intensity of each band was quantified and the background was
subtracted in the Fiji software (Schindelin et al., 2012). Relative amounts of radiolabeled
amino acid incorporation were calculated by dividing the intensity of the protein-specific
band at the end of the pulse period by the measured total protein-contained radioactivity
in the corresponding sample. Secretion of newly synthesized proteins was assessed by
expressing the amount of radioactively labeled protein present in the media at a given
time point as a percent of the total (secreted + cell-associated) radioactively labeled
protein measured at the same time point.
2.22. qRT-PCR
To harvest RNA, cells were lysed in RLT buffer (350 μL/well, supplemented with
0.14 M 2-mercaptoethanol), processed using Qiashredder (Qiagen) and the lysates stored
at -80°C. RNA was isolated using the RNeasy kit (Qiagen) with the additional on column
DNase I digestion, and stored again at -80°C. qRT-PCR was performed on 10 or 50 ng
total RNA using the QuantiFast SYBR Green RT-PCR kit (Qiagen) and QuantiTect
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Primer Assay kits (Qiagen) specific for human GAPDH (QT00079247), RAB1B
(QT00046396), APOE (QT00087297), APOB (QT00020139) and ALB (QT00063693),
respectively. Fold changes in mRNA expression levels were determined using the ΔΔCt
method (Livak and Schmittgen, 2001), using GAPDH as reference housekeeping gene.
HCV RNA levels were quantified against a standard curve using a one-step qRT-PCR
assay (Multicode-RTx HCV RNA kit, Luminex Corp.) targeting the 3' UTR of the viral
genome. Cycling was performed on a Roche Light Cycler 480 (Roche). Data analysis
was performed on the Light Cycler 480 Software (Roche) and on the MultiCode-RTx
Analysis Software (EraGen Biosciences).
2.23. Transcript expression levels by RNA sequencing
Huh-7.5 RNA sequencing (RNAseq) expression data for members of the Rab
GTPase family, as well as for several other selected genes were extracted from datasets
previously generated (Luna et al., 2015). The genes were ranked in ascending order of
their expression levels. Genes to which no reads mapped were nonetheless assigned a
score of -10 Log2CPM, to allow them to be included in the graph. Unpublished RNAseq
data from human fetal liver cultures, or HFLCs (Andrus et al., 2011) was kindly provided
by Drs. William Schneider, Joseph Luna and Linda Andrus.
2.24. Statistical analyses
Unpaired two-tailed Student's t-test was performed in most cases. For analysis of
the DN Rab screen data, the unpaired two-tailed Student's t-test with Bonferroni
correction was performed. For HCV experiments, a two-way ANOVA test was
performed. P-values were calculated in Microsoft Excel or in GraphPad Prism. I am
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grateful to Dr. Michelle Itano for expert advice and help on performing statistical
analyses.
2.25. Miscellaneous methods
Rab protein amino acid sequences were aligned using the ClustalW function of
the Megalign program of DNAStar Lasergene. Rab1b crystal structure, Protein Data
Bank structure 3NKV (Muller et al., 2010) was manipulated using PyMOL (Schrödinger
Inc.).
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Chapter 3
A Dominant Negative Rab GTPase Screen
Identifies Regulators of Hepatic Cargo Secretion

3.1. The concept
While progress has been achieved in characterizing the transport pathways
mediating the secretion of hepatic lipoproteins (Sundaram and Yao, 2012; Tiwari and
Siddiqi, 2012) and of HCV (Lindenbach, 2013; Lindenbach and Rice, 2013), further
elucidation is required to improve our understanding of these processes. To investigate
hepatic cargo secretion, I relied on the knowledge that Rab GTPases control relatively
specific steps of intracellular vesicular transport (Hutagalung and Novick, 2011;
Stenmark, 2009). For example, the Rab1, Rab2, and Rab6 subfamilies control traffic
between the ER and the Golgi compartment, and within the Golgi (Chavrier et al., 1990a;
Goud et al., 1990; Martinez et al., 1994; Plutner et al., 1991; Segev et al., 1988; Tisdale
and Balch, 1996; Tisdale et al., 1992); the Rab3 and Rab8 subfamilies control post Golgi
exocytosis (Fischer von Mollard et al., 1990; Fischer von Mollard et al., 1991; Huber et
al., 1993a; Huber et al., 1993b); the Rab5 subfamily controls early steps of endocytosis
(Bucci et al., 1992; Gorvel et al., 1991); and the Rab11 subfamily controls recycling of
endocytosed proteins (Ren et al., 1998; Ullrich et al., 1996). Indeed, Rabs are considered
a class - although not the only one - of identity markers that define the nature of a
particular membrane-bound compartment (Barr, 2013; Pfeffer, 2013). I thus hypothesized
that by inhibiting the function of individual Rab proteins and by measuring the effects
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this inhibition had on the efficiency of cargo secretion, I may well be able to identify the
Rabs, and therefore the vesicular transport pathways involved in the secretion of hepatic
cargoes.
This is not the first screen of this nature. Previous studies have utilized
overexpression of proteins regulating the Rab functional cycle, such as GAPs and GEFs,
and/or knockdown experiments to attain similar goals (Fuchs et al., 2007; Pilli et al.,
2012; Udayar et al., 2013; Yoshimura et al., 2010). Their success cemented my belief that
this idea was sound. Furthermore, the wealth of knowledge accumulated over the past
three decades of investigation of the regulation of intracellular transport by the Rab
proteins (Hutagalung and Novick, 2011) allowed me to design an experimental approach
whose implementation relied on the use of many previously described molecular tools.
These include well characterized DN mutants, functional fusions of fluorescent proteins
to the Rabs, activators and repressors of endogenous Rab function (Barr and Lambright,
2010), and an ever-growing list of known Rab effectors (Hutagalung and Novick, 2011).
3.2. DN Rab screen outline
The outline of the screen is depicted in Figure 3.1. Since expression of DN Rab
mutants is a well established method of inhibition of Rab function, I expressed a panel of
such mutants in a liver-derived cell line (Figure 3.1A). For each DN Rab (red text and
cartoons), I used expression of the WT Rab (blue text and cartoons) as the control
condition (Figure 3.1B). I did so in an attempt to distinguish between effects due to mere
overexpression of the Rabs and the effects due to functional differences between the WT
and the DN versions of a given Rab. Following expression of WT-DN Rab pairs, I
washed the cells to remove cargo loosely attached to the cell surface or to the plate, and
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then performed a secretion assay. At the end of the secretion assay, I quantified the
amount of cargo released into the media, and also estimated the cellular mass present in
the well and thus responsible for secretion (Figure 3.1C). By dividing the secreted cargo
amounts by the cell mass measurement (Figure 3.1D), I calculated a normalized level of
secretion in each well. I then compared these normalized secretion values obtained in the
presence of WT and DN Rab expression (Figure 3.1E). I interpreted significant
differences between the two values to signify that the Rabs causing them were likely to
be involved in regulating secretion of the tested cargo. To elucidate the fine details of the
control of secretion by any given Rab would of course require further analysis.

Figure 3.1. Outline of the DN Rab GTPase screen. Hepatic cells (A) were made to
express WT (blue) or DN (red) Rab GTPases (B). Secretion assays were performed and
secreted cargo amounts and cell masses were measured (C). The amounts of cargo
secreted were divided by the corresponding well’s cell mass measurement to obtain
normalized secretion values (D). The normalized secretion values obtained in the
presence of DN Rab expression were compared to those obtained in the presence of the
WT Rab (E).
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3.3. The experimental system
I performed the DN Rab GTPase screen in the Huh-7.5 human hepatoma cell line
(Blight et al., 2002). I chose this cell line since I wanted to be able to directly contrast the
effects of inactivation of the hits of the Rab screen on lipoprotein secretion to their effects
on HCV egress. The Huh-7.5 cells (Blight et al., 2002; Lindenbach et al., 2005) possess
the ability to support the entire HCV lifecycle, which includes permitting high levels of
HCV RNA genome replication and infectious HCV particle release. I remain aware that
the parental Huh-7 cells (Meex et al., 2011), as well as the Huh-7.5 cells themselves
(Ursula Andreo, personal communication), remain defective in secreting ApoB100 in the
appropriate VLDL density fraction, and instead preponderantly secrete IDL/LDL-like
ApoB100-containing particles. Confirmation that a certain Rab GTPase is involved in the
secretion of HCV and/or lipoproteins in a more physiologic setting would require further
testing in more informative, but also more expensive, and potentially less easily tractable
or readily available primary cell or in vivo system(s).
A final requirement of this experimental design was that I be able to estimate the
mass of cells present at the time of the measurement of cargo secretion. Therefore, I
transduced the Huh-7.5 cells with a lentivirus expressing firefly luciferase (FLuc). I
confirmed that in the resulting Huh-7.5 FLuc cell line, the measured luciferase activity
correlated linearly with the number of cells present in the culture (Figure 3.2A).
Furthermore, this tight correlation, together with the simplicity of the luciferase activity
assay, its large dynamic range and its high sensitivity made this a more suitable cell-mass
estimation method than total protein concentration measurements (Figure 3.2B).
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Figure 3.2. Characterization of luciferase-expressing Huh-7.5 FLuc cells. Two-fold
serial dilutions of Huh-7.5 FLuc cells were plated each in 4 wells of a 24-well plate and
the cell lysates were harvested the next day. Luciferase activity (A) and total protein
concentration (B) were measured in each sample and were plotted against the dilution
factor. Values are means ± standard deviation (s.d.) of the values obtained in 4 replicate
wells. RLU, relative light units; BSA, bovine serum albumin; l.o.d. limit of detection of
the protein concentration assay.
3.4. Expression of WT and DN Rab GTPase constructs
To ensure relatively uniform construct expression in an overwhelming majority of
the cells in culture, I utilized lentivirus transduction as the preferred method of Rab
expression. In preliminary experiments, I had noticed that the transduction efficiencies of
lentiviruses expressing DN Rab1 constructs were regularly lower than those of the
lentiviruses expressing WT Rab1 or irrelevant proteins, despite the fact that the lentiviral
vectors had been packaged into lentiviral particles in parallel, using the same protocol.
This observation was not surprising since I pseudotyped the lentiviral particles using
VSVg. Loading of VSVg onto the budding lentiviral particle requires transport of VSVg
to the plasma membrane, the site of HIV-1 lentivirus assembly (Jouvenet et al., 2006).
Since Rab expression was driven by the constitutively-active CMV promoter, DN Rabs
expressed in the lentivirus particle-packaging HEK293T cells could interfere with
lentivirus particle infectivity by affecting the exocytic transport of VSVg (Tisdale et al.,
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1992). It thus became important for me to ensure that equal doses of infectious WT and
DN Rab-expressing lentiviruses were delivered to the target cells. I therefore established
a method for relatively large-scale lentivirus production, followed by concentration of the
virus stock and determination of its infectivity. To measure lentivirus titers, I utilized a
flow cytometry-based protocol which used as readout the fluorescence of the mCherry
protein expressed from the lentiviral vector pLVX Che-hi3 (Figure 2.1B) in which I
cloned the WT and mutant Rabs. Using this protocol I routinely prepared concentrated
Rab-expressing lentivirus stocks with titers in the range of 2x107 to 5x108 infectious units
(I.U.)/mL, which were measured on Huh-7.5 cells, the same cell type that I used in most
of the experiments.
I also confirmed that the fluorescence measured in the transduced cells and used
to determine lentivirus titers was due to infection by the viral particles themselves, and
not by unspecific staining of the target cells by the lentivirus particle inoculum. This was
a concern since I used a proprietary commercial reagent to concentrate the lentivirus
stocks, and I had no information on whether the concentration protocol could also enrich
exosomes, which are expected to be produced alongside the lentivirus particles (Cantin et
al., 2008) and could deliver mRNAs from the lentivirus producing cells (Valadi et al.,
2007). Carryover of the DNA that had been used to launch lentivirus production could
also, in principle, cause mCherry expression in the transduced cells. I thus produced
lentiviral particles using an mCherry-expressing lentiviral vector, VSVg, and either the
packaging system encoded by pCR/V1 NL GagPol (Zennou et al., 2004), or a plasmid
encoding only HIV-1 Gag (Graf et al., 2000). Although HIV-I Gag retains the ability to
form lentivirus-like particles (Zennou et al., 2004), it nevertheless cannot support particle
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infectivity since it lacks essential enzymatic activities such as protease, reverse
transcriptase and integrase, all of which are contained in HIV-1 Pol and required for
productive infection (Freed, 2015). Indeed, when I titrated the lentivirus stock produced
using HIV-1 Gag, I detected roughly 100- to 1000-fold fewer positive cells in the
transduced population than I did when I titrated the lentivirus stock produced using
GagPol (Figure 3.3A). The positive cells obtained by transduction with HIV-1 Gagpackaged particles also had lower fluorescence levels than the positive cells obtained by
transduction with GagPol-packaged particles (Figure 3.3B). This difference was not due
to production of fewer particles in the presence of HIV-1 Gag, since both virus stocks
contained comparable amounts of material that was recognized by an α-capsid (CA)
antibody (Figure 3.3C). Capsid is one of the domains of HIV-1 Gag (Bieniasz, 2009). As
expected, HIV-Gag (p55) did not undergo proteolytic processing in the absence of the
Pol-encoded protease activity (Figure 3.3C, left lane), but was cleaved in the presence of
Pol (Figure 3.3C, right lane). This test therefore confirmed that the readout from the
titration assay was primarily due to lentivirus infection-dependent gene expression.
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Figure 3.3. Specificity of lentivirus transduction. Concentrated lentivirus particle
stocks were made using an mCherry-expressing lentiviral vector and either an HIV-1
GagPol-expressing packaging plasmid (red) or a control HIV-1 Gag-expressing plasmid
(blue). Huh-7.5 cells were transduced with serial dilutions of each of the stocks. The
abundance of mCherry-positive cells (A) and their associated mCherry fluorescence
amounts (B) are plotted. MFI, median fluorescence intensity. (C) lentiviral particles from
each of the stocks were concentrated and analyzed by Western blotting using an α-HIV-1
capsid (CA) antibody. Molecular weights (kDa) of the major bands are listed at the right.
Cleavage of full length Gag (p55) is indicated by the appearance of the p42 and p24
bands.
Having established a method to produce high titer lentivirus stocks, I next tested
the efficiency of target cell transduction using these viruses. Previous reports have
overexpressed Rab1 constructs by infecting target cells with adenoviruses or lentiviruses
at a MOI of 5-100 I.U./cell (Filipeanu et al., 2004; Filipeanu et al., 2006; Li et al., 2010;
Yin et al., 2011). I tested two doses of lentivirus within this range, namely 25 and 100
I.U./cell. Both doses were sufficient to transduce the overwhelming majority of the target
cell population (Figure 3.4A) and to yield a fluorescent signal easily detectable by
fluorescence microscopy (Figure 3.4B).

Therefore, I planned to express the Rab

constructs under the control of a CMV promoter using a lentivirus vector which also
expressed the fluorescent protein reporter mCherry from a PGK promoter (Figure 2.1D).
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Figure 3.4. Lentivirus transduction efficiency in Huh-7.5 cells. Cells were left
uninfected or were infected with an mCherry-expressing lentivirus stock at a MOI of 25
or 100 I.U./cell, and were then analyzed 48 h later by flow cytometry (A) or fluorescence
microscopy (B). A.U., arbitrary units; BF, brightfield. Scale bar, 50 μm.
3.5 The Rabs
I chose to test the involvement of 62 human Rab GTPases in regulating hepatic
cargo secretion (listed in the Table 2.1; the NCBI reference sequence identifiers for their
amino acid sequences are listed in the table as well). Amino acid sequences were
numbered by assigning position 1 to the predicted START methionine residue.
Alignment of these sequences revealed, as expected (Diekmann et al., 2011; Gurkan et
al., 2005; Wittinghofer and Vetter, 2011), a high degree of sequence similarity,
particularly in the regions predicted to participate in the formation of the conserved Rab
GTPase domain (Figure 3.5). These amino acid stretches contained two conserved
phosphoryl binding sites and a guanine ring binding site, respectively, as identified in a
previous study (Tisdale et al., 1992) and highlighted in blue in the consensus sequence
listed at the top of the alignment (Figure 3.5).
Several mutations that interfere with various aspects of the Rab functional cycle
exist; these include mutations that target conserved residues that affect the Rab guanine
nucleotide binding and hydrolysis cycle (Table 1.1, and highlighted in red ink Figure 3.5)
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and have been widely used to inhibit Rab function. One mutation targets the conserved
serine/threonine residue involved in phosphoryl binding, equivalent to Rab1aS25. This
serine/threonine residue is conserved in all the Rab sequences in the list except for
Rab40b and 40c, where it is replaced by glycine. Mutation of this residue to asparagine
yields proteins that cannot stably bind GTP, and thus remains locked in the inactive
GDP-bound form (Nuoffer et al., 1994). Another mutation targets the conserved
glutamine residue involved in (basal or stimulated) GTP hydrolysis and equivalent to
Rab1aQ70. Mutation of this residue may yield proteins defective in GTP-hydrolysis which
causes them to be locked in the GTP-bound active state (Mishra et al., 2013). This
residue is not conserved in 4 Rabs: Rab11c (replaced by leucine), Rab20 (replaced by
arginine), Rab24 (replaced by serine) and Rab42 (replaced by histidine). A third mutation
targets the conserved asparagine residue involved in guanine ring binding. Mutation of
this residue to isoleucine may prevent the Rab from stably binding the GDP or GTP
nucleotides (Pind et al., 1994). Rabs 24, 34, and 36 carry a serine or threonine at this site,
while Rabs 39a, 39b and 42 carry a histidine. The sequence of Rab15, however, did not
align well in this region with the rest of the Rab sequences (depicted in orange in Figure
3.5).

120

Figure 3.5.

Alignment of Rab protein sequences (next page). The amino acid

sequences of 62 Rab proteins were aligned to one another, and the alignment within
selected conserved sequences is shown. The consensus sequence is listed at the top. The
two phosphoryl binding sites and the guanine ring binding site, as defined in (Tisdale et
al., 1992), are highlighted in blue within the consensus sequence. Conserved, functionally
important amino acids, as defined in the text, are highlighted in red. The position of the
first amino acid in each set of sequences is listed in purple at the left of the alignment.
The divergent Rab15 sequence within the guanine ring binding site is highlighted in
orange.
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Since introduction of the GTPase inactivating mutation does not always yield a
DN Rab (Tisdale et al., 1992), and since in preliminary experiments the nucleotide
binding mutant Rab1bN121I caused a stronger Rab1b inactivation phenotype than the
GDP-locked mutant Rab1bS22N, I chose to substitute isoleucine for the asparagine residue
equivalent to Rab1b's N121 to create a panel of DN Rab mutants. The only exception was
Rab15, for which I used the GDP-locked T22N mutant instead. Therefore, for all of the
Rabs listed in Figure 3.5, I cloned sequences encoding the WT and the indicated mutant
protein into the reporter lentiviral vector pLVX Che-hi3 (Figure 2.1B). I, then, used these
constructs to make lentiviral particles, which I concentrated and whose titers I determined
before using them in the DN Rab screen.
3.6. DN Rab screen: technical considerations
While the technical details involved in performing the DN Rab screen
experiments are described in detail in Chapter 2, I wish to underline some technical
aspects which I find informative in ensuring a proper interpretation of the results. First,
the screen was performed in Huh-7.5 FLuc (Figure 4.2) cells which allowed me to easily
quantify changes in the cell mass by measuring luciferase activities in the cell lysates.
Second, I infected these cells with two doses of infectious virus, MOI 25 and 100
I.U./cell, respectively (Figure 4.4). Since the effectiveness of the DN Rabs in inhibiting
Rab function is likely correlated with the ratio between the expressed mutant and the
natively expressed WT Rab (Nuoffer et al., 1994), by using two doses of Rab-expressing
vectors I hoped to enhance the likelihood that I would express just the right amount of
DN Rab constructs, which would then allow me to detect DN Rab-mediated changes in
cargo secretion.
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Third, all infections with a given WT-DN pair of Rabs were done in wells of a
single plate to ensure that the wells were exposed to very similar environmental
conditions and that any variations among the time lengths needed to process the samples
belonging to each WT-DN Rab pair were small. Similarly, luciferase activity and ELISA
assays for all paired samples for each of the Rabs were performed on a single plate.
Fourth, the amount of each of the three cargoes tested: albumin, ApoE and
ApoB100 was measured in each biological sample. I reasoned that this procedure would
help minimize technical and/or biological variations which could cause cargo-related
differences in the effects exerted by the inhibition of a given Rab.
3.7. Effects of DN Rab expression on cellular luciferase activity
By comparing the luciferase activities of lysates from cells transduced with DN
Rabs with those of the lysates from cells transduced with the corresponding WT Rabs, I
found that for most Rabs expression of the DN form did not significantly change the
luciferase activity values (Figure 3.6A-B). For roughly one third of the comparisons
where luciferase activity significantly differed between the WT and the DN-transduced
conditions, the differences were within one Log2 distance from the reference value. I was
encouraged by the lack of any larger differences in luciferase activities. I cannot, based
on this data alone, discount the possibility that, under these experimental conditions, DN
(or WT) Rab expression was accompanied by any number of toxic effects on cell
physiology. However, the magnitude of the differences observed suggests that if any
toxic effects accompanied Rab expression, they likely were of a limited nature in this
experimental setting.
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Figure 3.6. Effects of DN Rab expression on cell mass (next page). Huh-7.5 FLuc cells
were transduced with WT (blue) or DN (red) Rab-expressing lentiviruses at MOI of 25
(A) or 100 (B) I.U./cell. A secretion assay was performed at 48 h. Mean luciferase
activity values in WT Rab-transduced cells were set to 1. The resulting relative luciferase
activities were plotted on a Log2 scale. Shown are means ± s.d. from n=3 parallel wells.
Significant changes in activity (Student’s t-test, p<0.05) are highlighted in gray.
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3.8. Effects of DN Rab expression on cargo secretion
For each WT-DN Rab pair tested, for each of the cargoes tested, namely albumin,
ApoE and ApoB100, and for each of the two doses of lentivirus particles that I used, I
compared the normalized secretion measured in the presence of DN Rab expression to
the normalized secretion measured in the presence of the WT Rab expression (Figure
3.1). The results are presented in Figure 3.7A-C for the MOI = 25 I.U./cell condition and
in Figure 3.8A-C for the MOI = 100 I.U./cell condition. Each Rab for which I identified a
significant difference between the secretion of cargo measured in the presence of the WT
form and that measured in the presence of the DN form is highlighted by a gray
background bar. In some cases, DN Rab expression caused a decrease in secretion, when
compared to WT expression (i.e. DN Rab1c/35 at MOI 100 caused a decrease in the
secretion of albumin, ApoE and ApoB100, although the ApoE change was not
significant). In other cases, DN Rab expression caused an increase in secretion (i.e. DN
Rab11b expression increased the secretion of all three cargoes, and at both doses).
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Figure 3.7. Effects of DN Rabs on cargo secretion at MOI 25 I.U./cell (next page).
Huh-7.5 FLuc cells were transduced with WT (blue) or DN (red) Rab-expressing
lentiviruses at MOI 25 I.U./cell. A secretion assay was performed at 48 h post
transduction. Secreted cargo amounts were measured by ELISA and divided by the
corresponding well’s luciferase activity. The mean secretion values of WT Rabtransduced cells were set to 1. The relative secretion values of albumin (A), ApoE (B)
and ApoB100 (C) are plotted on a Log2 scale. Shown are means ± s.d. from n=3 parallel
wells. Significant changes in cargo secretion values (Student’s t-test with Bonferroni
correction, p<0.0167) are in gray.
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Figure 3.8. Effects of DN Rabs on cargo secretion at MOI 100 I.U./cell (next page).
Huh-7.5 FLuc cells were transduced with WT (blue) or DN (red) Rab-expressing
lentiviruses at MOI 100 I.U./cell. A secretion assay was performed at 48 h post
transduction. Secreted cargo amounts were measured by ELISA and divided by the
corresponding well’s luciferase activity. The mean secretion values of WT Rabtransduced cells were set to 1. The relative secretion values of albumin (A), ApoE (B)
and ApoB100 (C) are plotted on a Log2 scale. Shown are means ± s.d. from n=3 parallel
wells. Significant changes in cargo secretion values (Student’s t-test with Bonferroni
correction, p<0.0167) are in gray.
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To more easily organize and interpret these results, I defined a DN Rab effect
score as follows. For each Rab, every instance in which secretion of a cargo was affected
was assigned a score of 1. Thus, the maximum score for any given Rab was 6 (2 Rab
lentivirus doses tested x 3 cargoes). For the purposes of this analysis, I did not distinguish
between a case when cargo secretion was increased and a case when cargo secretion was
decreased. I only asked whether the difference between the effect on secretion of the DN
Rab was significantly different from the effect of its WT control. Then, I ranked the Rabs
in descending order based on their total effect scores (Figure 3.9). For the Rabs which
had the same total score, I ranked them in descending order of the sub-score obtained
using the higher dose of Rab-expressing lentivirus (Figure 3.9, filled bars). The hits were
also organized by known protein function (Table 3.1), following the information
summarized in a recent comprehensive review (Hutagalung and Novick, 2011). Of note,
most significant effects were caused by WT-DN Rab pairs previously implicated in
exocytic (including ER to Golgi transport, intra-Golgi transport, Golgi structure
maintenance; post-Golgi exocytosis) or recycling processes (Table 3.1). Conversely,
Rabs involved in endocytic trafficking had either a low effect on secretion, or none at all
(Figure 3.9 and Table 3.1). Similarly, the Rab3 subfamily, whose major function is to
control regulated exocytosis (Fukuda, 2008), such as that of neurotransmitters in the
nervous system, was underrepresented among the hits of this DN Rab screen. The
functional clustering of the hits was thus consistent with albumin and the lipoproteins
being constitutively secreted cargoes (Dashti et al., 1980), and attests to the usefulness of
the methodology that we developed to identify likely regulators of cargo secretion.

132

Figure 3.9 Ranking of Rab effects on cargo secretion. To each Rab, for each cargo
whose secretion the DN Rab expression significantly changed, an effect score of 1 was
awarded. Scores accumulated at MOI 25 I.U./cell are marked with open bars; scores
accumulated at MOI 100 I.U. /cell are marked with filled bars. The Rabs are ranked first
in descending order of the total score, and then in descending order of the score obtained
at MOI 100 I.U./cell.
3.9. Rab expression profiles in hepatic cells
I next inquired whether the Rabs that I identified as likely regulators of hepatic
cargo secretion were expressed in the cells in which I performed the screen. If a DN
effect was detected but the endogenous Rab was not expressed, I was concerned that the
effect may have been unspecific. I thank Dr. Joseph Luna for providing RNAseq data
(Luna et al., 2015) for Rab gene expression in Huh-7.5 cells (Figure 3.10A). I
furthermore thank Drs. Joseph Luna, William Schneider and Linda Andrus for providing
unpublished RNAseq expression data from human fetal liver cultures (HFLC, Figure
3.10B). HFLCs represent a primary hepatocyte cell culture system (Andrus et al., 2011;
Marukian et al., 2011). I ranked the Rabs in ascending order of their expression level in
each of the two hepatocyte cell culture systems. I also included in this analysis several
genes known to be ubiquitously expressed (such as those encoding β-actin and β-tubulin),
genes expressed in hepatocytes (such as those encoding ApoE, ApoB100, albumin, and
the tight junction proteins claudin-1 and occludin), and genes whose expression is
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expected to be confined to other cell types (such as those encoding the T-cell receptor
subunits α and β, and the photoreceptor rhodopsin). Unsurprisingly, the housekeeping
genes and the hepatocyte-specific genes were amongst the highest expressed genes, while
the non-hepatocyte genes had undetectable expression levels (I graphed these nonetheless
by assigning them an expression level of -10 Log2CPM. Of the Rabs which I identified as
hits in the DN screen (Figure 3.9), Rabs 40b and 40c had expression levels amongst the
lowest of all the Rabs in the Huh-7.5 cells. Rab41, similarly, had a very low expression
level in the Huh-7.5 cells, while its expression was not detected in HFLCs. Rab11c/25
transcripts were not detected in the Huh-7.5 cells, and their expression level was also
very low in HFLCs. Due to their low or even undetectable expression levels, Rabs 11c,
40b, 40c and 41 were not considered for further analysis.
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Figure 3.10. Rab expression levels in hepatic cultures. Rab-specific transcript
expression levels (Log2CPM) from RNAseq analysis of Huh-7.5 (A) and HFLC (B)
cultures were ranked in ascending order. The Rabs are listed by their numbers. Included
were expression levels of genes encoding the T cell receptor subunits α and β, (TCRA,
and TCRB, respectively), rhodopsin (RHO), β-actin (ACTB), β-tubulin (TUBB), occludin
(OCLN), claudin1 (CLDN1), albumin (ALB), ApoE (APOE) and ApoB100 (APOB).
When no reads mapping to the transcript were detected, an artificially low -10 Log2CPM
was assigned to the respective constructs.
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3.10. On the interpretability and meaning of the results
For the remaining Rab hits, further investigation is required to confirm their
involvement in cargo secretion. The screen only identified whether there was a difference
between the effect that a WT Rab had on secretion and the effect of its DN mutant. The
screen did not distinguish between an effect on secretion mediated by changes in the
expression of cargo mRNAs, in the rate of their translation or translocation into the ER,
or in the rate of protein transport along the secretory pathway. Furthermore, it is
important to bear in mind that if a DN Rab caused a relative decrease in cargo secretion,
this effect may have been mediated through inhibition of secretion by the DN Rab,
through stimulation of secretion by the corresponding WT Rab, or through a combination
of these two scenarios. Conversely, if a DN Rab caused a relative increase in cargo
secretion, this may have been mediated through stimulation of secretion by the DN Rab,
through inhibition of secretion by the corresponding WT Rab, or through a combination
of these two scenarios. Lastly, some DN Rabs affected the secretion of more than one
cargo. In some cases, such as those of Rab11A and Rab11B, the secretion of all cargoes
was affected in the same direction (Figures 3.7 and 3.8). A possible explanation of such a
phenotype is that the examined Rab controls the transport of all the cargoes whose
secretion was affected. In other cases, a DN Rab caused a relative increase in the
secretion of one cargo, while, in the same sample, causing a relative decrease in the
secretion of another cargo. For example, Rab1b appeared to stimulate ApoE secretion but
at the same time to inhibit ApoB secretion (Figure 3.8 and Chapter 5). A possible
explanation of such a phenotype is that the Rab differentially controls the transport of the
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several cargoes tested; which would make the Rab an interesting candidate for further
investigation.
3.11. Overview of the hits
The Rabs which were determined to be expressed in the Huh-7.5 cells and in the
HFLCs, and whose DN mutants significantly altered the secretion of one or several of the
hepatic cargoes tested, were considered for further analysis. Ongoing efforts to elucidate
the involvement of Rabs 11a, 11b, 8a, and 8b in hepatic cargo secretion are presented in
greater detail in Chapter 4. The characterization of the differential control of hepatic
cargo egress by Rab1b is presented in Chapter 5. I summarize herein some possibly
interesting notes that I have gathered on documented functions of some of the other Rab
hits. I also suggest potential means by which these Rabs may control cargo secretion in
general, and secretion of the hepatic cargoes albumin, the lipoproteins, and HCV, in
particular. Some of these functions are selectively summarized in Table 3.1.
Rab1c (more widely known as Rab35) controls various aspects of endocytic
recycling and endosome function, including delivery of membrane vesicles to the
cytokinesis furrow of dividing cells (Kouranti et al., 2006). Since Rab1c/35 inactivation
impaired the secretion of all the cargoes tested, it would be interesting to analyze the
extent to which, if any, it mediates transport of vesicles containing these cargoes. The
experiments would need to carefully rule out domino effects on secretion caused
downstream of inhibition of cell division, which would be a major general concern in all
experiments inhibiting Rab1c/35 function.
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Table 3.1. Selected known functions of the DN Rab screen hits.
Function
Rab
References
Rab1a,
(Plutner et al., 1991; Segev et al., 1988; Tisdale et al.,
Rab1b
1992)
Rab2a,
(Chavrier et al., 1990a; Tisdale and Balch, 1996;
ER to Golgi
Tisdale et al., 1992)
traffic; intra Rab2b
(Goud et al., 1990; Martinez et al., 1994)
Golgi traffic; Rab6b,
Rab6c
Golgi
structure
Rab30
(Thomas et al., 2009)
maintenance Rab33b
(Zheng et al., 1998)
Rab43
(Dejgaard et al., 2008; Fuchs et al., 2007; Haas et al.,
2007)
Rab1c/35
(Allaire et al., 2010; Hsu et al., 2010; Patino-Lopez et
al., 2008)
Rab3b
(Fischer von Mollard et al., 1990)
Rab3d/16
Post-Golgi
Rab8a
(Huber et al., 1993b)
secretion and
Rab8b
recycling
Rab11a
(Casanova et al., 1999; Ren et al., 1998; Ullrich et al.,
1996)
Rab11b
Rab11c/25
Rab13
(Nokes et al., 2008; Zahraoui et al., 1994)
Rab1a
(Winslow et al., 2010; Zoppino et al., 2010)
Rab1b
Autophagy
Rab24
(Munafo and Colombo, 2002)
Rab33b
(Itoh et al., 2008)
Rab1c/35
(Kouranti et al., 2006)
Rab4a
(van der Sluijs et al., 1992; Van Der Sluijs et al.,
1991)
Rab5c
(Chavrier et al., 1990a)
Endocytic
Rab7b
(Chavrier et al., 1990a)
transport and
Rab9a
(Lombardi et al., 1993)
endolysosoma
Rab12
(Matsui et al., 2011)
l functions
Rab21
(Simpson et al., 2004)
Rab22a
(Mesa et al., 2001)
Rab23
(Eggenschwiler et al., 2001; Evans et al., 2003)
Rab39a
(Chen et al., 2003)
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Rab3d/16 inactivation affected albumin secretion in our assays, and Rab3d has
previously been implicated in HCV release (Coller et al., 2012). It may well be one of the
Rabs which controls the final stages of cargo release. From the same functional group of
Rabs associated with regulated secretion, the Rabs 3b and 37 also exhibited phenotypes
in our assays and may also be involved in hepatic cargo secretion (Fukuda, 2008).
Rab12 inactivation stimulated ApoE and ApoB100 release, but not albumin
release. A previous study has implicated Rab12 in regulating transport of cargo destined
for degradation from a recycling compartment to an endolysosomal compartment (Matsui
et al., 2011). Since hepatocytes control lipoprotein release by in part regulating their
intracellular degradation, including from post-Golgi compartments (Pan et al., 2008a),
and since Rab12 mediates such a process, then the observed selective stimulation of
cargo secretion could be easily explained. The lipoprotein cargo that would no longer be
targeted for degradation in the presence of DN Rab12 could instead find its way out of
the cells. It would be interesting to evaluate if the density distribution profile of secreted
ApoB100-containing lipoproteins changes in response to Rab12 inactivation.
Rab13 inactivation impaired the release of all three cargoes I tested. An inquiry
into Rab13 function could tease out whether Golgi to TGN traffic inhibition by
expression of DN Rab13 (Nokes et al., 2008) is the only cause or the main cause of the
observed phenotype, or whether other Rab13 secretory functions may also play a part
(Sun et al., 2014). For experiments also focusing on HCV release, care should be taken to
avoid inhibition of early events in the HCV life cycle by inactivation of Rab13 function
in tight junction formation and maintenance. Such a concern is valid since HCV uses the
tight junction proteins claudin-1 and occludin as essential entry co-receptors (Evans et al.,

139

2007; Ploss et al., 2009), while the same tight junction proteins are known Rab13 cargoes
(Marzesco et al., 2002; Morimoto et al., 2005; Terai et al., 2006; Yamamura et al., 2008;
Zahraoui et al., 1994). Tight junction disruption could thus interfere with HCV infection
and may skew interpretation of any HCV release experiments where the HCV was
introduced into the cells via infection.
Rab23 also exhibited an interesting phenotype, since its DN mutant decreased
albumin secretion while simultaneously increasing ApoE secretion. Rab23 regulates
Sonic hedgehog signaling and has been implicated in the developmental disease
Carpenter syndrome (Eggenschwiler et al., 2001; Evans et al., 2003; Jenkins et al., 2007;
Wang et al., 2006). Future experiments would need to carefully account for any change in
the activation state of the cells that may result from interference with Rab23 function.
Autophagy has also been implicated in the regulation of the secretion of hepatic
lipoproteins, HCV and other viruses (Chen et al., 2015; Pan et al., 2008a; Shrivastava et
al., 2015). That several Rabs associated with autophagosome formation, namely Rabs 1,
24, and 33B (Itoh et al., 2008; Munafo and Colombo, 2002; Winslow et al., 2010;
Zoppino et al., 2010) were identified as hits in the secretion screen attests to the
importance of this process for cell physiology and potentially for the secretion or the
quality control of these cargoes.
Finally, several other Rabs (4a, 5c, 7b, 9a, 21, 22a and 39a) involved in endocytic
and degradative processes were hits of the DN Rab screen, but their cumulative score was
relatively small (Figure 3.9 and Table 3.1). It is possible that these effects were indirect.
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3.12. Discussion: On the future the DN Rab screen
As I hope I have shown in this chapter, and as I will describe in further detail in
the following two chapters, expression of a collection of 62 DN Rab GTPases has proven
to be an effective and unbiased method that I used to inhibit secretion events from cells,
and to identify transport pathways utilized by the tested secretory cargoes. The
experiments that I described above outline a succession of inquiry steps that can be easily
applied to other cellular systems and other cargoes. Indeed, since the Rab constructs were
expressed using VSVg-pseudotyped lentiviruses, they could be easily and efficiently
delivered to a great number of other cell types, including hard to transfect ones. I suspect
that the facility with which I was able to transduce the overwhelming majority (Figure
3.4) of the cells in culture may well have been instrumental in ensuring the success of the
approach. While preparation of the virus stocks was not trivial, it did not necessitate large
scale operations or specialized equipment. It was particularly advantageous that
ultracentrifugation was not required to concentrate the virus stocks. Furthermore, the titer
determination method was sufficiently easy and amenable to multiplexing, even though I
did all the steps manually. All of these methods can easily be transferred to an averagely
equipped laboratory that also had access to a flow cytometer.
The methodology of the screen could nevertheless be further improved. For
example, the lentiviral vectors could be modified to express Renilla luciferase from an
IRES downstream of the Rab protein. In this setting, the efficiency of target cell
transduction could be easily monitored biochemically, while continuing to estimate cell
mass by the FLuc measurements (Figure 3.2). Alternatively, a cargo of interest could be
modified by tagging it with an enzymatic reporter, such as a luciferase domain. Of
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course, functional assays would need to be first performed to confirm that the tagged
cargo molecule reproduced the secretory behavior of the endogenous protein, as outlined
for ApoE-GFP in Chapter 6. If the tagged cargo proved functional, however, fast, easy
and inexpensive enzymatic assays of the media and of the cell lysates may replace the
somewhat cumbersome and expensive ELISA assays that I employed, and would
therefore mitigate the effort and cost associated with developing and characterizing such
a cargo reporter.
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Chapter 4
Ongoing Characterization of the Involvement of
Rab11 and Rab8 in Hepatic Cargo Secretion
The DN Rab screen (discussed in the previous chapter) identified several potential
regulators of hepatic cargo egress. For reasons described throughout this chapter, the
Rabs 11a, 11b, 8a, and 8b were particularly interesting hits. Efforts are underway to
understand how are these Rabs, as well as the transport pathways that they regulate,
involved in lipoprotein, albumin, and HCV secretion. Since this work is not yet complete,
I present only the preliminary experiments that I have set up to advance this inquiry. I
also outline some immediately obvious experiments that I am performing in order to gain
a better understanding of the process that I am studying. Experiments further down the
line will need to be decided based on results that have not yet been generated, so I shall
not subject the reader to an exercise in long-term experimental planning. I do discuss
however the implications of some possible findings, while being fully aware that, in the
large scheme of scientific inquiry, experiments may provide unexpected results.
4.1. Overview: Rab11 and Rab8 functions in cargo secretion
Rab11a and Rab11b were interesting hits of the DN Rab screen (Chapter 3), since
expression of their DN mutants caused some of the largest phenotypes measured. The
major known functions of the Rab11 subfamily members Rab11a, Rab11b and Rab11c
(also known as Rab25), have been recently reviewed (Kelly et al., 2012; Welz et al.,
2014) and are summarized in Table 4.1. In non-polarized cells, Rab11 localizes at and
controls the function of the recycling endosome, including recycling and secretory
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activities associated with it. For example, Rab11 mediates transferrin recycling and postGolgi exocytosis of VSVg in non-polarized cells (Chen et al., 1998). In contrast, in
polarized cells, Rab11 functions primarily at the apical pole, where it localizes at the
apical recycling endosome (Casanova et al., 1999; Goldenring et al., 1996). There, Rab11
primarily controls secretory and recycling activities of apical cargoes, with little or no
involvement in basolateral secretion and recycling (Brown et al., 2000; Casanova et al.,
1999; Cresawn et al., 2007; Hoekstra et al., 2004; Leung et al., 2000; Sheff et al., 1999;
Thompson et al., 2007; Wang et al., 2000).

Table 4.1 Summary of known Rab11 functions
Rab11 cargoes or functions
Reference
Plasma membrane receptor transport or recycling
Transferrin and the transferrin receptor in non(Ren et al., 1998; Ullrich et al., 1996;
polarized cells
Wilcke et al., 2000)
Fc receptor FcRn
(Tzaban et al., 2009; Ward et al.,
2005)
Glucose transporter GLUT4
(Uhlig et al., 2005)
Chemokine scavenging decoy receptor D6
(Bonecchi et al., 2008)
Langerin and CD1α in Langerhans cells
(Gidon et al., 2012; Salamero et al.,
2001; Uzan-Gafsou et al., 2007)
Transforming growth factor-β (TGF-β) receptor
(Mitchell et al., 2004)
Fibroblast growth factor receptor 4, FGFR4
(Haugsten et al., 2014)
Protease-activated receptor 2, PAR2
(Roosterman et al., 2003)
CXCR2
(Fan et al., 2003; Fan et al., 2004)
Low-affinity formyl peptide receptor FPRL1
(Ernst et al., 2004)
Angiotensin II type 1 receptor AT1R
(Dale et al., 2004; Hunyady et al.,
2002)
Thromboxane A2 receptor TPβ
(Hamelin et al., 2005; Theriault et al.,
2004)
β1-adrenergic receptor β1AR
(Gardner et al., 2011)
β2-adrenergic receptors β2AR
(Moore et al., 2004)
M4 muscarinic acetylcholine receptor
(Volpicelli et al., 2002)
μ-opioid receptor
(Wang et al., 2008)
V2 vasopressin receptor
(Innamorati et al., 2001)
E-cadherin
(Lock and Stow, 2005)
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Table 4.1 Summary of known Rab11 functions
Rab11 cargoes or functions
Reference
Channel and transporter recycling
H+-K+-ATPase of gastric parietal cells
(Calhoun and Goldenring, 1997;
Calhoun et al., 1998; Duman et al.,
1999; Goldenring et al., 1994)
V-ATPase in salivary duct cells
(Oehlke et al., 2011)
Bile salt export pump, BSEP or ABCB11
(Wakabayashi et al., 2005;
Wakabayashi et al., 2004)
Hepatic multidrug resistance-associated protein (Park et al., 2014)
2, MRP2
Cystic fibrosis transmembrane conductance (Gentzsch et al., 2004; Silvis et al.,
regulator, CFTR
2009; Swiatecka-Urban et al., 2005;
Swiatecka-Urban et al., 2007)
Dopamine transporter
(Furman et al., 2009)
Various cation channels: HCN2, HCN4,
(Best et al., 2011; Butterworth et al.,
KCNA5, KCNQ1, KCNE1, TRPV5, TRPV6,
2012; Hardel et al., 2008; McEwen et
Cav1.2, ENaC
al., 2007; Seebohm et al., 2007; van
de Graaf et al., 2006)
Secreted cargo transport
Insulin
(Sugawara et al., 2009)
Human growth hormone
(Khvotchev et al., 2003)
Interferon-γ and tumor necrosis factor α
(Reefman et al., 2010)
Soluble vascular endothelial growth factor
(Jung et al., 2012);
Matrix metalloproteinase secretion
(Yu et al., 2014)
Other Rab11 functions
Ciliogenesis and transport to the primary cilium
(Deretic et al., 1996; Knodler et al.,
membrane
2010; Li et al., 2007; Mazelova et al.,
2009a; Satoh et al., 2005; Thuenauer
et al., 2014; Ward et al., 2011;
Westlake et al., 2011)
Intestinal and hepatic apical transport defects
(Girard et al., 2014; Knowles et al.,
associated with microvillus inclusion disease
2014; Knowles et al., 2015)
Exosome production and multivesicular body(Savina et al., 2005; Savina et al.,
plasma membrane fusion
2002)
β-amyloid production
(Udayar et al., 2013)
Stretch-regulated exocytosis of discoidal(Khandelwal et al., 2013; Khandelwal
fusiform vesicles in bladder umbrella cells
et al., 2008)
Colocalization with epidermal lamellar granules (Ishida-Yamamoto et al., 2007)
in keratinocytes
Melanin transfer between melanocytes and
(Tarafder et al., 2014)
keratinocytes
Macrophage phagocytosis
(Cox et al., 2000)
Sorting activities in the renal proximal tubule
(Mattila et al., 2014)
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Table 4.1 Summary of known Rab11 functions
Rab11 cargoes or functions
Reference
Membrane recycling during cell migration
(Assaker et al., 2010; Jones et al.,
2006; Kessler et al., 2012; Prigozhina
and Waterman-Storer, 2006)
Membrane delivery during cytokinesis
(Fielding et al., 2005; Neto et al.,
2013; Wilson et al., 2005)
Neuronal dendrite and axon growth
(Takano et al., 2012; Takano et al.,
2014)
Developmental signaling
(Emery et al., 2005; Jafar-Nejad et
al., 2005; Ossipova et al., 2015;
Ossipova et al., 2014)
General apical lumen formation
(Alvers et al., 2014; Bryant et al.,
2010)
Bile canaliculus formation
(Wakabayashi et al., 2005)
IgA transcytosis
(Casanova et al., 1999; Sheff et al.,
1999; Xu et al., 2011; Xu et al., 2013)
VSVg post-Golgi transport in non-polarized cells (Chen et al., 1998; de Graaf et al.,
2004)
Functions in host cell-pathogen interactions
(Varthakavi et al., 2006)
HIV-1 Vpu function
Influenza A virus particle formation
(Amorim et al., 2011; Bruce et al.,
2010; Chou et al., 2013; Eisfeld et al.,
2011; Momose et al., 2011)
Hantavirus (Andes virus) release
(Rowe et al., 2008)
HCV release
(Coller et al., 2012)
Porphyromonas gingivalis exit from recycling (Takeuchi et al., 2011)
endosomes
Functionally associated with Rab11 are two other hits of our screen, the Rab8
isoforms Rab8a (Chavrier et al., 1990b; Chen et al., 1993) and Rab8b (Armstrong et al.,
1996). They localize to the cell periphery (Chen et al., 1993) and have been involved in
cargo secretion (Huber et al., 1993a; Huber et al., 1993b), cell shape regulation (Peranen,
2011), and primary cilium formation and function (Das and Guo, 2011; Nachury et al.,
2007). These known functions are summarized in Table 4.2. As with Rab11, Rab8
involvement in both basolateral (Huber et al., 1993a; Huber et al., 1993b) and apical
(Nachury et al., 2007; Sato et al., 2014; Sato et al., 2007) cargo transport has been
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described. The functional coordination between Rab11 and Rab8 (Khandelwal et al.,
2013; Knodler et al., 2010; Wang et al., 2012; Westlake et al., 2011) is likely due to a
well described axis of control that involves these two GTPases: GTP-loaded Rab11
recruits Rabin8, a Rab8-specific GEF, which in turn recruits and activates Rab8 (Knodler
et al., 2010; Westlake et al., 2011). Unsurprisingly therefore, in our assays, the phenotype
associated with DN Rab11a or Rab11b expression, namely an increased relative
secretion, was mirrored by that associated with DN Rab8b expression, which also caused
a significant increase in relative cargo secretion (Figures 3.7 and 3.8). Expression of DN
Rab8a, in contrast, impaired the relative cargo secretion (Figures 3.7 and 3.8). That
inactivation of three Rabs that are expected to function in tandem (Rabs 11a, 11b, and 8b)
caused similar effects on cargo secretion strongly supports the conclusion that these Rabs
are likely involved in the same secretion pathway(s).
Table 4.2 Summary of known Rab8 functions
Rab8 cargoes or functions
VSVg
Semliki Forest virus E2 glycoprotein transport
Intestinal and hepatic apical transport defects
associated with microvillus inclusion disease
Primary ciliogenesis and transport

Cell membrane protrusion formation and actin
reorganization

Wnt signaling
Stretch-regulaterd exocytosis of discoidalfusiform vesicles in bladder umbrella cells
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References
(Ang et al., 2003; Ang et al., 2004;
Huber et al., 1993b; Schuck et al.,
2007)
(Huber et al., 1993a)
(Knowles et al., 2014; Sato et al.,
2014; Sato et al., 2007)
(Feng et al., 2012; Knodler et al.,
2010; Nachury et al., 2007; Omori et
al., 2008; Sato et al., 2014; Westlake
et al., 2011) (Deretic et al., 1995;
Moritz et al., 2001; Wang et al.,
2012; Ward et al., 2011)
(Hattula et al., 2002; Hattula et al.,
2006; Huber et al., 1993a; Huber et
al., 1995; Peranen et al., 1996; Powell
and Temesvari, 2004; Simons et al.,
1999)
(Demir et al., 2013)
(Khandelwal et al., 2013)

Table 4.2 Summary of known Rab8 functions
Rab8 cargoes or functions
Vesicle delivery during cytokinesis
Melanosome movement

References
(Kaplan and Reiner, 2011)
(Chabrillat et al., 2005; Chakraborty
et al., 2003)
Glucose transporter GLUT4 vesicle translocation (Ishikura and Klip, 2008; Randhawa
et al., 2008; Sun et al., 2010b)
Zymogen granule formation in pancreatic acinar (Faust et al., 2008)
cells
Cryptococcus neoformans capsular
(Yoneda and Doering, 2006)
polysaccharide secretion
E-cadherin transport
(Yamamura et al., 2008)
Membrane Type-1 matrix metalloproteinase
(Bravo-Cordero et al., 2007)
secretion
Adenocorticotropic hormone secretion
(Chen et al., 2001)
AMPA glutamate receptor recycling
(Brown et al., 2007; Gerges et al.,
2004)
Anti-mycobacterial autophagy
(Pilli et al., 2012)
Transferrin receptor traffic
(Vaibhava et al., 2012)
Apical lumen formation
(Galvez-Santisteban et al., 2012)
Metabotropic glutamate receptor subtype 1
(Esseltine et al., 2012)
traffic
Dense granule release in platelets
(Hampson et al., 2013)
Endospanin interaction
(Hirvonen et al., 2013)
KCNN4 potassium channel trafficking
(Bertuccio et al., 2014)
Cytotoxic T-lymphocyte-associated protein 4
(Banton et al., 2014)
α2B- and β2-Adrenergic receptors
(Dong et al., 2010)
Dengue virus 2
(Xu et al., 2009; Xu et al., 2008)
ABCA1 function and cholesterol efflux
(Linder et al., 2009; Linder et al.,
2007)
Sucrase-isomaltase and lactase-phlorizin
(Cramm-Behrens et al., 2008)
hydrolase
How do Rab11 and Rab8 GTPases control hepatic cargo secretion? In my hands,
Rab11a, 11b and 8b inactivation by expression of DN mutants resulted in significant
stimulation of the secretion of albumin, ApoE and ApoB100, while DN Rab8a expression
inhibited cargo secretion (Figures 3.7 and 3.8). Albumin, ApoE and ApoB100 are
expected to be secreted basolaterally, since all are secreted into the bloodstream. It is not
surprising therefore that inactivation of a basolateral secretion factor, Rab8a (Huber et al.,
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1993a; Huber et al., 1993b), would result in decreased secretion of these cargoes. That
inactivation of Rabs primarily involved with apical transport (Rabs 11a, 11b, and 8b)
would result in stimulation of basolateral cargo secretion could be easily explained if
competition existed between apical and basolateral secretion activities. Common factors
utilized by both apical and basolateral secretion processes (recycling endosome
membranes come to mind as obvious candidates, although Rab effectors or other
vesicular traffic regulators may also be involved) could be limiting. In such a scenario, if
apical secretion is stimulated (by WT Rab11 or 8b overexpression), then basolateral
secretion is expected to become inhibited. Conversely, if apical secretion is impaired (by
DN Rab11 or 8b overexpression), then basolateral secretion is expected to become
stimulated. If either or both of the above scenarios is true, then the overall effect of paired
WT-DN Rab expression would be a relative stimulation of basolateral cargo secretion,
similar to what I observed. Of course, other plausible transport regulation scenarios could
be invoked to explain the observed phenotype.
The pattern of Rab11 and Rab8 potential involvement in polarized hepatic cargo
secretion that I proposed above is corroborated by the findings of a study testing the
function of these Rabs in the release of Andes virus, a New World hantavirus (Rowe et
al., 2008). Several hantaviruses, the etiologic agents of the often lethal hantavirus
pulmonary syndrome, have been shown to be released primarily at the apical side of
polarized cell cultures (Krautkramer et al., 2012; Ravkov et al., 1997; Rowe and Pekosz,
2006), with roughly 1,000-fold higher viral titers being shed apically compared to
basolaterally (Ravkov et al., 1997; Rowe and Pekosz, 2006). This preference for
polarized apical release is consistent with a predominantly respiratory mode of Andes
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virus transmission (Padula et al., 2004). Andes virus release was severely inhibited by
Rab11a, 11a and 11b, or 8a and 8b knockdown, but not by Rab8a knockdown alone
(Rowe et al., 2008). While these experiments were done in sparsely-plated monolayergrown African green monkey kidney cells Vero E6/C1008 (Rowe et al., 2008), I wish to
emphasize that these cells do possess the capacity to form polarized monolayers and to
support polarized cargo transport (Srinivas et al., 1986; Zhou et al., 2011). In this context,
the similarity between my findings and those of (Rowe et al., 2008) lie in the functional
grouping of the Rab effects. Rab11a, 11b and 8b inhibition apparently stimulated
basolateral cargo secretion (Figures 3.7 and 3.8), while Rab11a and 8b inhibition
impaired apical cargo secretion (Rowe et al., 2008). In contrast Rab8a inhibition
apparently impaired basolateral cargo secretion (figures 3.7 and 3.8), while not affecting
(or even slightly stimulating) apical cargo secretion (Rowe et al., 2008). These correlated
observations, therefore, together with the cumulative knowledge of Rab11 and Rab8
involvement in polarized cargo secretion (Tables 4.1 and 4.2), identify these Rabs as
interesting targets more in-depth investigations.
4.2. Experiments investigating Rab11 and Rab8 involvement in secretion
The approach that I am using to investigate the involvement of Rab11 and Rab8
in hepatic cargo secretion parallels to some extent the line of inquiry that I pursued to
investigate the involvement of Rab1b in hepatic cargo secretion and which I present in
detail in the next chapter. Briefly, the following steps are part of my immediate
experimental plan:
1. Repeat the experiments detailed in the DN Rab screen to confirm the
reproducibility of the observed phenotype. Also include in this assay the GTPase-

150

deficient and the GDP-restricted DN Rab mutants, besides the already used
nucleotide-binding mutants.
2. Quantify cargo expression levels in the presence of DN Rab expression to
determine whether any DN Rab-associated changes in expression levels may
need to be accounted for when interpreting the observed changes in cargo
secretion.
3. Inducibly express DN and WT Rab11 and Rab8 constructs and quantify cargo
secretion. As explained in more detail below and in Chapter 5, inducible DN Rab
expression is preferable to lentivirus-mediated transient expression, since
potentially confounding experimental variations associated with lentivirus
transduction may be easily avoided.
4. Perform colocalization analyses between the Rabs and the cargo. I show in
Chapter 6 that an ApoE-GFP fusion protein is functional with respect to
lipoprotein egress, which will facilitate such colocalization experiments.
5. Assess the effect of inhibition of Rab11 and Rab8 on cargo egress from a
polarized, primary hepatocyte-like cell culture system.
6. Assess the effects of DN Rab11 and Rab8 expression on HCV egress.
Some of the experiments outlined above have been performed, and I present my
findings below.
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4.3. Effects of expression of a panel of DN Rab11 and Rab8 mutants on
hepatic cargo secretion
To confirm the secretion phenotypes that I observed when I overexpressed the
nucleotide-binding DN mutants of Rab11 and Rab8, I repeated the lentivirus infection
experiment. This time, besides the WT and the nucleotide-binding DN Rab mutants, I
included both the GDP-restricted and GTPase mutants of Rabs 11a, 11b, 8a, and 8b. I
reasoned that if one of a given Rab's mutants specifically affected cargo secretion, then
the other mutants are also likely to do so, since they likely inhibit the same process, albeit
at a different stage. In a parallel experiment, I also quantified cargo mRNA levels in the
transduced cells to determine whether Rab expression was associated with changes in
cargo expression that may account, at least in part, for the secretion phenotype observed
(Figure 4.1).
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Figure 4.1. Confirmation of the effects of DN Rab11 and Rab8 expression on cargo
secretion (next page). (A) Huh-7.5 FLuc cells were transduced with 100 I.U./cell of
lentiviruses expressing the indicated constructs. At 48 h, a secretion assay was
performed. Secreted cargo amounts and lysate luciferase activities were measured.
Normalized secreted cargo amounts are shown relative to the WT values, on a Log2 scale.
(B) Huh-7.5 cells were transduced as in (A), RNA was extracted at 48 h post
transduction, and cargo mRNA levels were measured. Shown are relative cargo
expression levels, on a Log2 scale. (A and B). Shown are means ± s.d. from n=3 parallel
wells. Statistical significance (Student’s t test): *, p<0.05; **, p<0.01; ***, p<0.001:
****, p<0.0001.
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Expression of all three Rab8a mutants caused a significant decrease in the
secretion of all three cargoes tested (Figure 4.1A), consistent with previous observations
(Figure 3.8). Cargo mRNA levels, however, were also decreased in the presence of DN
Rab8a expression (Figure 4.1B), raising the possibility that some or all of the observed
decrease in secretion could have been due to downregulation of cargo expression. Further
tests are needed to distinguish the change in secretion levels due to downregulation of
cargo expression and any possible direct effects of DN Rab8a construct expression on
cargo transport.
In contrast to Rab8a, expression of the Rab8b and Rab11a mutants resulted in
increased secretion levels for all three cargoes tested. Expression of the nucleotidebinding (N124I) and of the GDP-restricted (S25N) DN Rab11b also stimulated cargo
secretion, while expression of the GTPase mutant (Q70L) of Rab11b resulted in impaired
cargo secretion. The later result correlated with a downregulation of cargo expression
levels by Rab11bQ70L. Similarly, increased secretion caused by Rab8bQ67L or Rab11bN124I
partly correlated with increased cargo expression. For all the other mutants, namely
Rab8bN121I, Rab8bT22N, Rab11aN124I, Rab11aS25N, Rab11aQ70L, and Rab11bS25N, the
increased secretion associated with DN Rab expression did not correlate with increased
cargo mRNA levels in the transduced cells, suggesting that the observed secretion
phenotypes may be primarily due to effects of the DN Rabs on the vesicular transport of
these cargoes. Nonetheless, additional experimentation is required to further parse these
reproducible secretion phenotypes.

155

4.4. Cell lines inducibly expressing DN Rab11 and Rab8
A drawback of using concentrated lentivirus particles to express the DN Rabs in
the short term expression experiments described above and in Chapter 3 is that other
material besides the lentivirus particles may be present in the virus stock. Such
contaminants may include cell debris from the lentivirus producing HEK293T cells,
exosomes, or the DNA transfected into these cells to make the lentivirus particles. To
exclude confounding and likely unaccountable effects of non-lentivirus components of
the lentivirus preparation, I created cell lines that can be induced to express mCherrytagged Rabs. To do so, I transduced the Huh-7.5 TetON cell line with retroviruses
expressing the mCherry-tagged WT and mutant Rabs from a tetracycline response
element (Figure 2.1D), then selected stably transduced cell populations. I used mCherry
expression as a marker that allowed me to easily identify and quantify Rab construct
expression. I preferred this inducible expression approach to long-term constitutive
expression of the DN Rab constructs, in part because Rab11a (Sobajima et al., 2014; Yu
et al., 2014) and Rab8a (Sato et al., 2014; Sato et al., 2007) knockouts are lethal in mice.
These cell lines are in the process of being characterized. They robustly induced
Rab construct expression after exposure to doxycycline (Figure 4.2A), and the mCherryRab fusions were easily detected by Western blotting in the lysates of the induced cells
(Figure 4.2B). Ongoing experiments in these inducible expression cell lines are designed
to quantify the effects of DN Rab11 or Rab8 expression on cargo mRNA levels, and on
cargo secretion as determined by quantifying both the cell-associated and secreted cargo
amounts, as described in detail for Rab1b in the next chapter.
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Figure 4.2. Cell lines for inducible expression of Rab11 and Rab8 constructs (next
page). Huh-7.5 TetON cells were transduced with retroviruses expressing the indicated
constructs under the control of a tetracycline response element, and were then selected.
(A) Induction of mCherry-Rab expression after 2 days of treatment with 3 μg/mL of
doxycycline was characterized by flow cytometry. Red traces, non-induced cells; blue
traces, induced cells. (B) Cell lysates from cells treated as in (A) were harvested and
immunoblotted with an α-dsRed antibody (recognizes mCherry) and an α-actin antibody.
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4.5. A polarized, primary hepatocyte-like cell culture system
As discussed at the beginning of this chapter, the increase in cargo secretion
observed in the DN Rab screen and in the confirmatory experiments described above was
puzzling, since Rab11 (and Rab8 acting downstream) have overwhelmingly been shown
to control the secretion or recycling of apically-targeted secretory or membraneassociated cargoes (Tables 4.1 and 4.2). Albumin, ApoE (Lee et al., 2003; Traber et al.,
1987), and ApoB (Traber et al., 1987) are basolateral secretory cargoes. Is the phenotype
that I observed a manifestation of defective polarized transport that might occur in the
Huh-7.5 cell line, or is it revealing of a potentially interesting regulation of hepatic
basolateral secretion by Rab11?
Historically, hepatocyte cell culture systems have been difficult to use for the
study of at least some polarity-associated processes (Treyer and Musch, 2013). Even in
cases where the cells retained a polar phenotype, this phenotype has manifested in
formation of bile canaliculi-like structures between adjacent cells (Andrus et al., 2011;
Chiu et al., 1990; Ploss et al., 2010; Treyer and Musch, 2013). A separation of basolateral
and apical compartments easily amenable to biochemical investigations, such as that
obtained by growing the epithelial cell lines MDCK or Caco-2 on trans-well filters has
not been achieved for hepatocyte cell culture models. I am fortunate that Dr. Viet Loan
Dao Thi and Dr. Xianfang Wu of the Rice lab are currently leading an effort to develop
and characterize a promisingly useful hepatocyte polarity model. I am very thankful to
Dr. Dao Thi, Dr. Wu, Dr. Ursula Andreo, and soon-to-be-Dr. Rachel Belote for their
wonderful collaboration on this project. The system is still being characterized, and I only
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mention here some preliminary findings that informed us that this system may aid in the
analysis of polarized secretory transport by hepatocytes.
Briefly, the system is based on in vitro differentiation of human embryonic stem
cells along the endoderm/hepatocyte lineage. The resulting cells were called iHeps
(induced hepatocyte-like cells). During differentiation, the iHeps were plated on transwell filters, where they were allowed to complete their differentiation. The resulting
filter-grown iHep monolayer (Figure 4.3A) had the following properties (Viet Loan Dao
Thi, Xianfang Wu, Ursula Andreo and Rachel Belote, personal communications): (i) the
cells expressed hepatocyte-specific genes; (ii) the monolayer formed a tight diffusion
barrier, as evidenced by measurement of high trans-epithelial resistance values and by
impermeability of the monolayer to diffusion of fluorescent dextrans; (iii) the monolayer
secreted bile acids exclusively in the inner chamber of the trans-well filter (Figure 4.3A),
which I will refer to from here on as the "apical chamber"; (iv) the iHeps secreted
ApoB100-containing lipoproteins which floated in a density gradient at density fractions
consistent with those of properly lipidated VLDL particles; and (v) the cells formed a
continuous tight junction network and displayed some polarized protein localization
patterns.
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Figure 4.3. Hepatic cargo secretion by polarized iHeps (A) Schematic representation
of the polarized iHeps growth setup. Cells were grown on a trans-well filter with media
on both sides. The chamber within the insert was designated as “apical” compartment,
while the chamber surrounding the insert was designated as “basolateral” compartment.
(B) Preponderantly basolateral secretion of albumin and apolipoproteins by the polarized
iHeps. Media from both apical and basolateral chambers was collected after a 6 h
secretion assay and its cargo content was quantified by ELISA. The amount secreted in
the basolateral chamber was expressed as fraction of the total (apical + basolateral)
secreted cargo amount. Shown are means ± s.d. from n=3 trans-wells.

The focus of this work is to investigate the regulation of the secretion of
basolaterally-targeted hepatocyte cargoes. I therefore measured the amounts of albumin,
ApoE, and ApoB100 that were released by trans-well-grown iHeps in both the apical and
basolateral chambers of the growth set-up (Figure 4.3A). I expressed the cargo amounts
secreted on the basolateral side as percentages of the total (basolateral + apical) secreted
cargo amounts. The results of one such experiment are shown in Figure 4.3B. All cargoes
were reproducibly secreted primarily on the basolateral side of the trans-well filter, as
expected by the site of secretion of these cargoes in vivo. Furthermore, the percentages of
cargo amounts secreted by the iHeps in the basolateral chamber (63% for albumin, 78%
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for ApoE, and 75% for ApoB100, Figure 4.3B) were similar to the percentages of
triglycerides (60-80%) or apolipoproteins (75-100%) shown to be secreted basolaterally
by the polarized intestinal cell line Caco-2 (Traber et al., 1987). That the basolaterallysecreted albumin fraction was slightly smaller than the fractions of the basolaterallysecreted ApoE or ApoB100 (Figure 4.3B) was not surprising, since albumin may be
transcytosed across epithelial barriers (Monks and Neville, 2004). This result, together
with the totality of the data obtained by my collaborators, indicated that the likely
polarized filter-grown iHeps may become a useful cell culture model for the study of
polarized hepatic secretion.
To investigate the involvement of Rab11 and Rab8 in polarized hepatic cargo
secretion from these iHeps, we are modifying the parental embryonic stem cells to allow
for inducible expression of WT or DN Rab constructs. We will then differentiate these
cells into filter-grown iHeps, induce the expression of the Rab constructs, and then
quantify the amounts of cargoes released in the apical and basolateral chambers of the
trans-well culture system. The effects of DN Rab11 or Rab8 constructs on total and
chamber-specific albumin and lipoprotein secretion will be therefore measured. They will
be contrasted to any changes in apical bile salt secretion that we will measure in the
apical chamber. Since bile salt transporters are recycled through the Rab11-positive
apical recycling endosome (Wakabayashi et al., 2005; Wakabayashi et al., 2004), I expect
that Rab11 inhibition will decrease the amounts of bile salt secretion secondary to
intracellular endosomal retention of the bile salt transporters. The apical bile salt
measurements will therefore serve as a positive control for Rab11 inactivation. Barring of
course any unexpected experimental difficulties, we are poised to determine to what
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extent these basolaterally-secreted hepatic cargo transport processes are dependent on
Rab11 or Rab8 function.
4.6. Rab11 involvement in HCV secretion
My interest in defining the involvement of Rab11 and Rab8 in hepatic cargo
egress was also in part prompted by a recent report which proposed that Rab11a controls
infectious HCV secretion (Coller et al., 2012). This conclusion was based on two main
findings. First, the authors showed that treatment of Huh7.5 cells with a cocktail of 4
small interfering RNAs (siRNAs) or with any of two individual siRNAs directed against
the Rab11a message resulted in decreased release of infectious HCV, and concurrent
accumulation of intracellular infectious virus (Coller et al., 2012). While the authors
detected a substantial decrease in Rab11a message levels in siRNA-treated cells, they did
not investigate whether Rab11a protein levels had decreased as well (Coller et al., 2012).
Furthermore, the authors did not exclude the possibility that the observed phenotype was
due to off-target effects of the two active siRNA molecules (Coller et al., 2012). Such
off-target effects have been documented in other settings (Chung et al., 2014) and would
need to be ruled out in order to better interpret the results of knockdown experiments.
Indeed, an experiment attempting to rescue HCV infectivity release by expressing an
siRNA-resistant Rab11a construct was not performed (Coller et al., 2012). The authors
do however perform colocalization experiments showing that HCV Core, labeled using a
tetracysteine-tagged HCV Core protein expressed from the viral genome and
FlAsH/ReAsH staining (Griffin et al., 1998), colocalized with GFP-Rab11a (Coller et al.,
2012). The authors interpreted this observation to mean that HCV particles were secreted
through Rab11a-positive recycling endosomes. Unfortunately, this conclusion is also
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insufficiently supported for the following reasons. First, the FlAsH/ReAsH labeling
involved treatment of the cells with 500 μM of the reducing agent 1,2-ethanedithiol
(Coller et al., 2012). Significantly lower concentrations of a very similar reducing agent,
dithiothreitol can be used to induce the unfolded protein stress response: 0.025-25.6 μM
(Carpio et al., 2015) or 0.1-10 mM (Cox et al., 2011). As such, the possibility that the
cells behaved aberrantly due to physiological stress was not excluded. Second, the
labeled tetracysteine-Core puncta observed in these cells could have undergone nonproductive transport, by having become diverted from productive secretion routes into
Rab11a-positive recycling endosomes and from there potentially into degradative
compartments. Third, the cell line used in this study, Huh-7.5, expresses the full
complement of HCV entry receptors and supports HCV entry (Evans et al., 2007;
Lindenbach et al., 2005; Ploss et al., 2009). As a result, tetracysteine-Core could have
made its way into Rab11a-positive recycling endosomes after first being secreted through
Rab11a-independent pathway(s), followed by internalization and endocytic recycling
transport. For these reasons, while the results of these experiments are consistent with the
authors' conclusion that Rab11a controls HCV egress through the recycling endosome,
the same experimental results may not add up to sufficiently strong evidence to rule out
alternative scenarios.
When considering the implications of HCV secretion through a Rab11-positive
endosome, one must view this model in the larger context of the intra-host and inter-host
virus transmission dynamics and evolutionary history. Studies of other viruses, such as
influenza A virus (Amorim et al., 2011; Bruce et al., 2010; Chou et al., 2013; Eisfeld et
al., 2011; Momose et al., 2011), HIV-I (Varthakavi et al., 2006), and Andes virus (Rowe
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et al., 2008), have implicated Rab11a in virus release. Both influenza A virus (Rodriguez
Boulan and Pendergast, 1980; Rodriguez Boulan and Sabatini, 1978) and Andes virus
(Rowe and Pekosz, 2006) are released at the apical pole of infected cells, therefore Rab11
involvement in the biogenesis of these viruses is not surprising. HCV epidemiological
history suggests however that the primary (or at least the recent primary) route of virus
transmission is through the blood or blood products, secondary to medical procedures,
injection drug use, or risky sexual practices (Thomas, 2013). A potential implication of
this mode of transmission is that HCV may be a virus that is primarily released at the
basolateral sides of the hepatocytes. Therefore, Rab11 should not be involved in HCV
release. Release of the virus at the apical side would also be problematic since HCV is an
enveloped virus. HCV, unlike the non-enveloped hepatitis A and E viruses, which are
primarily transmitted between hosts by a fecal-to-oral route (Protzer et al., 2012), might
not survive the digestive environment of the duodenum where the bile products - and the
apically released hepatotropic viruses - would access the digestive tube. Several questions
arise then. Was Rab11 implicated in HCV release as a result of over interpretation of
experimental findings, or as the manifestation of an in vitro phenotype with little
significance for how HCV egress is regulated in the infected liver (Coller et al., 2012)?
Does Rab11 carry an unexpected function in the transport of a presumably basolateral
cargo, HCV, in the native hepatocyte? Or is the Rab11-HCV association an indication
that HCV may indeed be released apically? If yes, how would such a finding fit into the
larger picture of hepacivirus transmission and evolution? There is little information at the
moment as to how HCV was transmitted before its modern efficient spread facilitated by
advances in medical practice, or as to how the HCV-related hepaciviruses have evolved
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and crossed species barriers (Pybus and Theze, 2015). The entire family could have been
spread through blood-to-blood routes, perhaps mediated by tabanids such as horse flies
(Pybus et al., 2007), similar to how the more distantly related flaviviruses use ticks and
mosquitoes for transmission. If the hypothesized insect-mediated transmission was purely
passive, with the insects simply carrying infected blood from one host to the other, there
would be no need for the virus to possess capacity of being secreted apically. The virus
could have nonetheless retained apical secretion capabilities from a distant ancestor
which had been in fact released on the apical side of a producing cell. The virus may also
require apical secretion capabilities if insect-mediated transmission involved virus
replication in the vector's gut. Alternatively, vector-free transmission could have occurred
through secretions (respiratory secretions, saliva) (Pybus and Theze, 2015), in which case
apical secretion capabilities of the virus could be directly relevant. It is worth noting that
hepacivirus RNA has been detected in respiratory secretions of likely infected animals
(Kapoor et al., 2011), although it is unknown whether the presence of viral genetic
material at that site was due to passive processes, such as leakage-mediated
contamination of respiratory secretions by serum products in the context of an inflamed
mucosa, or active processes, such as replication and assembly of the virus in cells of the
lining of the upper respiratory tract.
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4.7. Conclusion
The nature of Rab11 (and Rab8) involvement in hepatic cargo secretion, be that of
the basolaterally targeted albumin and lipoproteins, or of HCV, remains at this time a
mystery. Obviously, much work is needed to generate answers to the questions that I
identified in this chapter, and my investigation into the regulation of these processes
remains in its infancy. I hope nonetheless that the discussion of the possible involvement
of Rab8 and Rab11 in cargo secretion, in both non-polarized Huh-7.5 cells or in polarized
hepatocyte-like cells, highlights some exciting, interesting and important avenues of
investigation.
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Chapter 5
Involvement of Rab1 in Hepatic Cargo Transport

5.1. Rab1 and ER-to-Golgi transport
Of the hits of the DN Rab screen (Chapter 3), Rab1b presented a peculiar
phenotype. Compared to WT Rab1b expression, expression of Rab1bN121I apparently
stimulated ApoE secretion when administered at an MOI dose of 25 (Figure 3.7) or 100
(Figure 3.8) I.U./cell, and apparently impaired ApoB100 secretion when used at 100
I.U./cell (Figure 3.8). This indicated that ApoE and ApoB100 secretion may respond
differently to Rab1 inhibition. I have therefore proceeded to analyze Rab1b's involvement
in cargo secretion in greater detail.
The partially redundant Rab GTPases, Rab1a and Rab1b (Nuoffer et al., 1994),
regulate anterograde vesicular transport from the ER to the Golgi system, and inhibition
of their function impairs early anterograde transport of many secretory cargoes, the most
extensively characterized being VSVg (Plutner et al., 1991; Tisdale et al., 1992). Other
cargoes include the viral envelope glycoproteins of HIV-1 (Nachmias et al., 2012) and
human herpes simplex-1 (Zenner et al., 2011); the Ebola virus VP40 capsid protein
(Yamayoshi et al., 2010); the G-protein coupled receptors (GPCRs) rhodopsin (Satoh et
al., 1997), angiotensin and adrenergic receptors (Filipeanu et al., 2004; Filipeanu et al.,
2006; Wu et al., 2001; Wu et al., 2003) and the calcium-sensing receptor (Zhuang et al.,
2010); ion channels (Flowerdew and Burgoyne, 2009; Robitaille et al., 2009); the βamyloid precursor protein (Dugan et al., 1995), and the secreted proteins human growth

168

hormone, interleukin-8 (Dong et al., 2012) and alkaline phosphatase (Ingmundson et al.,
2007).
Rab1 localizes at the ER, at the Golgi, ERGIC, and on vesicles that transport
cargo from the ER to the Golgi (Alvarez et al., 2003; Moyer et al., 2001b; Plutner et al.,
1991; Saraste et al., 1995). Rab1's function in early anterograde transport is underscored
by the list of its known effectors. These include several Golgi tethers or Golgi structural
proteins: p115 (Allan et al., 2000), GM130 (Moyer et al., 2001a; Weide et al., 2001),
golgin-84 (Diao et al., 2003; Satoh et al., 2003) and giantin (Beard et al., 2005). Through
these vesicle- and Golgi-associated proteins, Rab1 controls the delivery of secretory
cargo into the Golgi compartment. Other effectors are: MICAL-1 (Weide et al., 2003),
Iporin (Bayer et al., 2005), and GBF1 (Monetta et al., 2007). GBF1 is an Arf1 GEF that
activates Arf1 on the surface of Golgi compartments and by doing so initiates COPI
recruitment and therefore COPI-dependent vesicular transport (Alvarez et al., 2003;
Claude et al., 1999; Garcia-Mata et al., 2003; Kawamoto et al., 2002; Monetta et al.,
2007; Niu et al., 2005; Szul et al., 2005; Zhao et al., 2002).
Given that Rab1b inactivation as a consequence of expression of Rab1bN121I
differentially affected the secretion of the several hepatic cargoes tested (Figure 3.8), and
given that Rab1 controls anterograde transport from the ER to the Golgi, I inquired
whether transport of albumin, ApoE and ApoB100 between these compartments may be
differentially regulated. This idea was not unprecedented, since in vitro biochemical
assays had already documented that ApoB and ApoE (Gusarova et al., 2007), or ApoB
and albumin (Siddiqi, 2008), were packaged into distinct ER-derived vesicles. These
findings, combined with my own observations, raised the possibility that Rab1b may
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differentially control secretion of the cargoes that I investigated. I therefore set out to
investigate in greater detail the function of Rab1 in hepatic cargo secretion.
The main experimental approach that I utilized relied on inactivation of Rab1
function by expression of DN Rab1 mutants. DN Rab1a or Rab1b mutants have been
shown to inactivate Rab1 function (Nuoffer et al., 1994; Pind et al., 1994; Tisdale et al.,
1992). When VSVg anterograde transport was investigated, the GDP-restricted mutants
(i.e. Rab1bS22N) and the nucleotide binding mutants (i.e. Rab1bN121I) blocked VSVg
transport from the ER to the Golgi, while the WT versions and the GTPase-inactivating
mutants (i.e. Rab1bQ67L) did not interfere with this process (Nuoffer et al., 1994; Pind et
al., 1994; Tisdale et al., 1992). Furthermore, the transport stages at which the GDPrestricted and the nucleotide binding mutants blocked VSVg progression were distinct.
The GDP-restricted mutant blocked VSVg exit from the ER (Nuoffer et al., 1994), while
the nucleotide binding mutant caused accumulation of VSVg in an ERGIC-like
compartment (Pind et al., 1994). I therefore used this knowledge, and these Rab1 mutants
to investigate the secretion of hepatic cargoes in greater detail.
Before going onto describing the results, I wish to caution the reader that
throughout this chapter I have used two methods to quantify cargo egress. In both
methods, the amount of cargo that accumulated in the cell culture media was quantified
by ELISA, but these measurements of secreted cargo by themselves were not sufficient to
assess secretion. I needed to also control for the possibility - the fact even - that the
various treatment conditions resulted in different amounts of cells being present in the
culture at the time of the secretion assay, and therefore being responsible for the secretion
activities measured. I utilized two methods to account for variation in cell mass. One took
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advantage of luciferase activity measurements that I performed on cell lysates at the end
of the secretion assay, the other used cell-associated cargo amounts measured in similar
lysates. As I will explain throughout this chapter, the two methods estimated different
aspects of secretion. While the overall results are facially different, I hope to convince the
reader by the end of this chapter that the findings obtained using each of the methods do
indeed agree with each other.
5.2. Confirmation of DN Rab screen results
I began my inquiry into how Rab1 controls hepatic cargo egress by repeating the
type of secretion assays I performed as part of the DN Rab screen. I transduced Huh-7.5
FLuc cells with lentiviruses expressing Rab1b or Rab1bN121I. In parallel, I also tested
mCherry-tagged Rab1b constructs, both the WT form and the N121I mutant. I performed
secretion assays and normalized the secreted cargo amounts by the luciferase activity of
the cell lysates. The results were consistent with the previous observations (Figures 3.7
and 3.8). Thus, untagged Rab1bN121I expression had only a small effect on albumin
secretion (Figure 5.1A) while mCherry-Rab1bN121I had no detectable effect (Figure 5.1B).
In contrast, ApoE secretion was stimulated by tagged or mCherry-tagged Rab1bN121I
expression, while ApoB secretion was inhibited, by the same constructs (Figure 5.1A and
B). As before, Rab1bN121I construct expression was associated with decreased luciferase
activity in the cell lysates (Figure 5.1C).
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Figure 5.1. Confirmation of Rab1bN121I effect on hepatic cargo secretion. Huh-7.5
FLuc cells were infected with lentiviruses expressing WT (blue circles) or N121I mutant
(red squares) versions of untagged Rab1b (A) or mCherry-Rab1b (B), respectively, all at
an MOI of 100 I.U./cell. At 48 h post transduction, a 6 h secretion assay was performed.
Albumin, ApoE, and ApoB100 amounts in the media were measured by ELISA, and the
results were normalized by the luciferase activity in the cell lysates of the corresponding
wells. Cargo secretion levels in the presence of the DN Rab1b constructs were plotted as
relative to the secretion levels in the presence of WT Rab1b constructs, on a Log2 scale.
(C) Relative luciferase (Luc) activities (Log2 scale) in the cell lysates from the
experiments presented in panels (A) and (B), respectively. For each condition, means ±
s.d. of values obtained in 3 parallel wells are presented. Significant differences (Student’s
t-test): n.s., non-significant; **, p<0.01; ***, p<0.001; ****, p<0.0001.
5.3. Functional characterization of the mCherry-tagged Rab1b constructs
Since mCherry-Rab1bN121I caused a secretion phenotype similar to the one caused
by the untagged Rab1b mutant (Figure 5.1A-B), it was likely that mCherry tagging of
Rab1b did not impair its activity. Indeed, GFP-Rab1 constructs have been shown to
successfully carry out Rab1 functions (Alvarez et al., 2003; Moyer et al., 2001b). Since
using mCherry-tagged Rab1b constructs in experiments would facilitate direct
measurement of Rab construct expression levels and since the fusion proteins could be
used in imaging experiments, I set out to more comprehensively characterize the
functionality of these constructs.
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Expression and localization of mCherry-Rab1b fusion proteins. I created
constructs that encoded mCherry at the amino terminus of WT, N121I, S22N and Q67L
Rab1b. When expressed in cells, these fusion proteins migrated on SDS-PAGE gels as
single polypeptides of the expected ~ 49 kDa molecular weight (Figure 5.2A).
Furthermore, the constructs displayed subcellular localizations (Figure 5.2B) similar to
those previously described for GFP- and epitope-tagged Rab1 (Alvarez et al., 2003;
Moyer et al., 2001b). These patterns of localization were: reticulate ER-like, perinuclear
Golgi-like, and punctate vesicle-like signals for the WT and Q67L forms; ER-like and
cytosolic for the S22N form; and largely cytosolic and nuclear for the N121I form
(Figure 5.2B).

Figure 5.2. Expression and characterization of mCherry-Rab1b constructs. (A)
Western blot of lysates of HEK293T cells transfected with mCherry- or mCherry-Rab1b
expressing plasmids. mCherry was detected using an α-dsRed antibody. (B) Subcellular
localization of mCherry-Rab1b constructs in Huh-7.5 cells. The cells were transduced
with lentiviral particles expressing the indicated WT or mutant forms of mCherry-Rab1b
and imaged by epifluorescence microscopy at 48 h post transduction. Scale bar, 10 μm.
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Functionality of mCherry-Rab1b constructs. I next confirmed that the
mCherry-Rab1b constructs could functionally interfere with VSVg anterograde transport.
VSVg is amongst the best characterized Rab1 cargoes, and its tsO45 mutant allows for
synchronized analysis of cargo egress (Bergmann et al., 1981). I co-transfected cells with
a plasmid encoding mCherry or mCherry-Rab1b constructs and a plasmid encoding
VSVgtsO45-GFP (Presley et al., 1997). I then allowed expression of the proteins at 39.5°C,
under which conditions VSVgtsO45-GFP is retained in the ER (Kreis and Lodish, 1986;
Presley et al., 1997) and its N-linked glycan chains are sensitive to digestion with both
endoglycosidase H (Endo H) and peptide-N-glycosidase F (PNGase F). Next, I switched
a set of the transfected cells to 32°C, a temperature which allows transport of this VSVg
mutant out of the ER, through the Golgi system, to the plasma membrane (Bergmann et
al., 1981). Transport of VSVg through the Golgi is accompanied by modification of its
glycan chains by Golgi-resident enzymes, resulting in an Endo H-resistant, but PNGase
F-sensitive form (Schwaninger et al., 1991). The cartoon in Figure 5.3A depicts the
expected SDS-PAGE migration patterns of glycosidase-digested (Endo H- and PNGase
F-sensitive) VSVg that has been retained in the ER either by the 39.5°C temperature
block or by the lack of Rab1 activity (Figure 5.3A, the three bands at the left). The same
cartoon also depicts the expected migration patterns of glycosidase-digested (Endo Hresistant but PNGase F-sensitive) VSVg that has been transported out of the ER at the
permissive temperature and in the presence of active Rab1 (Figure 5.3A, the three bands
at the right).
In my hands, regardless of the construct expressed from the co-transfected
plasmid, VSVg-transfected cells that had been incubated solely at 39.5°C displayed
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VSVg migration patterns on the SDS-PAGE gel that were expected of ER-retained
VSVg. In these conditions, VSVg was sensitive to both Endo H and PNGase F digestion
(Figure 5.3B, left three columns of bands). After release from the 39.5°C block, and as
predicted by previous studies (Tisdale et al., 1992), mCherry, or WT or Q67L mCherryRab1b allowed processing of a significant fraction of the VSVg protein to an Endo Hresistant form (Figure 5.3B, top three sets of bands). Some VSVg protein remained
unprocessed in the presence of WT or Q67L mCherry-Rab1b, but not in the presence of
mCherry, presumably due to DN-like effects of the high overexpression of otherwise
functional mCherry-Rab1b constructs that can be achieved in some of the transfected
cells. In contrast to the WT and Q67L constructs, overexpression of S22N or N121I
mCherry-Rab1b potently inhibited VSVg processing to the Endo H-resistant form (Figure
5.3B, bottom two sets of bands).

175

Figure 5.3. Effects of mCherry-Rab1b constructs on VSVg glycan chain processing.
(A) Schematic depiction of expected ER-retained or ER-exported VSVg mobilities on
SDS-PAGE gels. ER-retained VSVg is expected to be sensitive to deglycosylation by
both Endo H and PNGase F and therefore to gain a higher mobility after digestion with
either enzyme. VSVg that had been transported out of the ER is expected to become
resistant to Endo H digestion, but to remain sensitive to PNGase F digestion. (B)
VSVgtsO45-GFP and the noted mCherry or mCherry-Rab1b constructs were co-transfected
into HEK293T cells maintained at 39.5°C. After 24 h, one set of plates was transferred to
32°C to allow VSVg transport out of the ER and processing of its glycan chains. Next all
cell lysates were harvested, digested with PNGase F, Endo H, or left undigested, and
finally processed by Western blotting with an α-GFP antibody that recognized both the
lower mobility glycosylated and higher mobility deglycosylated forms of VSVg-GFP.
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I also confirmed, in the Huh-7.5 cell line, that VSVg-GFP was able to reach the
plasma membrane in the presence of mCherry, or of WT or Q67L mCherry-Rab1b
expression, where it decorated the contours of the cells, while it was retained
intracellularly in the presence of continued 39.5°C temperature block, or of S22N or
N121I mCherry-Rab1b construct expression (Figure 5.4A-B). These biochemical and
localization results document that the mCherry-Rab1b constructs affected the anterograde
transport of VSVg as predicted by previous studies (Alvarez et al., 2003; Tisdale et al.,
1992). These findings further supported using WT and DN mCherry-Rab1 constructs to
investigate the role of Rab1 function in hepatic cargo egress.
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Figure 5.4. Effects of mCherry-Rab1b constructs on VSVg transport to the plasma
membrane (next page). (A) Huh-7.5 cells were transfected with VSVgtsO45-GFP and the
indicated mCherry, or mCherry-Rab1b constructs, and maintained at 39.5°C before being
switched to the indicated temperatures and then fixed and imaged. Representative single
deconvolved planes in the GFP (left column), mCherry (middle column) and overlayed
(right column) fluorescent channels are presented. Signal intensities along the white lines
depicted on the overlay images were quantified and are shown in panel B. Scale bar, 10
μm. (B) Line scan quantification of signal intensities in the GFP channel (green trace)
and mCherry channel (red trace) along the white lines depicted in panel A. The mCherry
or mCherry-Rab1b construct expressed in each of the cells is listed at the top of each
graph, along with the temperature that the cells were exposed to before fixation. The left
column of graphs shows examples where the VSVg-GFP signal was transported to the
plasma membrane as denoted by the clear GFP signal peaks (black arrows) that encase
the mCherry signal. Right column of graphs shows examples where the VSVg-GFP
signal was retained intracellularly, as depicted by the absence of clear GFP signal peaks
at the periphery of the mCherry and GFP signal traces, indicated by black arrowheads.
A.U., arbitrary units.
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5.4. Endocytic activity in the presence of mCherry-Rab1b expression
To alleviate the concern that expression of the DN mCherry-Rab1b constructs
affected cargo secretion through general toxic effects on cell physiology, following
inhibition of ER to Golgi traffic, I measured the ability of mCherry-Rab1b-expressing
cells to endocytose fluorescently labeled transferrin. Transferrin endocytosis is mediated
by a membrane transport process that is functionally, mechanistically and topologically
divergent from the early exocytic events regulated by Rab1 (Luck and Mason, 2012). I
therefore expressed WT or mutant mCherry-Rab1b constructs, or the control mCherry
protein alone, in the Huh-7.5 cells, by lentiviral transduction. I detached these cells from
the plate using a non-proteolytic method to help preserve integrity of cell surface
transferrin receptors. I then allowed the Alexa Fluor 647-labeled transferrin (Tf-AF647)
to bind to the cell surface at 4°C and split the cell culture in two samples. I washed one
sample while keeping it at 4°C, while I allowed the second sample to undergo endocytic
uptake at 37°C, before cooling it and washing it as well. I then quantified the amounts of
fluorescent transferrin taken up by the cells in each condition. This transferrin-uptake
assay was capable of discerning between non-specific transferrin staining (Figure 5.5A,
4°C trace) and active uptake (Figure 5.5A, 37°C trace). Furthermore, live Huh-7.5 cells
transduced with lentiviruses expressing mCherry or mCherry-Rab1b constructs took up
transferrin to comparable levels (Figure 5.5B). These findings are consistent with
previous reports documenting retention of endocytic activity concurrent with inactivation
of ER to Golgi transport (Lippincott-Schwartz et al., 1991; Miller et al., 1992).
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Figure 5.5. Effects of mCherry-Rab1b constructs on transferrin uptake. (A) Huh-7.5
cells were transduced with 25 I.U./cell of a lentivirus expressing mCherry. At 48 h post
transduction, the cells were harvested, a fluorescent transferrin uptake assay was
performed, and the cells were analyzed by flow cytometry. Traces represent distributions
of transferrin staining in live cells after incubation at 4°C (black trace) or 37°C (red
trace). (B) Huh-7.5 cells were transduced with 25 I.U./cell of lentiviruses expressing the
indicated constructs, then allowed to take up transferrin at 37°C. Traces show
distributions of Alexa Fluor 647-labeled transferrin (Tf-AF647) signal levels in single
live cells.
5.5. Cell lines inducibly expressing mCherry-Rab1b
To gain better control of the expression of the mCherry-Rab1b constructs, I once
again used the Huh-7.5 TetON cells (Figure 2.2). I transduced the Huh-7.5 TetON Clone
9 cell line (Luna et al., 2015), with retroviruses expressing mCherry-Rab1b constructs
under the control of a tetracycline response element. I also transduced the resulting cells
with a second luciferase-expressing vector to allow estimation of cell culture mass by
luciferase activity measurements (Figure 3.2). Doxycycline treatment of these cultures
induced mCherry-Rab1b expression in the overwhelming majority of the cells in culture,
as detected by microscopy (Figure 5.6A), flow cytometry (Figure 5.6B) and Western
blotting (Figure 5.6C). Furthermore, Huh-7.5-specific cell shapes were retained in the
cells expressing DN mCherry-Rab1b constructs (Figure 5.6A).
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Figure 5.6. Cell lines inducibly expressing mCherry-Rab1b. (A) The cell lines
expressing the indicated mCherry-Rab1b constructs were imaged either in the absence of,
or after 2 days of treatment with doxycycline. For each cell line, the left column shows
brightfield images, while the right column shows epifluorescence images acquired with
mCherry-specific filters. Scale bars, 50 μm. (B) The cell lines expressing the indicated
mCherry-Rab1b constructs were analyzed by flow cytometry after growth for 24 h in the
presence (Dox, red traces) or absence (Control, blue traces) of 3 μg/mL doxycycline. (C)
Lysates from these were harvested after 24 h of induction with doxycycline and analyzed
by Western blotting with antibodies against dsRed and β-actin.
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5.6. Inducible mCherry-Rab1b: cargo secretion normalized to cell lysate
luciferase activity
Using the doxycycline-inducible mCherry-Rab1b cell lines, I further investigated
the effects of mCherry-Rab1b construct expression on the secretion of albumin, ApoE
and ApoB100. Once again I used the luciferase activity of the cell lysates to normalize
the ELISA measurements of the cargo amounts secreted in the media. Induction of
expression of WT or Q67L mCherry-Rab1b had no detectable effect on the luciferase
activity values, while induction of expression of the S22N and N121I mutant constructs
caused at most a 2-fold activity decrease over 48 h of growth, when compared to the
uninduced condition (Figure 5.7A). When compared to the uninduced control condition,
induction of mCherry-Rab1bN121I expression for various lengths of time caused an
increase in ApoE secretion, and a decrease in albumin and ApoB100 secretion (Figure
5.7B). This effect was specific for the N121I mutant, since expression of the WT (Figure
5.7C), Q67L (Figure 5.7D) or S22N (Figure 5.7E) constructs only minimally affected, if
at all, the secretion of the three cargoes tested, as detected by this method of estimating
secretion. These results paralleled those obtained using lentivirus-mediated delivery of
the untagged or mCherry-tagged Rab1b constructs (Figure 5.1).
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Figure 5.7. Effects of inducible mCherry-Rab1b construct expression on cargo
secretion. I: Secretion normalized by cell lysate luciferase activity. (A-E) Inducible
cell lines expressing the noted mCherry-Rab1b constructs were treated with doxycycline
(Dox) for the indicated durations, or were left untreated, before a 6 h secretion assay was
performed and the amounts of albumin, ApoB100, and ApoE secreted in the media from
each well were quantified by ELISA, and normalized by the luciferase activity of the
corresponding well's cell lysate. The values (mean ± s.d., n=3 parallel wells for secretion
assays, and 4 parallel wells for the luciferase assay) are depicted relative to those
obtained from uninduced cells, on a Log2 scale. (A) Relative luciferase activities in the
cell lysates harvested at the indicated time points. (B-D) Relative cargo secretion levels in
the presence of induction of the indicated constructs.
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5.7. mCherry-Rab1bN121I upregulates ApoE and ApoB100 expression
The method that I employed so far to measure cargo secretion accounted for
changes in the mass of the cells that were responsible for secretion by normalizing the
secreted cargo amounts using the luciferase activity of the cell lysates. However, this
method did not account for any cargo expression changes that may be associated with
expression of the Rab1 constructs. Rab1 overexpression has been shown to induce
transcriptional changes in cells (Romero et al., 2013). To investigate whether such an
effect existed in my experimental setting, I quantified, using qRT-PCR, the transcript
levels of all three cargoes and of Rab1 in cells induced to express mCherry-Rab1b
constructs and compared them to their transcript levels in uninduced cells. As expected,
doxycycline-mediated induction of mCherry-Rab1 constructs caused an increase (3-8
fold in magnitude, depending on the construct expressed) in Rab1b message levels
(Figure 5.8). I note that the primers used in the qRT-PCR assay are predicted to recognize
both the natively-expressed Rab1b and the induced mCherry-Rab1b species. Of note, this
level of mRNA overexpression, if translated into protein amount changes, is similar to
the amount of excess Rab1bS25N that was used to achieve transport inhibition in a
previous in vitro study (Nuoffer et al., 1994). In my experimental setup, WT, Q67L or
S22N mCherry-Rab1b induction affected ApoE, ApoB and albumin mRNA levels very
little, if at all. In contrast, mCherry-Rab1bN121I expression caused an increased (up to 2fold) expression of ApoE and ApoB100 transcripts, while having little effect on albumin
mRNA expression (Figure 5.8). This observation may be explained either by increased
transcription of ApoE and ApoB100 mRNAs in the presence of Rab1bN121I expression, or
by their increased stability. In a recent study, WT Rab1b overexpression in non-secretory
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cell types was shown to cause increased expression of transcripts encoding proteins
involved in the functioning of the secretory system (Romero et al., 2013). Under those
conditions, Rab1bN121I had no detectable transcription-inducing activity (Romero et al.,
2013). The differences between (Romero et al., 2013) and the current findings may be
explained by the use of different experimental systems: the secretory cell-derived Huh7.5 line used here versus the non-secretory cell-derived HeLa line. Alternatively, the
complex mechanisms involved in the regulation of lipoprotein transcript expression may
be involved (Zannis et al., 2001a; Zannis et al., 2001b). For example, cholesterol loading
was shown to cause upregulation of ApoE and ApoB100 mRNA levels (Dashti, 1992;
Mazzone et al., 1987). Since Rab1bN121I expression reduced ApoB100 egress (Figures
5.1, 5.7, as well as 5.10 and 5.11 below), it is plausible that it also inhibited ApoB100mediated cholesterol egress and the resulting accumulation of intracellular cholesterol
may be invoked as one of the mechanisms that could explain the observed upregulation
of ApoE and ApoB100 mRNA levels.

186

Figure 5.8. Effects of mCherry-Rab1b expression on cargo mRNA levels. Cell lines
inducibly expressing the noted mCherry-Rab1b constructs were treated with doxycycline
(black bars) or left untreated (white bars) for the indicated durations. mRNA was
harvested and analyzed by qRT-PCR. Relative mRNA levels for Rab1b, ApoE, ApoB100
and albumin transcripts are shown (mean ± s.d., n=3 parallel wells). Statistical
significance (Student’s t-test): *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
Since mCherry-Rab1bN121I expression caused an increase in the transcript levels
of ApoE and ApoB100 (Figure 5.8), I next inquired whether this induction of gene
expression manifested itself at the protein level as well. I thank Dr. Ursula Andreo for
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performing all radioactivity experiments described here. We compared the relative
incorporation of

35

S-cysteine and methionine into newly synthesized cargo molecules

during a 20-min pulse. In cells expressing mCherry-Rab1bN121I or in control cells, we
divided the newly synthesized cargo amounts by the total amounts of newly synthesized
protein in the cells, and compared the resulting values. Under these experimental
conditions we observed an increase of the relative albumin synthesis, but this increase
was not statistically significant (Figure 5.9). In contrast, both ApoE and ApoB100
synthesis was significantly increased, to a magnitude of about two-fold, in the presence
of mCherry-Rab1bN121I expression (Figure 5.9). Furthermore, this increase in the relative
amount of ApoE and ApoB100 translation closely paralleled the observed elevated
mRNA levels for these two species (Figure 5.8).

Figure 5.9. Effects of mCherry-Rab1bN121I on cargo translation rate. mCherryRab1bN121I expression was induced using 3 μg/mL doxycycline for 24 h (black bars) or
left uninduced (control, white bars), then the cells were pulsed with

35

S-cysteine and

methionine for 20 min and lysed. Albumin, ApoE, and ApoB100-specific incorporation
of radiolabeled amino acids was quantified and was reported to the total radioactivity
incorporated into the sample. The values (mean ± s.d. of 3 parallel wells) are expressed
relative to the control condition. Statistical significance (Student's t-test): n.s., nonsignificant; *, p<0.05; **, p<0.01.
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5.8. Alternative means to quantify cargo secretion
As highlighted above, the use of cell lysate luciferase activity, while accounting
for variations of cell mass between wells and experimental conditions, did not account for
changes in apparent secretion due to changes in pre-transport processes, such as cargo
synthesis. Since mCherry-Rab1bN121I increased the synthesis of ApoB100 and of ApoE
(Figures 5.8 and 5.9), it became important to calculate the effective secretion of cargo
while taking into account the changes in total cargo mass. I therefore used ELISA to
quantify not just the amounts of secreted cargo, but also the amounts cargo that had
remained cell-associated at the end of the secretion assay. I then expressed the amount of
secreted cargo as fraction of total (secreted + cell-associated) cargo, or calculated a
secretion index, defined as the ratio of secreted cargo to cell-associated cargo. Secretion
index measurements have previously been used to monitor changes in cargo secretion in
other systems (Pan et al., 2008b), and the two measurements are related as follows:
1
The major difference between the two values is that while the values for the
fraction secreted can vary from 0 to 1, the values for the secretion index can vary from 0
to infinity. As such, large changes in the secretion index of a cargo efficiently secreted
(for which the secretion fraction is closer to 1) will nonetheless translate into small
changes in the cargo's secreted fraction.
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Fraction secreted analysis. I once more performed secretion assays in the
mCherry-Rab1b inducible cell lines in the presence or absence of doxycycline-mediated
mCherry-Rab1b expression. This time I quantified both secreted and cell-associated
cargo amounts by ELISA in an attempt to simultaneously account for variations in cell
mass as well as cargo expression levels. Expression of mCherry-Rab1b did not alter the
secretion of ApoE, ApoB100, or albumin (Figure 5.10A). In contrast, expression of
mCherry-Rab1bN121I impaired the secretion of the same set of cargoes (Figure 5.10B).
The magnitude of the secretion impairment differed as the ApoE secreted fraction
decreased by 18% or 19% from the control value at 24 h or 48 h, respectively. The
albumin secreted fraction decreased by 31% or 32%, and the ApoB100 secreted fraction
decreased the most, by 39% or 50%, for the 24 h or 48 h time points, respectively (Figure
5.10B). I note that expression of the S22N construct impaired the secretion of albumin
and of ApoB100, but not that of ApoE (Figure 5.10C). Lastly, expression of the Q67L
construct reproducibly impaired only albumin secretion (Figure 5.10D). Taken together,
these results establish the involvement of Rab1 function in the secretion of albumin,
ApoE and ApoB100.
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Figure 5.10. Effects of inducible mCherry-Rab1b construct expression on cargo
secretion. II: Percent secretion. Cell lines inducibly expressing the noted mCherryRab1b constructs were treated with doxycycline for the indicated durations (black bars),
or left uninduced (white bars) before a 6 h secretion assay was performed. Secreted and
cell-associated amounts of albumin, ApoE and ApoB100 were measured by ELISA and
the amounts of secreted cargo were expressed as fraction of total (secreted + cellassociated) amounts. Shown are means ± s.d., n=3 parallel wells. Statistical significance
(Student's t-test): *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
Secretion index analysis. The pattern of the effects of the mCherry-Rab1b
mutants on the secretion of the tested cargoes (Figure 5.10) was preserved when secretion
indexes were compared (Figure 5.11). Expression of the WT construct did not affect the
secretion of either of the three cargoes (Figure 5.11A), while expression of mCherryRab1bN121I impaired secretion across the board (Figure 5.11B). Once again, the S22N
mutant affected the secretion of both albumin and ApoB, but not that of ApoE while the
Q67L mutant affected albumin secretion but not ApoE or ApoB secretion (Figure 5.11C191

D). Since even small, but significant changes in the fractions of cargo secreted (Figure
5.10), corresponded to significant and substantial changes in the cargo secretion indexes
(Figure 5.11), I argue that small magnitudes of secreted fraction differences are unlikely
to have been caused by technical variations in how the secretion was measured, but are
rather true reflections of differences between the secretion capabilities of the cells under
these experimental conditions.

Figure 5.11. Effects of inducible mCherry-Rab1b construct expression on cargo
secretion. III: Secretion index analysis. Cell lines inducibly expressing the noted
mCherry-Rab1b constructs were treated with doxycycline for the indicated durations
(black bars), or left uninduced (white bars) before a 6 h secretion assay was performed.
Secretion indexes were calculated by dividing the amounts of cargo secreted by the
amounts of cargo that had remained cell-associated. Shown are means ± s.d., n=3 parallel
wells. This data was obtained from the same samples as the data shown in Figure 5.10.
Statistical significance (Student's t-test): *, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001.
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5.9. mCherry-Rab1bN121I impairs secretion of newly synthesized cargo
I next inquired, again with the help of Dr. Ursula Andreo, whether the observed
impairment of cargo secretion caused by mCherry-Rab1bN121I expression (Figures 5.10
and 5.11) was correlated with a decreased rate of secretion of newly synthesized cargo.
We thus followed cells that had been pulsed with

35

S-cysteine and methionine as they

secreted cargo during a chase in the presence of excess cold cysteine, methionine and
cycloheximide. At regular time intervals we collected the media and the cell lysates,
immunoprecipitated albumin, ApoB100 and ApoE and measured the radioactivity
associated with each species. We expressed the amount of newly synthesized cargo
species present at any given time point in the cell media as fraction of the total (secreted
+ cell-associated) amount of newly synthesized cargo recovered at that time point. Using
this analysis, we observed that lower fractions of newly synthesized albumin, ApoE and
ApoB100 were secreted in the presence of mCherry-Rab1bN121I expression, compared to
control, by magnitudes in the range of 10-30% (Figure 5.12). The decrease in total cargo
secretion observed in the presence of mCherry-Rab1bN121I expression (Figures 5.10 and
5.11) thus correlates with a decrease in the rate of secretion of newly synthesized cargo
(Figure 5.12).
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Figure 5.12. Effects of mCherry-Rab1bN121I on the secretion of newly synthesized
hepatic cargoes. mCherry-Rab1bN121I expression was induced for 24 h (red trace) or left
uninduced (blue trace), then the cells were pulsed with

35

S-cysteine and methionine for

20 min and then chased. Newly synthesized amounts of albumin, ApoE and ApoB100
were quantified at the indicated chase time points in both media and cell lysates. The
radioactivity of secreted cargo at each time point is expressed as a fraction of the total
(secreted + cell-associated) radioactivity of that cargo. Means ± s.d. of 3 parallel wells
are depicted.
5.10. Inactivation of endogenous Rab1 function
In the work presented so far, secretion of cargo was impaired by overexpressing
DN Rab constructs. To test whether inactivation of endogenous Rab1 function also
affected cargo secretion, I engineered the Huh-7.5 TetON cells to inducibly express a L.
pneumophila protein, DrrA, which has been shown to be exported by the bacterium into
the cytosol of infected cells where it interferes with Rab1 function (Machner and Isberg,
2006; Murata et al., 2006). DrrA, also known as SidM (Machner and Isberg, 2006;
Murata et al., 2006), possesses several functional domains: a Rab1 AMPylation domain
(Hardiman and Roy, 2014; Muller et al., 2010), a Rab1 binding domain and a Rab1
GDF/GEF domain (Ingmundson et al., 2007; Murata et al., 2006; Schoebel et al., 2009;
Suh et al., 2010; Zhu et al., 2010) and a phosphatidylinositol 4-phosphate lipid binding
domain (Brombacher et al., 2009; Del Campo et al., 2014; Schoebel et al., 2010; Zhu et
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al., 2010). The DrrA construct which I used, GFP-DrrA61-647, but which I will refer to
from here on simply as GFP-DrrA, has part of the AMPylation domain (Muller et al.,
2010) deleted and does not exhibit the general cytotoxic effects of full length DrrA
(Murata et al., 2006). This construct also preferentially binds and acts on Rab1 GTPases,
and its expression interferes with ER to Golgi transport of β-1,4-galactosyl-transferase
and disrupts Golgi structure (Machner and Isberg, 2006; Murata et al., 2006), as expected
of a Rab1 inhibitor. I also engineered a TetON-GFP control cell line, and I transduced
both the GFP-DrrA and GFP cell lines with a luciferase-expressing lentivirus in order to
easily monitor the effects of construct expression on cell mass. In secretion assays, GFP
expression alone did not affect the secretion of either of the three cargoes tested (Figure
5.13A). In contrast, GFP-DrrA impaired the secretion of albumin and ApoB100, but not
that of ApoE (Figure 5.13B), mirroring the effect of mCherry-Rab1bS22N expression
(Figures 5.10C and 5.11C). The GFP and the GFP-DrrA proteins were detected in lysates
of the respective cell lines only after induction with doxycycline (Figure 5.13C). GFP
protein levels were significantly higher than GFP-DrrA levels, since the GFP-DrrA blot
required use of a more sensitive chemiluminescence substrate system to allow detection
of the GFP-DrrA band. At the same time GFP-DrrA expression did not decrease the
luciferase activity of the cell lysates (Figure 5.13D), thus alleviating concerns regarding
cytotoxicity, which is consistent with previous findings (Murata et al., 2006). Overall,
these results established that inhibition of endogenous Rab1 function impairs hepatic
cargo secretion and provided independent confirmation of the results obtained by
overexpressing the DN Rab1b constructs.
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Figure 5.13. Inactivation of endogenous Rab1 function impairs hepatic cargo egress.
Cell lines inducibly expressing GFP (A), or GFP-DrrA (B) were induced with
doxycycline (black bars) or left uninduced (white bars) for the indicated durations, then a
6 h secretion assay was performed. Secreted and cell-associated amounts of albumin,
ApoE and ApoB100 were measured by ELISA and the amounts of secreted cargo were
expressed as fraction of total (secreted + cell-associated) amounts. Means ± s.d. of values
obtained in three parallel wells are shown. Statistical significance (Student's t-test): *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. (C) Western blotting of cell lysates
from inducible GFP or GFP-DrrA cell lines after 2 days of induction with 0 or 3 μg/mL
Doxycycline (Dox). Proteins were detected with α-GFP and α-actin antibodies. Molecular
weight markers (kDa) are listed at the left of the blots. The GFP blot (top left) and the
actin blots (bottom) were developed with the less sensitive ECL Prime detection reagent,
while the GFP-DrrA blot (top right) was developed with the more sensitive West Femto
reagent. Expected molecular weights: GFP, 27 kDa; GFP-DrrA, 94 kDa.
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5.11. Rab1 and HCV secretion
HCV secretion and infectivity requires expression of amphipathic helixcontaining apolipoproteins (such as ApoE and ApoB100) by the HCV-producing cells
(Fukuhara et al., 2014; Hueging et al., 2014), raising the possibility that HCV employs
some of the same secretion route(s) as the lipoproteins. Having established that Rab1
inactivation impairs the secretion of the lipoprotein components ApoE and ApoB100 and
of the non-lipoprotein cargo albumin from the Huh-7.5 cell line, I next investigated the
effect of Rab1 inactivation on the secretion of HCV. In order to discern between a
previously proposed Rab1 function in genome replication (Nevo-Yassaf et al., 2012;
Sklan et al., 2007a; Sklan et al., 2007b) and its putative function in virus particle
secretion, I allowed the viral genome replication machinery to become established for
two days following viral RNA electroporation. Then, I induced mCherry-Rab1bN121I
expression to inactivate Rab1 function, and performed secretion assays (Figure 5.14A). I
performed several variations of this experiment, by varying either the duration of
mCherry-Rab1bN121I expression, or the length of the secretion assay (Figure 5.14A-B)
Despite varying these experimental parameters, inhibition of Rab1 function consistently
caused a significant increase of the fraction of HCV infectivity that remained cellassociated (Figure 5.14B). This result is consistent with expression of mCherryRab1bN121I impairing the transport of newly assembled infectious HCV particles from the
ER to the Golgi and causing their concomitant accumulation in an ER-related
compartment. These observations are also similar to those noted when anterograde
transport of HCV was inhibited by treatment of HCV producing cells with brefeldin A, a
potent, widely-used blocker of ER to Golgi transport (Gastaminza et al., 2008;
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Lippincott-Schwartz et al., 1989). Furthermore, I found that intracellular HCV RNA
levels were also slightly elevated in cells expressing the DN Rab1b construct (Figure
5.14C), consistent with impaired release of HCV RNA via the secretory pathway.
Without ruling out a Rab1b function in HCV replication, these results do not favor a
massive inhibition of this process by mCherry-Rab1bN121I. Lastly, the magnitudes of the
sensitivity of ApoE, albumin, and ApoB100 secretion from HCV-infected cells (Figure
5.14D) retained the same relative order as in HCV-free cells (Figures 5.1A-B, 5.7, 5.10
and 5.11). Thus, ApoB100 secretion remained most potently impaired, while ApoE
secretion was the least negatively affected, and albumin secretion displayed an
intermediate phenotype.
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Figure 5.14. Effects of mCherry-Rab1bN121I on HCV infectivity release. (A)
Experimental design: cells were electroporated with HCV RNA, allowed to establish
HCV infection for 2 days, then induced to express mCherry-Rab1bN121I by treatment with
doxycycline for a duration designated T1 (1 or 2 days), then a secretion assay was
performed for a period designated T2 (6 or 24 h). Control cells were treated identically
except that they were not induced with doxycycline. (B) Effects of mCherry-Rab1bN121I
expression on secretion of infectious HCV particles. The experimental format outlined in
panel A was followed, while varying T1 and T2, as listed under the graph. For each
experiment, 3 parallel HCV RNA electroporations were performed. For each
electroporation, 3 wells were induced to express mCherry-Rab1bN121I (black bars) and 3
wells were left uninduced (white bars). Secreted and cell-associated infectivity was
measured and the cell-associated infectivity in each well was expressed as fraction of the
total infectivity in that well. (C). Total cell-associated HCV RNA was quantified by qRTPCR in additional wells from the experiment for which T1 = 2 days and T2 = 6 h. (D)
Secreted cargo amounts were quantified by ELISA and normalized to the luciferase
activity of the corresponding wells (T1 = 2 days and T2 = 6 h). (B-D) Bars represent
means ± standard error of the mean for the 3 replicate electroporations. Statistical
significance (2-way ANOVA test): *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
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5.12. Discussion
Technical concerns. Before discussing the general findings of this Rab1-focussed
body of work, I wish to address two technical concerns. The first deals with potential
toxic effects caused by inhibition of ER-to-Golgi traffic by expression of the DN Rab1b
constructs. This concern stems from the knowledge that ER-to-Golgi traffic is essential
for cell viability, as evidenced by the findings that Ypt1 loss of function is lethal in yeast
(Haubruck et al., 1989; Schmitt et al., 1986; Segev and Botstein, 1987; Segev et al., 1988;
Wagner et al., 1987). Rab1 is the mammalian homolog of Ypt1 (Haubruck et al., 1989;
Segev et al., 1988; Touchot et al., 1987; Vielh et al., 1989; Zahraoui et al., 1989). Due to
this concern I have employed several means to assess cell health. The luciferase activity
measurements (Figures 5.1C and 5.7A) did indeed document decreased luciferase
activities in cells expressing the DN Rab1b constructs. These decreases were generally no
larger than a 2-fold change over 54 h of expression (48 h from the time of lentivirus
transduction or doxycycline induction + 6 hours of secretion assay). Such small decreases
are inconsistent with massive cell death, but could in turn be caused by growth delays
secondary to reduced rates of exocytic transport. Second, effects of DN Rab1 expression
on cargo secretion were evident even at early time points after induction (Figure 5.7B),
when the luciferase activity in the cell lysates had not changed or had decreased only
slightly (Figure 5.7A, 12 and 24 h time points). Third, a divergent membrane transport
process, transferrin endocytosis, remained unaffected by expression of various Rab1b
constructs, a finding inconsistent with the Rab constructs having caused overwhelming
toxicity (Figure 5.5). Fourth, while morphological changes did become noticeable in DN
Rab1-expressing cells, many cells in the culture retained the morphology specific to the
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Huh-7.5 cell line (Figure 5.6A). Fifth, that cells expressing mCherry-Rab1bN121I
synthesized cargo proteins at higher rates than the control cells (Figure 5.9), that this
increase in the rate of synthesis correlated with increased expression of cargo messages
(Figure 5.8), and that the secretion of the newly synthesized cargoes was decreased in the
same conditions (Figure 5.12), served as further evidence that, while affected in some
aspects, cell physiology retained a high degree of functionality. I thus argue that,
regardless of adverse effects on cell health caused by inhibition of anterograde transport
from the ER to the Golgi, the results of the experiments presented above were properly
interpreted to yield the conclusion that Rab1 was indeed involved in anterograde
transport of these cargoes.
The second technical issue deals with apparent differences between the results
obtained using the luciferase activity-based method of normalization (Figures 3.8, 5.1,
and 5.7), and those obtained using the normalization method using cell-associated cargo
amounts (Figures 5.10, 5.11, and 5.12). Both methods took into account the cell mass
responsible for the measured secretion. The later method also accounted for the observed
changes in cargo mRNA expression and cargo synthesis (Figures 5.8 and 5.9). For ApoE,
a two-fold increase in its translation rate (Figure 5.9) could overcome a 10-20% decrease
in transport rate (Figure 5.12), to cause an overall apparent increase in the amount of
cargo accumulated in the cell culture media (Figures 3.7, 3.8, 5.1A-B, and 5.7B). For
albumin, a smaller increase in expression counteracted by the observed decrease in
secretion could account for the relatively small observed net change in secretion amounts
(Figures 5.1A-B and 5.7B). ApoB100, in contrast, would have been expected to display a
phenotype similar to that of ApoE, since their rates of translation and of secretion had
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changed in similar ways in response to DN Rab1b expression (Figures 5.8 and 5.9).
However, ApoB100 also undergoes significant degradation associated with the ER
(Ginsberg and Fisher, 2009), which does not appear to be the case for ApoE or albumin
(Ye et al., 1992; Ye et al., 1993). Thus, although more ApoB100 was being synthesized,
if a significant portion of it was degraded along the secretion route, combined with a
slower secretion rate overall, these phenomena may well account for the observed overall
decrease in secretion. I believe therefore that the results obtained using luciferase-based
normalization and those obtained using the cell-associated cargo amounts for
normalization, while facially different, were nevertheless consistent with each other as
well as with a model in which Rab1 controls the secretion of the analyzed cargoes.
Rab1 functions in hepatic cargo secretion. As described in this chapter, I
investigated whether Rab1 mediated ER to Golgi transport of several hepatic secretory
cargoes. I found that inactivation of Rab1 function - by expression of DN mutants or of a
bacterial effector targeting Rab1 - impaired the secretion of albumin, ApoE, ApoB100
and infectious HCV particles. I propose that Rab1 mediates anterograde transport of these
cargoes, as it does for many other cargoes investigated to date (Dong et al., 2012; Dugan
et al., 1995; Filipeanu et al., 2004; Filipeanu et al., 2006; Flowerdew and Burgoyne,
2009; Ingmundson et al., 2007; Nachmias et al., 2012; Plutner et al., 1991; Robitaille et
al., 2009; Satoh et al., 1997; Wu et al., 2001; Wu et al., 2003; Yamayoshi et al., 2010;
Zenner et al., 2011; Zhuang et al., 2010). My findings are consistent with the documented
Rab1 association with in vitro-made vesicles loaded with VLDL (Rahim et al., 2012).
Further corroborating evidence comes from the documented functional association of
Rab1 with vesicle coat complexes COPII and COPI implicated in ER to Golgi transport.
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COPII mediates sorting of hepatic cargo into anterograde transport vesicles during ER
exit (Gusarova et al., 2003; Jones et al., 2003; Siddiqi, 2008; Siddiqi et al., 2003). COPI,
in turn, can mediate cargo transport from the ERGIC to the Golgi (Garcia-Mata et al.,
2003; Pepperkok et al., 1993; Peter et al., 1993; Shima et al., 1999; Stephens et al., 2000).
Rab1 interacts with and may be activated downstream of both COPII and COPI (Kim et
al., 2006; Slavin et al., 2011; Yamasaki et al., 2009). Once activated on the surface of
transport carriers, Rab1 may interact with a series of effectors, including the Golgi
tethering factor p115 (Allan et al., 2000), and GBF1, which is the GEF that activates Arf1
and thus initiates COPI recruitment (Alvarez et al., 2003; Monetta et al., 2007). The
ability of mCherry-Rab1bN121I to interfere with hepatic cargo transport could, for
example, be mediated through disruption of the function of these effectors. Indeed,
expression of Rab1bN121I has been shown to increase the mobility of p115, likely by
increasing the rate of its exchange between cytosolic and membrane-bound pools
(Brandon et al., 2006). Expression of the N121I mutant construct may also interfere with
COPII and/or COPI function in anterograde transport (Alvarez et al., 2003; Monetta et
al., 2007; Slavin et al., 2011), which may in turn impair cargo secretion.
Distinct pathways are likely involved in anterograde transport of albumin,
ApoE and ApoB100. A recurring observation in the experiments that I presented here
was that the various means used to impair Rab1 function differentially affected albumin,
ApoE and ApoB100 secretion. This was evident in the different magnitudes of the
disruption caused by the N121I mutant (Figures 5.10 and 5.11), and also in the lack of
effect of the S22N mutant or of GFP-DrrA on ApoE secretion (Figure 5.13). Since
measurements of the amounts of each cargo were performed in parallel in each sample, I
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do not view potential variations in cargo quantification efficiencies as a likely
explanation of these results. I cannot presently exclude confounding effects of other
biological processes, such as cargo degradation known to occur during secretion, or
lipoprotein particle maturation processes (Ginsberg and Fisher, 2009; Rutledge et al.,
2010; Ye et al., 1992; Ye et al., 1993). I nonetheless note that these results are consistent
with a model, supported by in vitro experiments (Gusarova et al., 2007; Siddiqi, 2008), in
which various hepatic cargoes are transported out of the ER in distinct carriers.
Furthermore, a quantitative electron microscopy study has shown that VSVg sorting into
ER-derived transport carriers is accompanied by a concentration of this cargo, to levels
maintained throughout exocytic transport (Balch et al., 1994). A similar observation was
described regarding the transport of human serum albumin from the ER to the Golgi in
the HepG2 human hepatoma cell line (Mizuno and Singer, 1993). This packing of cargo
in transport carriers, if sufficiently specific, may well yield the different populations of
cargo-specific carriers previously identified biochemically (Gusarova et al., 2007;
Siddiqi, 2008) and inferred from the different sensitivity of their transport to inhibition of
Rab1 function, as described here. Lastly, such differential regulation of anterograde
traffic appears not to be limited to hepatocyte function since dendrite and axon growth,
respectively, displayed distinct sensitivity to inactivation of the function of the early
exocytic regulators Sec23, Sar1 and Rab1 (Ye et al., 2007), while secreted and
transmembrane protein transport exhibited distinct sensitivities to GBF1 knockdown
(Szul et al., 2007). Further supporting this model, some anterograde cargoes may
undergo, under certain experimental conditions, Rab1-independent transport from the ER
to the cell periphery (Filipeanu et al., 2006; Wu et al., 2003; Yoo et al., 2002).
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Varied effects of the Rab1 inhibition methods. In my hands, albumin secretion
was inhibited by all three Rab1 mutants, and by the L. pneumophila effector DrrA. ApoB
secretion was not inhibited by the Q67L mutant, while ApoE secretion was only inhibited
by the N121I mutant. These differences raise questions as to how the various means of
blocking Rab1 function actually affected transport. The effect of the Q67L mutant on
albumin secretion stands out to begin with, since this mutant does not impair transport of
the model cargo VSVg (Tisdale et al., 1992). Rab1bQ67L possesses low intrinsic GTPase
activity, but is expected to have normal GAP-stimulated GTPase activity, since this Q67
residue, unlike the equivalent glutamine in other small GTPases, including other Rabs,
does not enact GTP hydrolysis in the presence of the cognate Rab1 GAP, TBC1D20
(Gavriljuk et al., 2012). Instead, TBC1D20 provides a catalytic glutamine residue
(Gavriljuk et al., 2012). As such, if transport of VSVg, ApoE and ApoB100 primarily
involve GAP-mediated GTP hydrolysis, then the lack of effect of the Q67L mutant is
unsurprising. Furthermore, it is plausible that albumin transport relies more heavily on
unstimulated Rab1 GTPase activity, which may in turn explain the current findings.
Alternatively, it is conceivable that Arf1 stabilization on membranes by Rab1bQ67L
(Monetta et al., 2007) may affect albumin secretion, although this would raise the
question as to why only albumin was affected.
The other means of Rab1 inactivation may affect cargo transport through different
mechanisms. Rab1bS22N is likely to compete with endogenous Rab1 for either a Rab1
GEF or for GDI (Nuoffer et al., 1994). GFP-DrrA, a protein which displays Rab1 GEF
activity and potentially concurrent Rab1 GDF activity (Ingmundson et al., 2007; Machner
and Isberg, 2007; Schoebel et al., 2009; Suh et al., 2010; Zhu et al., 2010), caused similar
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changes in cargo secretion as did mCherry-Rab1bS22N. DrrA may recruit Rab1 - and
activate it - at ectopic, PI4P-containing membranes, such as the plasma membrane
(Murata et al., 2006), thereby removing it from the native pathway of ER to Golgi
transport. It appears likely, therefore, that the similar effects of the Rab1bS22N and DrrA
constructs might be achieved through disruption - in distinct ways - of the activation of
Rab1 at the ER. In contrast, the unstable binding of nucleotides by the N121I mutant
likely causes a rapid oscillation between the GDP and GTP-bound forms, which likely
destabilizes effector recruitment to membranes (Alvarez et al., 2003; Brandon et al.,
2006; Monetta et al., 2007; Pind et al., 1994). The pan-cargo effects that we observed
when we used the N121I mutant imply that the ability of Rab1 to cycle between GTPand GDP-bound forms, or to bind effectors for a long-enough duration may be
universally required for the transport of Rab1-dependent cargoes. Since the N121I mutant
blocks VSVg transport at the ERGIC (Alvarez et al., 2003; Pind et al., 1994; Tisdale et
al., 1992), it is likely that the initial, COPII-mediated transport from the ER to the ERGIC
does not require lengthy Rab1-effector interaction. This would be further supported by
the spatial proximity between ER exit sites and the ERGIC (Bannykh et al., 1996). The
S22N, in contrast, causes retention of VSVg in the ER (Alvarez et al., 2003; Nuoffer et
al., 1994; Tisdale et al., 1992). VSVg, and likely albumin and ApoB as well, presumably
require Rab1 function for their COPII-mediated transport from the ER to the ERGIC. It is
surprising that ApoE secretion is insensitive to the Rab1bS22N or DrrA-mediated shift in
the GDP-Rab1/GTP-Rab1 balance. Whether ApoE utilizes a novel transport pathway out
of the ER may warrant further investigation.
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Rab1 functions in infectious HCV particle secretion. By documenting Rab1
involvement in infectious HCV particle secretion, this work complements previous
findings implicating Rab1, and its cognate GAP, TBC1D20, in HCV genome replication
(Haas et al., 2007; Nevo-Yassaf et al., 2012; Sklan et al., 2007a; Sklan et al., 2007b).
TBC1D20 interacts with HCV NS5A (Sklan et al., 2007b). Rab1b (Sklan et al., 2007a) or
TBC1D20 (Sklan et al., 2007b) knockdowns decrease HCV genome replication.
Expression of GFP-Rab1bN121I caused fragmentation of lipid droplets, organelles
implicated in HCV particle assembly (Miyanari et al., 2007), as well as changes in the
pattern of NS5A localization (Nevo-Yassaf et al., 2012). However, the effects of Rab1b
inactivation on the secretion of infectious HCV particles have not been assessed. Under
experimental conditions described above, DN Rab1b expression did not decrease the
abundance of cell-associated HCV genomes implying that HCV genome replication was
not greatly affected by expression of this mutant, while particle egress was impaired. It is
plausible that the Rab1 function in ER to Golgi transport that is inhibited by expression
of the N121I mutant be dispensable for HCV genome replication. I did not investigate
whether Rab1 function is important for earlier steps of the HCV life cycle, spanning from
entry through the establishment of the replication machinery, which could further explain
the documented Rab1b knockdown phenotype (Sklan et al., 2007a). Indeed, I inactivated
Rab1 function only after allowing replication to become established for 2 days following
electroporation of the HCV RNA. Presumably, by this stage, HCV RNA replication has
become largely insensitive to (DN-mediated) inhibition of Rab1 function. Another
difference between my work and the previous study (Nevo-Yassaf et al., 2012) is the
method of DN Rab1 expression. While (Nevo-Yassaf et al., 2012) employed plasmid
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transfection, in my hands this method of expression was accompanied by considerable
cytotoxic effects, potentially due to high levels of construct overexpression in transfected
cells. I was therefore necessitated to employ inducible gene expression from stable cell
lines, which may account for some of the observed differences. Nevertheless, our results
remain in agreement with previously published studies, and overall document the
involvement of Rab1-mediated ER-to-Golgi transport in the secretion of infectious HCV
particles.

208

Chapter 6
Functional Characterization of an ApoE-GFP Fusion

6.1. Introduction
The investigation into how hepatic cargo secretion is regulated, which I described
in the previous three chapters, was based primarily on genetic and biochemical assays. To
more comprehensively analyze hepatic cargo egress, I wanted to complement these
approaches with live cell imaging studies. Live cell imaging assays have the advantage of
providing both spatial and temporal dynamic views of the cellular processes studied
(Lippincott-Schwartz et al., 2001; Liu et al., 2015; Wouters et al., 2001). Furthermore,
live cell imaging of vesicular transport of secreted cargo may provide single-event-level
description of this process and therefore reveal unexpected behaviors otherwise lost by
the averaging of unsynchronized behaviors, which is inherent to many biochemical
approaches (Wennmalm and Simon, 2007). Expression of fluorescent protein-tagged
constructs has become a standard and powerful method used to study spatial and
temporal dynamics of proteins, membranes and organelles in live cells. The method relies
on fusing, in frame, a DNA fragment encoding one of an ever-growing list of fluorescent
proteins (Chudakov et al., 2010) to the 5'- or 3'-end of a DNA fragment encoding a
protein whose dynamics are to be studied, followed by expression of the resulting
chimeric gene. Powerful spatio-temporal studies may be carried out and their results
properly interpreted if fluorescent protein tagging does not detectably interfere with the
process studied (Jacobs et al., 1999). Unfortunately, fluorescent protein tagging may also
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result in DN, non-functional, or mislocalized fusion proteins, as outlined in greater detail
in a previous study (Rappoport and Simon, 2008). Thus, to avoid collecting and
interpreting artifactual data caused by expression of aberrantly-behaving fluorescent
protein fusions, an initial battery of functional tests should be performed (Rappoport and
Simon, 2008). I present in this chapter such a functional characterization of an ApoEGFP fusion protein for use in the investigation of lipoprotein and HCV secretion from
hepatic cells.
6.2. A roadmap for investigating ApoE-GFP functionality
Previous studies have described ApoE-GFP constructs that were used to image
microtubule-dependent ApoE secretion from macrophages (Kockx et al., 2007), or to
colocalize ApoE with fluorescently-labeled HCV Core-containing entities (Coller et al.,
2012). In the macrophage study, ApoE-GFP secretion from cells was comparable to that
of untagged ApoE. Additionally, its localization at the ER, Golgi, and within secretory
vesicles, as well as its movement along microtubules, was consistent with behaviors
expected of this secreted protein (Kockx et al., 2007), suggesting that this ApoE-GFP is a
good marker for the secretion of ApoE from macrophages. Whether ApoE-GFP is also a
useful marker for monitoring ApoE secretion from hepatic cells, in the presence or
absence of HCV infection, has not been formally addressed to date.
As I mentioned in Chapter 1, some of the lipid metabolic functions of ApoE are
mediated through its interaction with ApoB100-containing VLDL (Blum et al., 1980;
Havel et al., 1980). Hepatocyte-made ApoE, in particular, may associate intracellularly
with VLDL particles (Dolphin, 1981; Fazio and Yao, 1995; Gusarova et al., 2007), and
promote the secretion of VLDL-associated triglycerides (Huang et al., 1998; Kuipers et
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al., 1997). Furthermore, ApoE is incorporated into HCV particles that assemble at the
ER of infected hepatocytes (Andre et al., 2002; Catanese et al., 2013; Chang et al., 2007;
Lindenbach, 2013; Lindenbach and Rice, 2013; Miyanari et al., 2007; Nielsen et al.,
2006). This ApoE-HCV association is important for efficient production of HCV
particles and for the infectivity of the released virions (Chang et al., 2007; Fukuhara et
al., 2014; Hishiki et al., 2010; Hueging et al., 2014; Lee et al., 2014; Long et al., 2011;
Vogt et al., 2013).
Given these hepatocyte-specific functions of ApoE in lipoprotein and HCV
particle formation and release, I outlined several functional assays that are needed to
determine whether ApoE-GFP functionally reproduces the behavior of untagged ApoE
with respect to lipoprotein and infectious HCV particle release from hepatic cells. These
tests aimed to determine whether: i) ApoE-GFP was properly expressed in cells; ii)
ApoE-GFP colocalized with untagged ApoE; iii) ApoE-GFP was secreted from cells with
similar efficiency as untagged ApoE; iv) ApoE-GFP associated with secreted lipoprotein
particles; and v) tagged ApoE retained the ability to support infectious HCV production.
Overall, the results of the experiments designed to address these questions indicated that
ApoE-GFP faithfully reproduced known aspects of ApoE association with secreted
hepatic lipoproteins, and support its use in future imaging studies aimed at elucidating
dynamic spatio-temporal aspects of lipoprotein secretion.
6.3. ApoE-GFP expression
I tagged ApoE with GFP by fusing the fluorescent protein to the carboxylterminus of full length human ApoE3. Silent mutations were introduced in the ApoEcoding region to confer resistance to shRNA-mediated knockdown. I am grateful to Dr.
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Margaret Scull and Joshua Horwitz for their efforts in making this shRNA-resistant
ApoE-expressing cDNA clone. I tagged this ApoE sequence at its carboxyl-terminus with
monomeric enhanced GFP (mEGFP), which has a dimerization-disrupting A206K
mutation (Zacharias et al., 2002). I used the mEGFP variant to prevent potential GFPmediated artifactual aggregation of the resulting fusion protein. The linker between ApoE
and GFP is predicted to be identical with that found in the ApoE-GFP construct that was
previously characterized in macrophages (Kockx et al., 2007). From here on, I refer to the
shRNA-resistant ApoE3-mEGFP construct that I made as ApoE-GFP.
To characterize ApoE-GFP, I stably expressed it in human hepatoma Huh-7.5
cells, which secrete both ApoB100- and ApoE-containing lipoproteins and support the
complete HCV life cycle (Lindenbach et al., 2005; Meex et al., 2011). Huh-7.5/ApoEGFP cells expressed both ApoE-GFP (62 kDa predicted unglycosylated molecular
weight) and untagged endogenous ApoE (predicted 34 kDa), as detected using a
polyclonal α-ApoE antibody (Figure 6.1A). The ApoE-GFP fusion was also detected
using an α-GFP antibody (Figure 6.1B), but was not detected using a monoclonal α-ApoE
antibody (clone EP1374Y) raised against the C-terminus of ApoE (Figure 6.1C). Cterminal tagging of the ApoE sequence presumably renders this antibody's epitope
unrecognizable. ApoE-GFP was not detected in the parental Huh-7.5 cell line, nor in the
empty vector (EV) transduced control cell line Huh-7.5/EV Hygro (Figure 6.1A-B).
Similar amounts of cell lysate from each of the three cell lines were loaded, as detected
by an α-actin antibody (Figure 6.1D).
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Figure 6.1. Expression of ApoE-GFP in Huh-7.5 cells. Lysates from Huh-7.5 cells,
from Huh-7.5/EV Hygro cells, or from Huh-7.5/ApoE-GFP cells were immunoblotted
with the following antibodies: (A) α-ApoE, AB947 goat polyclonal, (B) α-GFP, (C) αApoE, clone EP1374Y, rabbit monoclonal, and (D) α-actin. Molecular weights (kDa) are
listed at the left of the blots. ApoE and ApoE-GFP bands are labeled at the right.
6.4. ApoE-GFP colocalizes with endogenous ApoE
I used the fortuitously discovered EP1374Y monoclonal antibody, which only
recognizes the untagged form of ApoE, to characterize the intracellular localization of
endogenously-expressed,
confirmed

that

untagged ApoE, relative to that of ApoE-GFP. We first

this monoclonal

antibody

did

not

recognize

ApoE-GFP in

immunofluorescence experiments. Neither HeLa cells, which do not express endogenous
ApoE (Smith et al., 1988), nor HeLa cells that had been transduced with the ApoE-GFP
construct, showed staining with the α-ApoE antibody, while HeLa cells expressing a
GFP-ApoE fusion (with GFP at the amino-terminus) became brightly stained under the
same conditions (Figure 6.2). Both ApoE-GFP and GFP-ApoE transduced HeLa cells
stained with an α-GFP antibody (Figure 6.2). I thank Caroline Gleason for performing
this reagent testing-experiment.
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Figure 6.2. An α-ApoE antibody does not recognize ApoE-GFP in immunofluorescence assays. The following cells were stained with the rabbit α-ApoE
monoclonal antibody EP1374Y: HeLa cells (do not express endogenous ApoE), HeLa
cells expressing ApoE-GFP, and HeLa cells expressing GFP-ApoE. An α-GFP antibody
was used to boost the GFP signal. While GFP staining occurred in both ApoE-GFP- and
GFP-ApoE-expressing cells, ApoE staining occurred only in the GFP-ApoE expressing
cells, where the C terminus of ApoE (the immunogen for EP1374Y) presumably
remained accessible. No staining was observed in untransduced HeLa. Scale bars, 50 μm.
Since the α-ApoE antibody did not recognize the ApoE-GFP fusion protein in
Western blotting (Figure 6.1C) or immunofluorescence (Figure 6.2) experiments, I
processed the Huh-7.5/ApoE-GFP cells for immunofluorescence using an α-GFP
antibody to boost the signal from the GFP, and with the monoclonal α-ApoE antibody.
The resulting signals displayed reticular and punctate distributions (Figure 6.3A),
consistent with expected ER and secretory vesicle localization. Perinuclear accumulation
of signal consistent with Golgi localization was also apparent. (Figure 6.3A, arrowhead).
Importantly, the ApoE-GFP and the ApoE signals overlapped, particularly within puncta
that likely represented secretory vesicles (Figure 6.3B, arrowheads).
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Figure 6.3. ApoE-GFP colocalizes with endogenous ApoE in Huh-7.5 cells. (A) Huh7.5/ApoE-GFP cells were processed for immunofluorescence using α-ApoE (EP1374Y)
and α-GFP (JL-8) and corresponding secondary antibodies. A single deconvolved slice is
shown. The GFP and ApoE signals colocalized throughout the cell. Arrow heads indicate
perinuclear signal concentrations consistent with Golgi localization. Scale bar, 10 μm.
(B) Detail view of the region highlighted in the overlay image of panel A. The arrow
heads indicate colocalized ApoE and ApoE-GFP puncta.
6.5. ApoE-GFP and endogenous ApoE secretion rates are indistinguishable
ApoE is a secreted protein (Dashti et al., 1980). To characterize ApoE-GFP's
kinetics of secretion from cells, we performed radioactivity pulse-chase experiments in
the Huh-7.5/ApoE-GFP cells and in the control Huh-7.5/EV Hygro cells. Once again, I
thank Dr. Ursula Andreo for lending to the project her experience with radioactivity
pulse-chase assays. After a short 35S-cysteine and methionine pulse, we chased the cells
in the absence of label while measuring ApoE- and ApoE-GFP- associated radioactivity
in both media and cell lysates at regular intervals. The percent of total ApoE-GFP (Figure
6.4, blue trace) that was recovered from the media was at all times undistinguishable
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from the percent of endogenously-expressed ApoE recovered from the same Huh7.5/ApoE-GFP cells (Figure 6.4, red trace) or from control Huh-7.5/EV Hygro cells
(Figure 6.4, black trace). ApoE-GFP thus possessed the same capacity to be secreted
from the Huh-7.5 cell line as endogenous ApoE.

Figure 6.4. ApoE-GFP and ApoE are secreted from cells at undistinguishable rates.
The rates of secretion of ApoE and of ApoE-GFP were measured using a radioactivity
pulse-chase experiment. At each time point, the amount of secreted radiolabeled cargo is
shown as percent of the amount of total (cell-associated + secreted) radiolabeled cargo.
ApoE amounts were measured during secretion from Huh-7.5/EV Hygro and Huh7.5/ApoE-GFP cells, and the ApoE-GFP amounts were measured in Huh-7.5/ApoE-GFP
cells, as noted in the legend at the right.
6.6. ApoE-GFP associates with secreted ApoE and ApoB100
ApoE is secreted from cells as lipoprotein particles of various sizes and lipid
compositions that include ApoB100-containing VLDL/LDL and ApoB100-free HDL
particles (Vance et al., 1984). To be a useful marker of lipoprotein egress, ApoE-GFP
should retain untagged ApoE's ability to associate with itself and with secreted ApoB100.
To test if this was the case, I performed immunoprecipitation assays on media
conditioned by either Huh-7.5/ApoE-GFP cells or control Huh-7.5/EV Hygro cells.
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These experiments were done in the absence of detergent, to preserve the integrity of the
lipoprotein particles. Immunoprecipitation of Huh-7.5/ApoE-GFP conditioned media
with an α-GFP antibody pulled down ApoE-GFP, as expected, but also untagged ApoE
and ApoB100 (Figure 6.5A, lane a). Reciprocal immunoprecipitation of the same media
with α-ApoB100 pulled down ApoB100, ApoE-GFP, and untagged ApoE (Figure 6.5A,
lane b). These results indicate that secreted ApoE-GFP associated with both ApoB100
and untagged ApoE, likely as part of lipoprotein particles. To establish the specificity of
the immunoprecipitation assay, I performed a control pull-down with normal speciesmatched IgG, as well as pull-downs of media conditioned by Huh-7.5/EV with the same
sets of antibodies. Immunoprecipitation of ApoE-GFP-free media with the α-ApoB100
antibody resulted in recovery of only untagged ApoE, as expected (Figure 6.5A, lane e),
while the other conditions resulted in minimal or no recovery of ApoE, ApoE-GFP or
ApoB100 (Figure 6.5A, lanes c, d, and f). I note that the media samples used in these
assays were conditioned by similar cellular amounts (Figure 6.5B), and contained
comparable total amounts of ApoB100 and ApoE (Figure 6.5C). All in all, these
localization, kinetic and biochemical assays established ApoE-GFP as a useful marker for
analysis of ApoE-containing lipoprotein secretion.
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Figure 6.5. ApoE-GFP associates with secreted untagged ApoE and ApoB100. (A)
Media was conditioned by Huh-7.5/ApoE-GFP cells or by Huh-7.5/EV Hygro cells, then
immunoprecipitated with antibodies listed at the top of the figure. The pulled down
material was then blotted using antibodies against ApoB100 and ApoE, as listed at the
left. Letters between the two panels correspond to the lane labeling described in the text.
(B) The cells that secreted the material analyzed in panel A were lysed and processed by
Western blotting using the antibodies listed at the left. (C) Input media used in the
immunoprecipitation experiment in panel (A) was processed by Western blotting using
the antibodies listed at the left. (A-C) The ApoE and the ApoE-GFP bands are marked at
the right of each blot.

6.7. ApoE-GFP and infectious HCV egress
Since ApoE is a functionally important component of infectious HCV particles
(Chang et al., 2007; Fukuhara et al., 2014; Hishiki et al., 2010; Hueging et al., 2014; Lee
et al., 2014; Long et al., 2011; Vogt et al., 2013), I investigated whether ApoE-GFP
expression supported infectious HCV production. To test this, I performed rescue
experiments in the context of ApoE knockdown. Dr. Margaret Scull had made and
characterized Huh-7.5-derived clonal cell lines in which ApoE expression was knocked
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down (clones ApoE KD1 and ApoE KD2, respectively) and a control Huh-7.5 derived
clonal cell line transduced with an empty shRNA vector (clone EV KD). She was very
gracious in sharing these cell lines with me. The ApoE knockdown cell lines ApoE KD1
and ApoE KD2 expressed barely detectable levels of ApoE, compared to parental Huh7.5 cells, or to the control knockdown cell line, EV KD (data not shown), consistent with
previous reports (Chang et al., 2007; Hishiki et al., 2010; Jiang and Luo, 2009; Lee et al.,
2014). I transduced these cell lines with lentiviruses expressing shRNA-resistant
untagged ApoE, shRNA-resistant ApoE-GFP, or with an empty control lentivirus (EV).
As expected, ApoE expression was not rescued by transduction of these cells with the
empty lentiviral expression vector (Figure 6.6A). In contrast, transduction with the
lentivirus expressing untagged ApoE resulted in rescue of ApoE expression, and
transduction with the lentivirus expressing ApoE-GFP resulted in comparable levels of
expression of the fusion protein (Figure 6.6A). I then launched HCV infection in these
cells by HCV RNA electroporation. I measured intracellular HCV RNA levels at 6 h and
at 72 h post electroporation, and also measured supernatant HCV infectivity titers
accumulated over 72 h post electroporation. The expression of ApoE-GFP in the EV KD
background, where endogenous ApoE remains expressed (Figure 6.6A), did not
significantly change HCV infectivity release compared to control, EV-transduced cells
(Figure 6.6B, left pair of bars). I interpret this result to mean that ApoE-GFP did not act
as a DN factor with respect to release of infectious HCV particles. Unfortunately, ApoEGFP expression in the ApoE knockdown cell lines did not rescue infectious HCV particle
release (Figure 6.6B), compare second and third black bars to the second and third white
bars, respectively). In these cells, the release of infectious HCV particles was
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indistinguishable from that observed when the ApoE KD clones were mock-rescued by
transduction with an EV (Figure 6.6B, white bars). In contrast, exogenous expression of
untagged ApoE partly rescued HCV infectious particle release (Figure 6.6B, compare
second and third gray bars to the second and third white bars, respectively). In all but one
cell population, intracellular HCV RNA accumulated to similar levels (Figure 6.6C).
Comparable HCV RNA amounts were delivered into these cells, as quantified at 6 h post
electroporation (Figure 6.6D). Overall, these findings ruled out a major inhibitory effect
of ApoE-GFP expression on HCV viral genome replication.
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Figure 6.6. ApoE-GFP does not support infectious HCV particle production. (A)
Huh-7.5 cells, Huh-7.5 cells engineered to downregulate endogenous ApoE protein
expression (clones ApoE KD1 and ApoE KD2) and control knockdown cells (clone EV
KD) were transduced with the rescue vectors: empty (EV), ApoE, or ApoE-GFP. Cell
lysates were immunoblotted using α-ApoE (top) and α-actin (bottom) antibodies.
Molecular weight marker positions (kDa) are at the left of the blots. (B) Infectivity of
HCV particles released by the indicated cell lines at 72 h post electroporation. The cells
expressed the following rescue vectors: EV (white bars), ApoE (gray bars) or ApoE-GFP
(black bars). Shown are means ± standard error of the mean obtained from 2 or 3
independent electroporations, with 3 virus samples analyzed for each electroporation. (C)
Cell-associated HCV RNA copies quantified by qRT-PCR at 72 h post electroporation in
samples from the experiment presented in panel B. (D) Cell-associated HCV RNA copies
quantified by qRT-PCR at 6 h post electroporation in parallel samples to those presented
in panels B and C. The lower RNA levels in the ApoE KD2/ApoE-GFP cells both at 6 h
(panel D) and at 72 h (panel C) likely reflected a lower electroporation efficiency in that
cell background. Statistical differences (Student's t-test: ns, p>0.05; *, p<0.05; **,
p<0.01; ***, p<0.001).
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6.8. Discussion
Previous studies have shown that knockdown of ApoE expression results in
decrease of infectious HCV release from Huh-7.5 cells (Benga et al., 2010; Chang et al.,
2007; Hishiki et al., 2010; Jiang and Luo, 2009; Lee et al., 2014), and that infectivity
release may be at least partly rescued by re-expression of knockdown-resistant ApoE
(Hishiki et al., 2010; Jiang and Luo, 2009; Lee et al., 2014). Our findings are consistent
with these studies. Since in our experimental system ApoE-GFP did not possess any
capacity to rescue HCV infectivity release, its usefulness in imaging experiments
analyzing spatio-temporal dynamics of HCV particle release may be severely limited.
ApoE-GFP might not associate with HCV particles, might associate with HCV particles
that are degraded before being released, or might promote the production of ApoE-GFPcontaining HCV particles which remain nonetheless non-infectious. A putative defect of
ApoE-GFP association with HCV particles would be unsurprising if the GFP tag
interfered with ApoE-HCV association. ApoE specifically binds the transmembrane
domain of the HCV glycoprotein E2 (Lee et al., 2014) and the GFP tag could cause a
conformational change in the ApoE polypeptide that could interfere with the E2
interaction. Alternatively, the relatively bulky GFP tag might sterically clash with the
E1E2 glycoprotein ectodomains on the surface of the HCV particle, or might mask
lipoprotein or glycoprotein domains involved in entry receptor interaction. If ApoE-GFP
associated with HCV particles, and the structure and rate of production of these putative
ApoE-GFP-containing HCV non-infectious particles were indistinguishable from the
structure and rate of production of infectious ApoE-containing HCV particles, then
ApoE-GFP may still be used in the analysis of HCV particle secretion. Unfortunately,
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only a small portion of released HCV particles are infectious, and they appear to be
difficult to purify and characterize structurally (Catanese et al., 2013; Gastaminza et al.,
2010). As such, documenting structural and compositional similarity between infectious
ApoE-containing HCV particles and the hypothesized non-infectious ApoE-GFPcontaining HCV particles would be challenging at best. I thus conclude that ApoE-GFP is
unlikely to be suitable to unambiguously mark and image infectious HCV particles
during secretion from hepatic cells.
Nonetheless, the results I present here do document a behavior of ApoE-GFP that
closely mirrors that of untagged ApoE with respect to lipoprotein release. We showed
that ApoE-GFP and untagged ApoE colocalized intracellularly and were secreted at
similar rates. I further showed that ApoE-GFP interacted with both endogenous ApoE
and ApoB100, as expected for a proper lipoprotein particle-associated marker. Our
findings are further corroborated by a battery of functional tests previously performed in
macrophages (Kockx et al., 2007) using the same construct that we used. I propose
therefore that ApoE-GFP (or similarly made constructs) may be used in studies aiming,
for example, to identify the route(s) of vesicular transport which shuttle ApoE-containing
lipoproteins out of producing cells. Colocalization - or lack thereof - between Rabs and
intracellular ApoE-GFP, for example, will inform whether a particular Rab protein
functions in ApoE-containing lipoprotein egress. Furthermore, quantitative kinetic
imaging studies, including the study of whether and how the various ApoE isoforms
affected the rates of lipoprotein secretion, may be performed using such fluorescent
protein tagged ApoE constructs. Besides characterizing ApoE-GFP behavior, this study
provides a framework for testing other fluorescently tagged markers of lipoprotein
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particles. Lastly, since ApoE has also been implicated in neurodegenerative diseases
(Corder et al., 1994; Corder et al., 1993) and cancer (Pencheva et al., 2012), ApoE-GFP
may likely be used in other disease-specific cellular contexts to answer cell biology
questions relevant for the understanding of those pathologies.
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Chapter 7
Concluding Remarks

Throughout the past several years, aided by wonderfully skilful assistance from
my friends and collaborators, I have pursued several lines of investigation, all converging
towards a larger unified goal: to molecularly characterize the vesicular transport
pathways involved in the secretion of such hepatic cargoes as serum albumin, the
lipoprotein components ApoE and ApoB100, and HCV. Some of the avenues of
investigation that I followed have yielded interesting results. Other branches of my
investigation have established experimental tools and protocols that may prove useful in
parsing out the functional details of other cellular processes. Finally, some of the
approaches that I initially undertook have failed, or I have chosen not to pursue them
further due to time restraints. I will not repeat here the individual discussion points that I
have expanded upon at the conclusion of the previous chapters. I will, however, reemphasize that the DN Rab GTPase screen may be adapted for use in other experimental
systems to parse out Rab family involvement in other secretion settings; that an elaborate
description of Rab11 and Rab8 function in polarized hepatic cargo secretion may yield
interesting revelations on how the hepatocytes handle the tremendous burden of
intracellular traffic functions that they must harmoniously juggle; that the peculiar
differences in the sensitivities of albumin, ApoE and ApoB100 to Rab1 inhibition may
reveal interesting regulation methods of ER to Golgi traffic; and that ApoE-GFP may
prove useful in quantitative spatial and temporal analyses of intracellular lipoprotein
transport.
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Were I to have more time to delve deeper into the investigation of hepatic cargo
secretion, not only would I like to continue pursuing the lines of investigation that I have
advanced as part of this work, but I would also like to reprise pursuing some other
projects that I have envisaged, and even commenced, during my graduate student tenure.
I have not included in the results section of this thesis a detailed description of all the bits
and pieces of work that I have done as part of the several projects that did not advance
significantly, beyond the Rab11 and Rab8 analysis. Those temporarily stalled lines of
inquiry may nonetheless be reprised and used to complement the genetic and biochemical
analysis of cargo transport that I presented in the pages above. For example, live cell
imaging experiments contrasting the transport of fluorescently labeled albumin, ApoE,
and HCV particles, with each other and with markers of individual secretion steps,
including the Rab GTPases, may provide a trove of information regarding the dynamic
spatial and temporal regulation of these model hepatic cargoes. Indeed, with assistance
from Caroline Gleason, I have made fluorescent protein-tagged albumin constructs. I
have also made HCV genomes expressing fluorescent protein-tagged E2 glycoproteins,
or encoding bacteriophage RNA loop arrays (Buxbaum et al., 2015) that may be used to
fluorescently label the HCV genome, as a collaboration between the Simon and Bieniasz
labs has successfully achieved in the case of the HIV-I genome (Itano et al., 2015;
Jouvenet et al., 2008). These fluorescent beacon-tagged constructs would need to be
tested in functional assays, as I have described for ApoE-GFP in Chapter 6. Once such
characterization is complete, imaging experiments will need to be performed, likely
combining several techniques. I am encouraged that such live cell imaging experiments
will be facilitated by advances in imaging techniques. Beyond the total internal reflection
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microscopy technique that has long been used in the Simon lab (Fix et al., 2004; Jouvenet
et al., 2008; Jouvenet et al., 2009; Jouvenet et al., 2011), just recently, super-resolution
imaging protocols and multi-focus simultaneous imaging techniques have been
developed here and have been successfully applied to address biological questions (Bleck
et al., 2014; Itano et al., 2015). These novel experimental techniques, which were not yet
available when I started my thesis work, will only hasten the pace of the inquiry. I hope
that whoever further pursues this investigation may find useful inspiration in the work
that I have done over the past several years, and the work that I have envisaged
continuing doing.
I also hope that one day scientists may be able to look back and say: "We know
all there is to know about hepatic lipoprotein and HCV secretion by the hepatocyte." This
likely is an unachievable dream. But advancements have been made, and will be made. I
am happy to think that I may have contributed something useful to the field, yet I am
humbled by the realization of how much more still belongs to the great domain of the
unknown.
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